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ABSTRACT OF DISSERTATION

KINETICS AND MECHANISMS OF CRYSTAL GROWTH INHIBITION OF
INDOMETHACIN BY MODEL PRECIPITATION INHIBITORS

Supersaturating Drug Delivery Systems (SDDS) could enhance oral bioavailability of
poorly water soluble drugs (PWSD). Precipitation inhibitors (PIs) in SDDS could
maintain supersaturation by inhibiting nucleation, crystal growth, or both. The
mechanisms by which these effects are realized are generally unknown. The goal of this
dissertation was to explore the mechanisms underpinning the effects of model PIs
including hydroxypropyl β-cyclodextrins (HP-β-CD), hydroxypropyl methylcellulose
(HPMC), and polyvinylpyrrolidone (PVP) on the crystal growth of indomethacin, a
model PWSD. At high degrees of supersaturation (S), the crystal growth kinetics of
indomethacin was bulk diffusion-controlled, which was attributed to a high energy form
deposited on the seed crystals. At lower S, indomethacin growth kinetics was surface
integration-controlled. The effect of HP-β-CD at high S was successfully modeled using
the reactive diffusion layer theory. The superior effects of PVP and HPMC as compared
to HP-β-CD at high S were attributed to a change in the rate limiting step from bulk
diffusion to surface integration largely due to prevention of the high energy form
formation. The effects of PIs at low S were attributed to significant retardation of the
surface integration rate, a phenomenon that may reflect the adsorption of PIs onto the
growing surface. PVP was selected to further understand the relationship between
adsorption and crystal growth inhibition. The Langmuir adsorption isotherm model fit
the adsorption isotherms of PVP and N-vinylpyrrolidone well. The affinity and extent of
adsorption of PVP were significantly higher than those of N-vinylpyrrolidone, which was
attributed to cooperative interactions between PVP and indomethacin. The extent of PVP
adsorption on a weight-basis was greater for higher molecular weight PVP but less on a
molar-basis indicating an increased percentage of loops and tails for higher molecular
weight PVPs. PVP significantly inhibited indomethacin crystal growth at high S as
compared to N-vinylpyrrolidone, which was attributed to a change in the growth
mechanism resulting in a change in the rate limiting step from bulk diffusion to surface
integration. Higher molecular weight PVPs were better inhibitors than lower molecular
weight PVPs, which was attributed to a greater crystal growth barrier provided by a
thicker adsorption layer.
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Chapter One
Statement of Aims
Oral bioavailability of poorly water soluble drugs has been successfully enhanced
in pre-clinical and clinical studies through the maintenance of supersaturation (i.e.,
maintenance of drug concentration above its equilibrium solubility) in the gastrointestinal
(GI) tract by using Supersaturating Drug Delivery Systems (SDDS).1-6 Precipitation
inhibitors

(PIs)

including

cyclodextrins,

polyvinylpyrrolidone

(PVP),

polyvinylpyrrolidone-vinyl acetate (PVP-VA), hydroxypropyl methylcellulose (HPMC),
hydroxypropyl methylcellulose-acetate succinate (HPMC-AS), polyethylene glycol
(PEG), d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS or vitamin E TPGS),
and polysorbate 80 have been incorporated into SDDS to maintain the supersaturation of
drugs to varying degrees of effectiveness.7-9

The PIs generally maintain the

supersaturation of poorly water soluble drugs by inhibiting nucleation, crystal growth, or
both.1 The degree of effectiveness of PIs depend on their mechanisms of action and the
physico-chemical properties of the PIs as well as drugs including hydrogen bonding
capacity, hydrophobicity, semi-rigid structure, and amphiphilic nature.9-13 In addition to
the intermolecular interactions between PIs and drug molecules in the bulk solution,13-16
the effects of PIs have been attributed to the adsorption on the growing crystal
surface.4,12,17-24 While the beneficial effects of PIs on the maintenance of supersaturation
of poorly water soluble drugs have been demonstrated by the above-mentioned studies,
the mechanistic understanding as to how PIs achieve their beneficial effects is generally
lacking.

Additionally, a correlation between the beneficial effects of PIs and the

molecular properties of drugs and PIs is not well understood. This significantly impacts

1

the ability of pharmaceutical scientists to rationally select a suitable PI for the
development of an SDDS. One of the reasons behind this gap in the scientific literature
could be a lack of simple techniques and models to study the beneficial effects of PIs on
the maintenance of supersaturation through the inhibition of nucleation, crystal growth,
or both for poorly water soluble drugs. The goal of this dissertation was to develop
methods and models to mechanistically explore the effects of model pharmaceutical PIs
including hydroxypropyl β-cyclodextrin (HP-β-CD), HPMC, and PVP on the
maintenance of aqueous supersaturation by crystal growth inhibition of indomethacin, a
model poorly water soluble drug. The following aims were completed as part of this
work:
a) Develop reliable methods and relevant mathematical models to study crystal
growth kinetics of indomethacin, a model poorly water soluble drug
The deficiency of quantitative explorations on the crystal growth inhibitory
effects of PI for poorly water soluble drugs in the literature could be attributed to a lack
of simple, reliable, and robust techniques to quantify the kinetics of crystal growth that
influence the maintenance of supersaturation. A non-invasive (online) technique was
developed to measure the crystal growth kinetics of indomethacin using second
derivative UV spectroscopy, batch crystallization, and a crystal seeding method in
Chapter 3.

The crystal seeding method was developed to study the crystal growth

kinetics by avoiding primary nucleation at high degrees of supersaturation (S). The
development of the seeding method consisted of steps to obtain narrow as well as
unimodal size distributions and to determine any change in seed size and number upon
mixing and crystal growth. Our hypothesis was that the second derivative UV method
2

would remove the interference in UV absorption from the growing seed crystals in the
solution, and in turn provide accurate measurements of indomethacin concentrations in
real time.

The indomethacin concentration vs. time profile would be utilized in

determining crystal growth rates. A mathematical model based on the two-step diffusionreaction theory for crystal growth was developed, and the rate limiting step for the crystal
growth of indomethacin at high S was identified based on the measurements of the mass
transfer and crystal growth rate coefficients of indomethacin. A different high energy
form was deposited on the seed crystals of indomethacin after crystal growth at high S.
This high energy form probably accounted for the bulk-diffusion controlled crystal
growth of indomethacin at high S.
b) Determine the effect of degree of supersaturation on the crystal growth kinetics
of indomethacin
To study the effect of PI on the crystal growth kinetics of indomethacin, it would
be important to derive a physical theory based model which describes the crystal growth
kinetics of indomethacin. Several factors including degree of supersaturation, impurities,
PI, chemical structure, physical conformation, bonds, and defects or disorder can
influence the kinetics of crystal growth.25,26 The thermodynamic driving force for crystal
growth (i.e., degree of supersaturation) could influence kinetic parameters such as the
rate limiting step of crystal growth.24 The effect of degree of supersaturation on the
crystal growth kinetics of indomethacin was determined in Chapter 4. The crystal growth
rate coefficients of indomethacin were determined over a wide range of degree of
supersaturation (1.6 ≤ S ≥ 9). An infusion-based method to measure the crystal growth
rate of indomethacin at very low S of 1.6 was developed to avoid the formation of the
3

high energy indomethacin form on seed crystals. While the high energy form probably
accounted for the rapid, bulk-diffusion controlled crystal growth of indomethacin at high
S, at low S (i.e., at a solution concentration above the solubility of the high energy form)
the mechanism of crystal growth was different and consistent with surface integration
control. The understanding of the fundamental relationship between the degree of
supersaturation and the rate limiting step for indomethacin crystal growth was further
employed in understanding the effects of model PIs such as cyclodextrins on crystal
growth and, in turn, the maintenance of supersaturation of indomethacin in Chapter 5.
c) Explore mechanisms and relevant mathematical models for the effect of model
precipitation inhibitors on the crystal growth of indomethacin
Despite some studies in the literature that have qualitatively screened or rank
ordered the effects of PIs on the maintenance of supersaturation, mechanistic explorations
on the beneficial effects of PIs using mathematical models have been seldom carried
out.8,9 In this aim, a quantitative approach to explore the inhibition of crystal growth and,
in turn, the maintenance of supersaturation of indomethacin by three model PIs including
HP-β-CD, PVP and HPMC was developed. The effects of model PIs on the driving force
and the rate determining step of the crystal growth kinetics of indomethacin were
determined in Chapter 5. Our hypothesis was that after accounting for the effect of PI on
the equilibrium solubility of indomethacin, two factors including the speciation in the
bulk solution and the impact of PI on the surface integration rate of indomethacin due to
the interactions of PI with the crystal surface of indomethacin would explain the
inhibitory effect of PI on the crystal growth of indomethacin. The inhibitory effect of HPβ-CD on the crystal growth of indomethacin at high S was successfully explained by a
4

reactive diffusion theory based mathematical model. The retardation of crystal growth by
PIs at high S was largely due to prevention of the formation of a high energy
indomethacin form on seed crystals. The effects of PI on surface integration may also be
a factor but that was a small effect, as surface integration was already quite slow at low S.
The inhibitory effects of all three model PIs on the surface integration of indomethacin
could be attributed to the adsorption of PI on the seed crystals of indomethacin.
d) Explore the relationship between the adsorption of PVP and the crystal growth
inhibitory effects of PVP for indomethacin
A majority of commonly used pharmaceutical PIs including PVP, PVP-VA,
HPMC, HPMC-AS, PEG, TPGS, and polysorbate 80 are polymeric in nature, which are
sometimes described as polymeric PIs (PPIs).9 Previous studies have proposed that the
inhibitory effects of PPIs on the precipitation of drugs could be attributed to their
adsorption on the growing drug crystal surface.12,17,18,20 For example, the inhibitory
effect of PVP on the crystal growth of bicalutamide was attributed to its adsorption onto
bicalutamide crystals.20 Despite these studies, the mechanisms of the inhibitory effects of
PPIs on drug precipitation are seldom proven directly or correlated with the adsorption of
PPI in a quantitative manner. Consequently, the nature of the adsorbed PPI layer as well
as the key physicochemical properties of PPIs and drugs such as molecular weight,
hydrogen bonding capability and hydrophobicity that could influence the adsorbed PPI
layer and, in turn, the effectiveness of a given PPI are not well understood. In this aim,
the effect of molecular weight and concentration of PVP, a model PPI, on its adsorption
onto the crystalline surface of indomethacin, a model poorly water soluble drug was
determined.

Additionally, the adsorption behavior of PVP was correlated with its
5

effectiveness as a crystal growth inhibitor of indomethacin in Chapter 6.

PVP

significantly inhibited the crystal growth of indomethacin at a high degree of
supersaturation, which was attributed to a change in the crystal growth mechanism of
indomethacin resulting in a change in the rate limiting step from bulk diffusion to surface
integration at a high S. The change in the crystal growth mechanism of indomethacin
could be due to prevention of the formation of a high energy form of indomethacin on the
seed crystals of indomethacin by PVP. The adsorption and the crystal growth inhibitory
effects of PVP for indomethacin correlated well across different molecular weights and
concentrations of PVP. The greater effectiveness of PVP as a crystal growth inhibitor of
indomethacin as compared to its monomer was not only attributed to the higher surface
coverage of indomethacin crystals but also to the greater barrier for the surface diffusion
of indomethacin molecules provided by a thicker PVP adsorption layer.

Copyright © Dhaval D. Patel 2015
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Chapter Two
Introduction
Supersaturating drug delivery systems (SDDS) contain precipitation inhibitors
(PIs), which could maintain supersaturation of poorly water soluble drugs over a
prolonged period of time in the GI tract and, in turn, enhance oral bioavailability.1-6 The
beneficial effects of PIs on the maintenance of supersaturation could be due to inhibition
of nucleation, crystal growth, or both for poorly water soluble drugs.

While the

nucleation and crystal growth of drugs could be influenced by the intermolecular
interactions between PIs and drug molecules in the bulk solution,13-16 the adsorption of
PIs on the growing crystal surface has been linked to their crystal growth inhibitory
effects.4,12,17-24 The inhibition of crystal growth by the adsorbed PIs may be attributed to
their effects on either bulk diffusion and/or surface integration of drug molecules.9,10,18,27
Their effectiveness has been linked to their hydrogen bonding capacity, hydrophobicity,
semi-rigid structure, and amphiphilic nature.10-13 Despite the above-mentioned studies, a
significant literature gap exists between present knowledge and for a more
comprehensive, mechanistic understanding of PI effects. Since the inhibitory effects of
PIs on nucleation, crystal growth, or both vary significantly with the combination of drug
and PI, predictive models are required to enhance the ability of pharmaceutical scientists
to rationally select suitable PIs a priori for the development of SDDS. A thorough
understanding of the correlation between the adsorption of a given PI and its crystal
growth inhibitory effect is needed to explore possible crystal growth inhibition
mechanisms such as the creation of a barrier for surface diffusion of the adsorbed drug
molecules or the blocking of active growth sites for the incorporation of drug molecules

7

into crystal lattices. The literature gap could be attributed to several reasons including:
(1) a lack of simple techniques and models that would allow scientists to explore the
effects of a given PI on drug precipitation kinetics by individually focusing on the
kinetics of nucleation and crystal growth of drugs in aqueous media, (2) a lack of
information on the solution-mediated phase transformations that could occur during drug
precipitation and its application in developing models for drug precipitation kinetics, and
(3) experimental difficulties encountered during robust measurements of supersaturated
drug concentrations.
To develop a quantitative and mechanistic understanding of the effects of PIs on
the maintenance of supersaturation by inhibiting nucleation or crystal growth, it is
essential to determine parameters that govern the kinetics of nucleation or crystal growth
of poorly water soluble compounds. Since nucleation is generally spontaneous and the
sizes of nuclei are very small, a clear experimental distinction between nucleation and
crystal growth is generally difficult.24

In many previous supersaturation studies,9,13

experimental methods were not well designed to study nucleation and crystal growth
independently. For example, the supersaturation of danazol was studied using a turbidity
method, which grossly detected the precipitation of danazol but did not differentiate it
further into nucleation and crystal growth.9 The lack of reliable methods to distinguish
between nucleation and crystal growth could impact the development of kinetic models
for drug precipitation in aqueous media.
The drug precipitation kinetic models could be further optimized by tracking
solution-mediated phase transformations that could occur during nucleation and crystal
growth and, in turn, by utilizing more specific values of the kinetic and thermodynamic
8

parameters of the newly detected solid phase (e.g., equilibrium solubility, dissolution
rate). The solution-mediated phase transformations observed during drug precipitation
could include: (1) the formation of new solid phase (amorphous or crystalline) in solution
by homogeneous nucleation, and (2) the formation of new solid phase including higher
energy forms such as metastable polymorphs or an amorphous form on the surface of the
most stable form, and vice versa.28-34 Epitaxial growth is defined as the growth of one
molecule on another substrate with similar structural features such as similar
crystallographic lattice.28,35-37 The epitaxial growth is commonly observed in crossseeding methods that are used to crystallize a material of choice on the surface of a
different seed crystal.35 The formation of surface disorder including lattice defects and
amorphous regions has been observed for inorganic and organic materials from either
precipitation at high degrees of supersaturation or mechanical activation through
milling.24,29,33-35,38-40

For example, samples of cephalothin sodium and cefamandole

nafate that were crystallized from supersaturated mother liquor exhibited higher
exothermic heats of solution as compared their 100% crystalline standards, which was
attributed to a higher crystal disorder on the surface of cephalothin sodium and to an
amorphous layer coating on the crystals of cefamandole nafate.33 Potassium perchlorate
crystals that were grown at different degrees of supersaturation and, in turn, at different
growth rates were identical as detected by PXRD and DSC; however, the crystals were
found to be different based on the surface density of dislocations.40 The crystals grown at
the fastest growth rate showed the highest mean dislocation density whereas the crystals
with the lowest dislocation density were grown at the slowest growth rate. Amorphous
indomethacin with different levels of crystallinity underwent solution-mediated phase
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transformation during dissolution in aqueous media.41 Unlike the completely amorphous
indomethacin sample where only γ polymorph had formed on the surface, the amorphous
indomethacin samples with partial crystallinity were covered with more than one
polymorph. Grinding of anhydrous monoclinic carbamazepine produced surface disorder
consisting of amorphous phases and lattice defects, which facilitated the surface
nucleation

of

carbamazepine

dihydrate.29

During

dissolution

of

theophylline

monohydrate, a decline in the dissolution rate from a peak was observed using a
combined UV imaging and Raman spectrometric technique, which was attributed to the
formation of a higher energy form (i.e., a new crystalline hydrate form or a crystalline or
amorphous dehydrated form on the surface of theophylline monohydrate crystals at levels
below the detection limit of PXRD or Raman measurements.31 Higher apparent solubility
obtained with mechanically activated griseofulvin was attributed to the higher energy,
disordered surface layer with the thickness of 40 to 50 nm, which was not detectable by
DSC.32 The stability of the higher apparent solubility of griseofulvin was explained by
the slower, surface integration controlled growth of griseofulvin.
Another experimental difficulty in studying the kinetics of drug precipitation is
the inability of common analytical methods to accurately measure the concentrations of
supersaturated samples. Previously, supersaturated concentrations have been measured
using several off-line (e.g., filtration, centrifugation) and on-line (e.g., real-time UV or
Raman or IR spectroscopy) techniques.2-6,42,43

However, the supersaturated

concentrations measured using the off-line methods including filtration and
centrifugation could be inaccurate in cases where drug might have precipitated due to
temperature fluctuations and/or physical contact of supersaturated solutions with solid
10

surfaces of syringes, filter membranes, and centrifuge tubes during off-line sample
collections.

Recently, non-invasive and online methods consisting of spectroscopic

techniques such as ATR-FTIR,44 Raman,17 and fluorescence20 have been employed to
measure supersaturated concentrations without the risk of off-line sampling errors.
A mechanistic understanding of the effect of pharmaceutical excipients such as
precipitation inhibitors (PIs) on the maintenance of supersaturation of poorly water
soluble drugs is essential to facilitate rational designs of SDDS. The objective of this
dissertation was to explore mechanisms underpinning the effects of model PIs on the
maintenance of supersaturation of a model poorly water soluble drug, indomethacin, via
crystal growth inhibition. The specific aims were: (1) to develop robust experimental
methods and models to study the crystal growth kinetics of indomethacin in water, (2) to
determine the effect of degree of supersaturation on the kinetics of indomethacin crystal
growth including its rate-limiting steps, (3) to explore mechanisms and develop relevant
mathematical models for the effect of model PIs including HP-β-CD, PVP and HPMC on
the crystal growth of indomethacin, and (4) to explore the relationship between the
adsorption of PVP and the crystal growth inhibitory effects of PVP for indomethacin.
The following topics are described in detail considering overall objective of this
dissertation.
1.

Supersaturating Drug Delivery Systems (SDDS)
Current pharmaceutical R&D pipelines are flooded with poorly water soluble

drug candidates mainly due to recent advances in high throughput technologies and
combinatorial chemistry for drug screening and hit identification.45 The emerging drug
candidates from these technologies generally have higher molecular weight, greater
11

lipophilicity and very low water solubility.46 Most of the emerging drug candidates
belong to the Class II and IV of the Biopharmaceutical Classification System (BCS)47
indicating that the oral absorption and, in turn, oral bioavailability of these drug
candidates could be limited by equilibrium solubility, dissolution rate, or both.

To

circumvent this issue, SDDS are specifically designed to enhance the solubility and/or
dissolution rate of poorly water soluble drugs by modifying the physico-chemical
properties of drugs as well as by using various formulation approaches. Some of these
approaches

include

salt

formation,48

cocrystal

formation,49

drug-excipient

complexation,7,43 lipid-based drug delivery systems,8,50-52 solid dispersions,3,53 and
nanoparticles.54,55 Oral administration of SDDS may achieve higher drug concentrations
than the equilibrium solubility of drug in the GI tract due to higher apparent solubility
(i.e., supersaturation) and/or the maintenance of supersaturation of drugs in the GI tract
resulting in higher oral bioavailability.1-6
The SDDS could be classified into two main classes: (1) SDDS developed
through formulation approaches, and (2) SDDS developed through the modification of
physico-chemical properties of drugs (Table 2.1). For both classes of SDDS, the primary
goal is to provide higher apparent solubility (also defined as “kinetic solubility”) and, in
turn, generate supersaturation of drugs. Some SDDS, especially the Class 1 SDDS, not
only generate supersaturation but also maintain or prolong supersaturation.

The

generation and maintenance of supersaturation by SDDS has recently been described by a
“spring and parachute” approach.56 For example, the higher energy form of drug that
generates supersaturation is compared with the “spring” analogy (i.e., sudden rise in drug
concentration), whereas PIs that maintain supersaturation by inhibiting drug precipitation
12

are compared with the “parachutes” analogy (i.e., slower decline of drug concentration).
If the supersaturation of drug in the GI tract is maintained through the absorption window
(i.e., the time interval for complete GI absorption), it could enhance oral bioavailability.9
The selection of a particular SDDS for drug product development mainly depends on
clinical and pharmacokinetic requirements as well as the physico-chemical properties of
drug candidates. For example, a drug candidate with high log P and high solubility in
lipid-based vehicles would be more suitable for lipid-based SDDSs as long as the
required concentration of drug candidate in the lipid vehicle as dictated by clinical
requirements (e.g., estimated human dose range) is not higher than the solubility of drug
candidate in the same lipid vehicle. If the drug concentration/loading requirements are
significantly higher than the solubility limit in the lipid-based SDDS), amorphous solid
dispersion SDDSs could be used to circumvent the solubility limitation of lipid-based
SDDSs.
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Table 2.1. Classification of Supersaturating Drug Delivery Systems (SDDS)
SDDS Class

Class 1:
SDDS Based on
Formulation
Approaches
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Class 2:
SDDS Based on
PhysicoChemical
Property
Modification
Approaches

SDDS

Example

Reference

Paclitaxel SEDDS
AMG-517 S-SEDDS
Piroxicam SMEDDS
Quercetin SNEDDS

5

Dipyridamole solid dispersion
Itraconazole hot-melt extrudate
Cefuroxime axetil nanoparticles
DB 67-SBE-CD complexes

59

Salts

Celecoxib sodium salt

56

Cocrystals

AMG-517 benzoic acid cocrystals

62

Amorphous forms
Metastable polymorphs
Prodrugs

Atorvastatin amorphous form
Carbamazepine anhydrous
Fosamprenavir

63

Lipid-based drug delivery
system
SEDDS
S-SEDDS
SMEDDS
SNEDDS
Solid dispersions
Spray drying
Hot-melt extrusion
Nanoparticles
Complexation

4
57
58

60
61
7

29
64

SEDDS: Self emulsifying drug delivery system; S-SEDDS: Supersaturating self emulsifying drug delivery system; SMEDDS: Self micro-emulsifying drug delivery system; SNEDDS: Self nanoemulsifying drug delivery system

1.1 SDDS Based on Formulation Approaches (Formulation-SDDS)
The formulation approaches utilized in the development of SDDS include spray
drying,53 hot-melt extrusion,3,65,66 co-precipitates/nanoparticles,54 self-emulsifying micro& nanoemulsions,4,52 and complexation.7 Since the in vivo supersaturation generated by
SDDS could lead to the precipitation of drug due to limited solubility in the highly
variable local aqueous in vivo environment, the optimal success of SDDS in terms of
ensuring higher and reproducible bioavailability depends on the maintenance of
supersaturation for a sufficient period of time to allow higher drug absorption. The
SDDS developed using the above-mentioned formulation approaches are specifically
designed not only to generate but also to maintain the supersaturation of drugs.
One of the most commonly used formulation approaches to develop SDDS is the
amorphous solid dispersions (ASD).

The ASD-based SDDS are developed using

techniques such as spray drying, hot-melt extrusion, and co-precipitation/co-processing,
lyophilization.7 In ASD, the drug is present in a high energy form such as amorphous
form and the high energy state of the drug is stabilized using a polymeric matrix.67 When
the drug is molecularly dispersed in the polymeric matrix, the ASD is also described as a
“solid solution”.68

However, it is very difficult to experimentally measure the

thermodynamic equilibrium solubility of drug in a solid solution, and therefore it is
challenging to determine if an ASD is truly a solid solution or not. The polymeric
matrices of ASD-based SDDS are generally composed of one or more polymers such as
PVP, PVP-VA, polyvinyl alcohol (PVA), HPMC, and HPMC-AS. The amorphous form
of drug along with precipitation inhibitors present in ASDs provides higher dissolution
rate and supersaturation (i.e., “kinetic solubility”). The ASD of itraconazole prepared by
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spraying itraconazole onto a highly porous carrier such as silica generated and maintained
supersaturation for about 4 hours at intestinal pH and, in turn, mitigated the negative
impact of pH-dependent solubility on oral bioavailability as observed earlier with
crystalline itraconazole.55 The ASD of itraconazole with HPMC (40:60 w/w) prepared
through a hot-melt extrusion technique significantly enhanced its dissolution rate as
compared to crystalline itraconazole.60 The dissolution of the itraconazole ASD and the
physical mixture of crystalline itraconazole and HPMC in 0.01N HCl at 37°C showed
that approximately 90% and 2% of the 200-mg dose of itraconazole dissolved after 120
minutes, respectively.
The co-precipitate-based SDDS, prepared from the co-precipitation of drug and
excipients, are generally used when conventional spray drying and melt-extrusion
techniques are not feasible due to process-related limitations. The drug and excipients
including PIs are simultaneously precipitated from mother liquor resulting in fine
particles containing the amorphous drug dispersed in an excipient matrix.

The co-

precipitate-based SDDS provide a high degree of supersaturation due to the amorphous
nature of the drug as well as the high surface area of fine co-precipitate particles.69,70
Celecoxib nanoparticles prepared using an emulsion method and a polymer such as ethyl
cellulose provided higher exposure and faster absorption as compared to the commercial
capsule dosage form containing crystalline drug.70
The lipid-based SDDSs do not require the dissolution of drugs since drug particles
are already solubilized in the liquid vehicle.

The lipid-based SDDSs include self-

emulsifying drug delivery systems (SEDDS), self-microemulsifying drug delivery
systems (SMEDDS), and self-nanoemulsifying drug delivery systems (SNEDDS). The
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lipid-based SDDSs are commonly composed of triglycerides such as glyceryl
tricaprylate/caprate, cosolvents such as PEG, and surfactants such as Cremophor® RH40.
They are commonly used with lipophilic drugs with sufficiently higher solubilities in the
vehicle of the lipid-based SDDS than clinical dose requirements.52,71

For example,

griseofulvin and other drugs with log P of ~2 having very low solubility in glycerides are
not good candidates for lipid-based SDDS. These would require other SDDS approaches
such as ASD. Drugs with high log P values (>5) including halofantrine or cinnarizine are
suitable candidates for lipid-based SDD.71 When administered orally, lipid-based SDDSs
form dispersions consisting of colloidal species of varying sizes.

While some

formulation components of lipid-based SDDS such as surfactants and oils could enhance
the solubilization capacity of the GI fluids, the solubilization capacity of the GI fluids
changes over time due to continuous dispersion and digestion of the lipidic components
of lipid-based SDDS leading to the generation of supersaturation.72

The piroxicam

SMEDDS containing Labrasol provided approximately 7-times higher apparent solubility
than its equilibrium solubility in the same medium.57 Precipitation of piroxicam occurred
upon the dilution of the SMEDDS. This was attributed to the change in organization of
Labrasol and, in turn, the conversion of microemulsion to fine emulsion upon dilution.
While the maintenance of supersaturation provided by regular lipid-based SEDDS
significantly depends on the dilution and digestion of the formulation components, novel
supersaturable SEDDS (S-SEDDS) are designed to enhance the maintenance of
supersaturation using additional PIs such as polymers.73 For example, the supersaturated
concentration of AMG 517 generated by a lipid-based S-SEDDS containing Tween 80
was effectively maintained by the addition of HPMC to the S-SEDDS.4
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Cyclodextrins have been used to prepare solid and liquid SDDS of poorly water
soluble drugs.46,74 A parenteral SDDS of DB-67, an experimental anti-cancer drug, in the
form of lyophiles was prepared using a sodium salt of the β-cyclodextrin sulfobutyl ether
(SBE-CD).7 The stable supersaturated solution of 20% w/v DB-67 was prepared by
chemically converting the ring-opened DB-67 to its lactone form using an acidified SBECD solution, which maintained the supersaturation for at least three days.
1.2 SDDS Based on Physico-Chemical Property Modification Approaches (Physical
Form-SDDS)
The SDDS developed by modifying the physico-chemical properties of drugs
include salts, cocrystals, prodrugs, and other higher energy forms (e.g., amorphous forms,
metastable polymorphs, and nanocrystals). The higher dissolution rate and apparent
solubility provided by the Physical Form-SDDS could generate supersaturation in the GI
tract. However, the main limitation of the Physical Form-SDDS, unlike the FormulationSDDS, is their inability to maintain supersaturation for a prolonged period of time.
Crystalline salt forms are one of the most popular Physical Form-SDDSs used in
drug product development.75 The crystalline salt is preferred over an amorphous solid
dispersion for the development of an oral solid dosage form for two main reasons: (1)
crystalline salts provide higher purity and, in turn, more efficient drug manufacturing
process as compared to the amorphous form, and (2) crystalline salts provide better
physical and chemical stability during manufacturing and storage as compared to
amorphous forms.48 For the salts of weakly basic drugs, chloride is the most commonly
used counter ion, whereas sodium is a popular counter ion for salts of weakly acidic
drugs.48,76 Crystalline salts often provide high supersaturation due to faster dissolution
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rates and higher apparent solubilities. For example, both the sodium salt and the sodium
propylene glycol salt of celecoxib provided approximately 10-fold higher apparent
solubility in water as compared to free celecoxib.56 The higher dissolution rate of salts is
often attributed to an alteration in the microenvironmental pH and solubility at the
surface of dissolving salt.48,77
Cocrystals are molecular complexes between two or more entities within a single
crystal lattice, which are viable alternatives to crystalline salts when drug molecules lack
ionizable functional groups.49

Higuchi and Ikeda78 showed in the early 1970s that

cocrystal formation between digoxin and hydroquinone significantly improved the
dissolution rate of digoxin. The formation of cocrystals for ionizable drug candidates is
preferred if their traditional salt forms are highly unstable during manufacturing and
storage. For example, AMG517, a weakly basic drug candidate, was highly sensitive to
degradation at acidic pH, which was required for salt formation.62 Several cocrystals of
AMG517 were formed using coformers such as carboxylic acids and carboxamides that
provided better stability and apparent solubility.79 The apparent solubility of benzoic
acid cocrystal was about 10 times higher than that of the free drug (21 µg/mL vs. 2
µg/mL). Cocrystals of itraconazole with fumaric and succinic acid generated 4 to 20-fold
higher supersaturation as compared to crystalline itraconazole.80
Prodrugs have been used to enhance bioavailability through higher solubility,
dissolution rate or both.64 For example, a water soluble prodrug of carbamazepine, Nglycylcarbamazepine, provided higher oral bioavailability as compared to carbamazepine.
It was determined that the prodrug was a peptidase substrate and rapidly cleaved to
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carbamazepine in vivo. A phosphate ester prodrug of phenytoin, fosphenytoin, provided
improved oral bioavailability over the parent drug.
The other higher energy forms of drugs that are used in SDDS are amorphous
forms, solvates, metastable polymorphs, and nanocrystals.

The amorphous form of

atorvastatin calcium provided >3-fold higher apparent solubility than the equilibrium
solubility of crystalline atorvastatin.63 While the supersaturated concentration decreased
from 460 to 200 μg/mL in 24 hours, an approximately 2-fold degree of supersaturation
was maintained for about 3 hours. The generation of supersaturation was attributed to a
very high dissolution rate of the amorphous atorvastatin. A significant increase in the
dissolution rate and apparent solubility of amorphous atorvastatin resulted in ~3-fold
higher oral bioavailability in rats.63

Nanocrystals of a crystalline drug, due to the

significant reduction of particle size to sub-micron ranges, not only enhance the
dissolution rate of drug but also increase the apparent solubility of drug as predicted by
the Ostwald-Freundlich or Kelvin equation.24 The main limitation of the SDDS based on
the modification of physicochemical properties is its inability to maintain supersaturation
for a prolonged period of time, which could lead to drug precipitation and, in turn, lower
and highly variable bioavailability. The sub-optimal bioavailability with respect to the
requirements of clinical research and development programs could terminate the
development of new drug candidates that are pharmacologically active for some of the
most unmet needs of patients including cancer, heart diseases, and AIDS.
1.3 Impact of SDDS on Bioavailability
A significant issue with the oral bioavailability of poorly water soluble drugs is
that the conditions in the GI tract including pH, amount of bile surfactant, and permeation
20

rate vary significantly based on the location in the GI tract. Due to the continuous
changes in the local GI microenvironment and a high patient to patient variability in the
local GI conditions, the aqueous solubility of poorly water soluble drugs in the GI tract
could vary by several orders of magnitude. This may result in local supersaturation and
rapid precipitation of solubilized/dissolving drug, which can lead to high variability in
oral bioavailability of poorly water soluble compounds. For example, weakly basic
drugs, due to their inherent pH-solubility profiles, are susceptible to significant
precipitation when they transit from the low pH environment of the stomach to a high pH
environment of the small intestine.
The benefits of supersaturation on the enhancement of in vitro drug transport
across membranes81,82 as well as in vivo drug absorption from the GI tract6,83,84 are well
documented in the scientific literature. Oral administration of SDDS could provide
higher drug concentrations in the GI tract than the equilibrium solubility of drug. If the
higher luminal concentration or supersaturation of drug is maintained during the GI
absorption phase, it could lead to higher oral absorption and, in turn, higher oral
bioavailability of poorly water soluble drugs.2,3,5,84 However, it should be noted that, in
addition to the higher drug concentration in the GI tract, oral bioavailability depends on
other absorption, distribution, metabolism, and excretion (ADME) related factors such as
efflux transporters, and gut wall metabolism. The beneficial effect of SDDS on oral
bioavailability is only realized when oral bioavailability is mainly governed by the drug
concentration gradient in the GI tract.85 In such cases, the relationship between the drug
concentration gradient and its absorption through the GI tract could be characterized by
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Fick’s First law. According to this law, the permeability of drug (P) and the drug
concentration gradient contribute to the flux of drug through the GI membrane.1
𝐽 = 𝑃𝐴(𝐶𝑔 − 𝐶𝑏 )

(2.1)

where Cg and Cb are the concentrations of drug in the GI lumen and in the intestinal
capillaries, respectively, and A is surface area. As shown in Eq. 2.1, the maintenance of
supersaturation could be advantageous for drugs with the solubility-limited absorption
(i.e., BCS Class II drugs). Moreover, the maintenance of supersaturation could help in
enhancing the flux across the GI membrane when permeability is low.85 The required
degree of supersaturation to provide higher absorption could be estimated using the
maximum absorbable dose (MAD) calculation:86,87
𝑀𝐴𝐷 = 𝑆 × 𝑘𝑎𝑏𝑠 × 𝑆𝐼𝑊𝑉 × 𝑆𝐼𝑇𝑇

(2.2)

where S is the solubility of drug at pH 6.5 (i.e., simulating drug solubility in the small
intestine), kabs is the intestinal absorption rate constant, which is related to permeability,
SIWV is the small intestinal water volume, assumed to be ~250 mL, and SITT is the small
intestinal transit time, assumed to be ~270 min or ~4.5 hours. Hence, from Eq. 2.2 and
the clinical dose of a drug candidate, the required intestinal concentration/solubility of
drug for maximum adsorption could be estimated. If the dose is low and permeability is
high, the required intestinal solubility would be relatively low. However, drugs with high
dose and low permeability would require higher intestinal solubility.85
Achieving a high degree of supersaturation from SDDS may not be sufficient to
get higher oral bioavailability unless the degree of supersaturation is maintained through
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the absorption window.88 While the natural surfactants present in the intestinal milieu,
food effects may be beneficial in prolonging supersaturation,89 PIs play an important role
in the maintenance of supersaturation. Since a majority of the Physical-Form SDDS
could not maintain supersaturation, they are generally accompanied with PIs.
Approximately 10-fold higher supersaturation generated by the sodium salt celecoxib, an
anti-inflammatory poorly water soluble drug, was maintained for about 30 minutes using
PIs such as HPC and TPGS or Pluronic F127, which resulted in higher oral
bioavailability as compared the commercial drug product containing a free acid form
(>90 vs. 30% bioavailability).56

A cocrystal of AMG 517, a vanilloid receptor 1

antagonist, with sorbic acid when formulated as a suspension using 10% (w/v) Pluronic
F108® in OraPlus® provided greater exposures in rats at a 30 mg/kg dose, which was
comparable to the exposures achieved using 500 mg/g of a free base form of the drug.62
A 20-fold greater exposure in rhesus monkeys was observed with the tartaric acid
cocrystal of a phosphodiesterase-IV inhibitor, L-883555, as compared to a free base form
of the drug.90 The ASD of itraconazole with Eudragit E100 or Eudragit E100-PVPVA64
showed faster and higher in-vitro dissolution as compared to itraconazole ASD with
HPMC, however the ASD with HPMC provided higher oral bioavailability as compared
to the ASD Eudragit E100 or Eudragit E100-PVPVA64 due to the longer supersaturation
maintenance provided by the HPMC-based ASD.88 Dai et al.2 observed that lower
bioavailability was obtained using formulations with less precipitation resistance as
compared the formulations with high precipitation resistance. Some of the SDDS that
contain PIs (e.g., ASD, and lipid-based SDDS) are specifically designed to maintain drug
supersaturation in the GI tract and, in turn, provide higher and less variable oral
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bioavailability of poorly water soluble drugs. A more comprehensive discussion on the
maintenance of supersaturation by PIs could be found in Section 3 of this chapter.
The relationship between the maintenance of supersaturation by various
Formulation-SDDS and its impact on oral bioavailability has been explored in recent
studies.

Recent studies on lipid-based SDDS have shown that the generation and

maintenance of drug supersaturation in the GI tract by lipid-based SDDS is more critical
for higher and less variable oral bioavailability than the enhancement of the solubilization
capacity of the GI fluids by lipid-based SDD as viewed historically.5,8,73 The generation
of supersaturation from lipid-based SDDS could be due to: (1) the dilution/dispersion of
highly concentrated lipid-based SDDS in the GI fluids, (2) the digestion of lipidic
components such as glyceride lipids and fatty acid ester surfactants in the GI tract, (3) the
micellar transformation of lipid-rich colloids by bile, and (4) lipid depletion from the
micelles by fatty acid absorption.8,71,73 The digestion of lipidic components changes the
solubilization capacity of colloids that are formed after the dilution/dispersion of lipidbased SDDS in the GI tract, which generates supersaturation.71 The lower solubilization
capacity of digested colloids is attributed to the increased water solubility of the digested
lipidic components. Moreover, the lipid-rich, large, liquid crystalline structures that are
formed after the dilution and digestion of lipid-based SDDS in the GI tract are converted
to smaller, bile-rich mixed-micelles and micellar colloids that further reduce the
solubilization capacity and therefore assists in generation of supersaturation.73

The

solubilization capacity of the micellar colloids is further reduced at the intestinal wall
where the adsorption of fatty acid from the micellar colloids occurs.73 As mentioned
earlier, the Formulation-SDDS including lipid-based SDDS are formulated with PIs such
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as polymers and surfactants to maintain drug supersaturation for a prolonged period of
time, which allows the maximum utilization of the higher thermodynamic activity of drug
for its maximum absorption. In other words, the success of SDDS in promoting higher
and less variable oral bioavailability of poorly water soluble drugs has often been
attributed to the generation and stabilization of supersaturated solutions in the GI tract.1
The knowledge of fundamental relationships between the mechanisms of crystallization
(i.e., nucleation and crystal growth) and the variables that govern the rate of
crystallization including pH, temperature, agitation, and the number of active growth sites
on the growing surface would be essential for understanding the effects of PIs on the
crystallization rate and, in turn, on the maintenance of supersaturation.
2.

Supersaturation and Drug Precipitation
Drug supersaturation could exist in liquid as well as solid systems. For example,

the supersaturation in solid systems such as ASD can be attributed to higher drug loading
than the equilibrium solubility of drug in ASD.53 The example of supersaturation in
liquid systems includes aqueous supersaturated solutions that could be produced in vivo
or in vitro after the dissolution/dispersion of SDDS.91 The liquid-state supersaturation is
generally produced due to the higher apparent solubility of drug in liquid media, which
could be attributed to PIs, higher energy drug forms, or both in the SDDS.
The supersaturated state is inherently thermodynamically unstable, which leads to
precipitation until an equilibrium state is achieved.92 Supersaturation, the thermodynamic
driving force for precipitation or crystallization, is the difference between the chemical
potentials of drug in solid phase as well as in solution phase.24 The chemical potentials
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of drug in the supersaturated solution state (µsupersaturated) and the saturated solid phase
(µsaturated) may be defined in terms of the standard potential, µ0, by24

µsup ersaturated = µ 0 + RT ln asup ersaturated

(2.3)

µ saturated = µ0 + RT ln asaturated

(2.4)

where asupersaturated and asaturated are the activities of drug in the supersaturated solution
state and the saturated solid state, respectively, R is the gas constant, and T is the absolute
temperature. The fundamental driving force for crystallization can be described as24
 asup ersaturated
∆µ = µsup ersaturated − µ saturated = RT ln
 asaturated

C

γ
 = RT ln sup ersaturated sup ersat

 γ saturated C saturated


 = RT ln S


(2.5)
where γsupersaturated and γsaturated are the activity coefficients of drug in the supersaturated
solution state and the saturated solid state, respectively, Csupersaturated and Csaturated are the
concentrations of drug in the supersaturated solution state and the saturated solid state
(i.e., equilibrium solubility), respectively, and S is the ratio-based degree of
supersaturation.

For practical purposes, it is assumed that the ratio of activity

coefficients, γsupersaturated/γsaturated, is unity.93

Hence, the ratio-based degree of

supersaturation (S) is most commonly expressed as
 Csup ersat
S = 
 C saturated
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(2.6)

Another commonly used expression for the degree of supersaturation, also defined as
relative supersaturation (σ), is25
 Csup ersat − C saturated
C saturated


σ = S − 1 = 





(2.7)

The drug crystallization process could be divided into several zones.24,93 The
stable zone is the area where drug concentration is either equal or below the equilibrium
solubility of drug. The crystallization of drug is impossible when the drug concentration
is in this zone. The zone above the stable zone can be termed as metastable zone. In this
zone, spontaneous crystallization is probable. Crystal growth occurs when the metastable
system is seeded with drug crystals. The top zone is defined as labile zone, where
spontaneous crystallization is probable, however it is not inevitable. Precipitation or
crystallization could be divided in two steps: (1) nucleation, and (2) crystal growth
(Figure 2.1). In nucleation, a new phase is separated by the birth of new nuclei or
crystals, whereas in crystal growth, the new nuclei or crystals grow in size. While the
maintenance of supersaturation could be achieved by inhibiting drug precipitation in the
presence of PIs, the abilities of PIs to prolong supersaturation of poorly water soluble
drugs could be linked to their effects on nucleation and/or crystal growth of drugs.4,20
Therefore, a quantitative and mechanistic understanding of the nucleation and crystal
growth of drugs is needed to effectively utilize PIs in maintaining the supersaturation of
drugs.
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Figure 2.1.

Schematic diagram illustrating the change in free energy during
94

crystallization.
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2.1 Nucleation
The nucleation process consists of the formation of stable nuclei, which are also
known as critical nuclei.93,95,96 The mechanism of nucleation can be divided into two
classes: 1) primary nucleation, and 2) secondary nucleation. Primary nucleation can
further be classified into homogeneous and heterogeneous nucleation (Figure 2.2).92
Homogenous nucleation occurs in clear solution and, generally, the free energy barrier is
significantly higher to create a new solid phase. In the case of heterogeneous nucleation,
the presence of a foreign substance or an impurity lowers the free energy barrier for
nucleation. In supersaturated solutions, weak aggregates or clusters of drug molecules
smaller than a critical size are unstable and redissolve. According to the classical theory
of nucleation, stable aggregates, also known as critical nuclei, are formed when the size
of the aggregates reaches a critical radius and the free energy barrier for the formation of
critical nuclei is overcome.92 The nucleation rate (J) which describes the number of
critical nuclei formed per unit time and volume of the bulk can be expressed as
−∆𝐺𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙

𝐽 = 𝐴𝑒𝑥𝑝 �

𝑘𝑇

�

(2.8)

where A is the pre-exponential factor, ΔGcritical is the free energy change for the formation
of stable nuclei, k is the Boltzmann’s constant, and T is the absolute temperature.24 In the
case of homogeneous nucleation, according to the classical theory of nucleation, the free
energy change for the formation of new phase is equal to the sum of free energy change
for the formation of new surface (i.e., surface excess free energy, ΔGsurface) and the free
energy change for the phase transformation into a very large particle, as known as the
volume excess free energy (ΔGvolume).24 Hence,
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∆𝐺 = ∆𝐺𝑠𝑢𝑟𝑓𝑎𝑐𝑒 + ∆𝐺𝑣𝑜𝑙𝑢𝑚𝑒 = 𝛽𝐿2 𝛾 + 𝛼𝐿3 ∆𝐺𝑣

(2.9)

where β and α are the area and volume shape factors, respectively, L is the characteristic
length, γ is the surface tension, and ΔGv is the free energy change of the phase
transformation per unit volume. For spherical nuclei, the critical radius (rcritical) can be
determined by setting dΔG/dr = 0:24
𝑑∆𝐺
𝑑𝑟

2
= 8𝜋𝑟𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙 𝛾 + 4𝜋𝑟𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙
∆𝐺𝑣 = 0
2𝛾

𝑟𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙 = − ∆𝐺

(2.10)

(2.11)

𝑣

From substituting for ΔGv

∆𝐺𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙 =

2
4𝜋𝑟𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙
𝛾

3

(2.12)

The growth of the critical nuclei is described by the Gibbs-Thompson relationship24
𝑙𝑛 𝑆 =

2𝛾𝜗

𝑘𝑇𝑟𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙

(2.13)

where υ is the molecular volume. Now substituting for rcritical
∆𝐺𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙 =

16𝜋𝛾3 𝜗 2

3(𝑘𝑇𝑙𝑛𝑆)2

(2.14)

Finally, the nucleation rate (J) can be expressed as24
−16𝜋𝛾3 𝜗2

𝐽 = 𝐴 𝑒𝑥𝑝 �3𝑘 3 𝑇 3 (𝑙𝑛𝑆)2 �
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(2.15)

It can be seen from Eq. 2.15 that temperature (T), degree of supersaturation (S) and
surface tension (σ) are three primary variables that govern the rate of nucleation. The rate
of homogeneous nucleation is difficult to measure experimentally as it is practically
impossible to minimize internal and foreign impurities and particles as well as inert
surfaces such as the walls of an apparatus, stirrers, and baffles.93 While heterogeneous
nucleation occurs due to the presence of foreign substances in supersaturated solution, the
presence of crystals in supersaturated solution causes secondary nucleation.92 The parent
crystals may provide a catalytic effect resulting in a nucleation event at lower degrees of
supersaturation than required for spontaneous homogeneous nucleation.93 Heterogeneous
nucleation and secondary nucleation may be more relevant from a biopharmaceutical
perspective than homogeneous nucleation as the supersaturated solution of drug would
encounter several different surfaces including gut wall, food particles, and undissolved
drug and excipient particles in the GI tract.
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2.2 Crystal Growth
Crystal growth process is a multistep process involving different mechanisms
(Figure 2.3). Several models including the diffusion-reaction (two-step) model, screw
dislocation (spiral growth) or Burton, Cabrera and Frank (BCF) model, and the surface
nucleation (Birth & Spread) model have been used to study the process of crystal
growth.24,25,93,97-103 Some of the above-mentioned models are described below:
a)

Diffusion-reaction model:
According to the diffusion-reaction theory, the major steps in the crystal growth

process are: (1) the diffusion step where solute diffuses from bulk solution to the
crystal/solution interface, and (2) the surface integration or surface reaction step where
solute integrates into the crystal lattice.24,92 The diffusion-reaction theory assumes that the
two major steps of the crystal growth process occur in series.24,26,92,93,101 Each step can be
described by the equation shown below24:
Diffusion step:
𝐴

𝑑𝑐

− 𝑑𝑡 = 𝑘𝑑 𝑉 (𝑐𝑏 − 𝑐𝑖 )
𝑏

(2.16)

where kd is the coefficient of mass transfer by diffusion, A/Vb is the surface area of
crystals per unit volume, cb is the solute concentration in bulk, and ci is the solute
concentration in solution at the crystal-solution interface
Surface Integration step:
−

𝑑𝑐𝑖
𝑑𝑡

𝐴

= 𝑘𝑟 𝑉 (𝑐𝑖 − 𝑐𝑠 )𝑟
𝑏

33

(2.17)

where kr is the rate coefficient for the surface reaction (integration) process, cs is the
solute concentration in solution at equilibrium (i.e., the saturation solubility), and r is the
order of the surface integration process. The driving force for the first step (i.e., bulk
diffusion) is determined from the difference between the solute concentration in the bulk
medium and the solute concentration in solution at the crystal-solution interface (ci). The
surface integration rate is a function of the driving force defined as the difference
between ci and the solute concentration at the solid surface (i.e., the saturation solubility).
Since ci is generally not obtainable experimentally, a simplified empirical crystal growth
model is often employed that assumes the overall driving force to be equal to the
difference between the bulk concentration and the equilibrium solubility.24,104
−

𝑑𝑐𝑏
𝑑𝑡

𝐴

= 𝑘𝐺 𝑉 (𝑐𝑏 − 𝑐𝑠 ) 𝑔
𝑏

(2.18)

where kG is an apparent crystal growth rate coefficient, and g is the apparent order of the
crystal growth process. When kd « kr, the crystal growth kinetics are bulk diffusion ratelimited and kG = kd, whereas when kr « kd, the crystal growth kinetics are surface
integration (or reaction) rate-limited and kG = kr.
The surface integration process could be divided into several sub-steps.26
Desolvation of solute occurs at the solid-liquid interface followed by the adsorption of
solute on the growing crystal surface.9 The adsorbed solute molecules diffuse on the
crystal surface until active growth sites such as defects, kinks, or steps are encountered
and solute molecules are incorporated into the lattice.101 Rapid and continuous crystal
growth continues until all active growth sites are occupied and a molecularly smooth
crystal surface is created.24 The crystal growth rates from molecularly smooth surfaces
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are slow, which require two-dimensional nucleation to occur on the smooth surface.96
Alternatively, crystal growth could occur through the spiral growth mechanism where
screw dislocations are formed that allow continuous and faster crystal growth.25 This
process does not lead to the formation of molecularly smooth crystal surfaces upon
crystal growth which, in turn, provides continuous crystal growth without the need for
two-dimensional nucleation.9
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Figure 2.3. Schematic diagram illustrating the two major steps (bulk diffusion and
surface integration) of a crystal growth process.
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b)

Screw Dislocation or Burton, Cabrera and Frank (BCF) Model:
The Burton, Cabrera and Frank (BCF) model is derived from the adsorption layer

theories.24,93,99,101 According to the adsorption layer theories, when solute molecules
arrive at the crystal surface they are not integrated into the crystal lattice instantaneously.
Rather they lose one degree of freedom and freely migrate over the crystal surface until
they find active centers such as a kink or dislocation for the reaction. This process is
known as surface diffusion that creates a loosely adsorbed layer of solute molecules
waiting for integration.101 In the BCF model, it is assumed that the integration occurs at a
site of dislocation (i.e., imperfection).105 One of the important types of dislocations is the
screw dislocation, which renders crystals growth in a spiral fashion (spiral growth). The
curvature of a spiral can reach a maximum value determined by the critical radius for a
two-dimensional nucleus. The BCF model can be expressed as:24,26,99
𝑅 = 𝐴𝜎 2 𝑡𝑎𝑛ℎ�𝐵�𝜎 �

(2.19)

where R is the crystal growth rate, σ is the degree of supersaturation, and A and B are
system related parameters defined as:24,26,99
𝐴=

2𝑘𝑇𝐷𝑠 𝐶𝑆𝐸 𝛽𝛾0

(2.20)

𝐵=

19𝑉𝑚 𝛾𝑠𝑙

(2.21)

19𝛾𝑠𝑙 𝑥𝑠

2𝑘𝑇𝑥𝑠

where k is the Boltzmann constant, T is temperature (°K), Ds is the solute diffusion
coefficient on the crystal surface (m2s-1), CSE is the equilibrium surface concentration of
the solute when σ=1 (i.e., saturation solubility), β is the retardation factor for a linear
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step, γ0 is the retardation factor for a kink, γsl is the interfacial energy between solid and
liquid (Jm-2), xs is the mean diffusion distance on the surface, and Vm is the volume of
solute molecule (m3).
c)

Birth & Spread Model:
The Birth and Spread model is based on the two-dimensional crystal surface

nucleation process, which is followed by the spread of the newly formed nuclei or
layer.24,93,101,105 This mechanism is invoked when the crystal growth process requires a
birth of nuclei on the crystal surface for its continuation. The model can be expressed by
the equations shown below:24,26,92,103
𝑅 = 𝐸𝜎 5/6 𝑒𝑥𝑝�𝐹�𝜎�
5/6

(2.22)

𝑣� 1/3 𝑛1 𝐷𝑠 𝐶𝑆𝐸 𝛽𝛾0 2/3

𝐸 = 2ℎ1/6 𝑉𝑚 �𝜋�
𝐹=

�

𝑥𝑠

�

2
𝜋ℎ𝑉𝑚 𝛾𝑠𝑙

𝑘2𝑇2

(2.23)

(2.24)

where R is the crystal growth rate, E and F are the system related constants, h is the step
height or lattice spacing, 𝑣̅ is the mean rate of adsorption of molecules on the surface, and
n1 is the equilibrium number of monomers on the surface of crystal per unit area.
2.3 Techniques to characterize supersaturation
Unlike routinely executed crystallization studies that require relatively low
supersaturation to precisely control and monitor growth rates during the manufacturing of
active pharmaceutical ingredients, very high supersaturation (10 to 1000-fold of
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equilibrium

solubility)

could

be

encountered

during

in-vitro

and

in-vivo

dissolution/dispersion of SDDS. At these high degrees of supersaturation, nucleation
kinetics is instantaneous and very difficult to monitor. Quantitative and mechanistic
explorations of drug precipitation (i.e., nucleation and crystal growth) in aqueous systems
have, in general, suffered due to a lack of simple and robust experimental techniques.
Undoubtedly, understanding the effect of excipients on drug precipitation kinetics
requires quantitative models describing both nucleation and crystal growth. In order to
understand the mechanisms involved in the PI mediated supersaturation maintenance, it
would be essential to measure the precipitation kinetics of drugs. Current methods to
study precipitation kinetics involve the monitoring of concentration remaining in solution
by filtration of precipitated solid at various time points and subsequently measuring
solution concentration. In such off-line analysis, the crystal growth process continues
while the solvent is being removed during separation, sometimes, rendering the crystal
surface with high degree of imperfections. This can significantly impact the downstream
analysis with other instruments. 93
Several approaches have been described in the crystal growth literature for the
measurement of crystal growth including: (1) using a single crystal vs. a population of
crystals, (2) monitoring the change in the properties of crystals (i.e., mass or size) vs. a
change in the properties of solution (i.e., solution concentration), and (3) varying growth
conditions (e.g., isothermal vs. non-isothermal).93 Each approach has its own advantages
and limitations. For example, the single crystal measurement technique is advantageous
in terms of measuring the growth rate of a specific crystal face of interest. However, it
poses limitations owing to the availability of a very small surface area as compared to a
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multiparticulate system. These limitations include higher sensitivity to the presence of
impurities (even at very low concentrations) as well as to the primary nucleation at higher
degrees of supersaturation. For our proposed studies, we have selected the
multiparticulate (population of crystals) method, which is also known as batch
crystallization. The advantages of this method are: (1) relevance to the GI conditions in
terms of maintaining supersaturation after primary nucleation, (2) simple technique, and
(3) less sensitive to small differences in crystal shapes or different number of
dislocations. The limitation of this method is that it gives an average of crystal growth
rates from individual faces of the crystal.93 Since the crystal growth rate is directly
proportional to the surface area, precise control over the seed number and size
distribution is critical to control the available surface area for the crystal growth.
Moreover, to provide a constant surface area for growth, it is important to maintain the
seed number and size distribution during the crystal growth experiment. The effect of
mixing using a magnetic stir on the seed number and size distribution could be
determined using particle size measurement techniques. Besides the direct measurement
of supersaturation from solution concentrations, the supersaturation can be measured
indirectly by measuring properties such as refractive index and density. However, such
methods require carefully controlled conditions in the laboratory.24

The growth of

precipitate in terms of particle size and shape has also been monitored by microscopy.
However, such methods cannot be used to monitor rapid kinetics at high supersaturation.
3.

Maintenance of Supersaturation and Precipitation Inhibitors
In order to achieve higher bioavailability and reduce inter-patient variability from

SDDSs, it is essential to maintain the supersaturation of drug by inhibiting precipitation
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(i.e., nucleation and/or crystal growth) using precipitation inhibitors (PIs).1,8
Pharmaceutical

excipients

including

cyclodextrins,

polyvinylpyrrolidone

(PVP),

hydroxypropyl methylcellulose (HPMC), polyethylene glycol (PEG), and their
derivatives (e.g., PVP-VA, HPMC-AS, TPGS, Cremophor RH 40, polysorbate 80) that
maintain the supersaturation of drug in solid and/or liquid dispersions have been
incorporated in various SDDSs as PIs.2,9,10,12,13,15,18,42,106,107 Recent studies, as discussed
in an earlier section, have clearly shown the impact of precipitation inhibitors on the
enhancement of oral bioavailability of poorly water soluble drug through the maintenance
of supersaturation.1-6,9,108
A majority of the precipitation inhibitors are polymeric in nature and hence could
be defined as polymeric precipitation inhibitors (PPIs).9 One of the most commonly used
non-polymeric PIs is cyclodextrin.46 The PPIs can be further classified as surface active
PPIs and non-surface active PPIs (Figure 2.4). Some of the surface active PPIs include
PEG, TPGS, Poloxamer, Pluronic F127, Cremophor EL, PG, and Carbomer. The surface
active PPIs, depending on the concentration above the critical micellar concentration,
could enhance the equilibrium solubility of drugs.

Hence, both the supersaturation

maintenance as well as the high equilibrium solubility provided by the surface-active
PPIs could enhance the bioavailability of poorly water soluble drugs.1
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Figure 2.4. Classification of precipitation inhibitors (PIs).
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The non-surface active PPIs can be further divided into two groups: 1) cellulosic
PPIs and 2) non-cellulosic PPIs (Figure 2.4). PVP, PVP-VA, PVA, PAA, and Eudragit
are some examples of the non-cellulosic PPIs.

PVP and its derivatives have been

successfully used to inhibit the precipitation of drugs in supersaturated solid as well as
liquid dispersions. PVP is commonly used as a dispersant for several chemical entities
such as drugs, dyes, and pesticides due to its amphiphilic nature. This property of PVP
could be attributed to its structural features including the highly polar amide group and
apolar methylene and methine groups. Due to the amphiphilic nature, PVP is soluble in
water and several other non-aqueous solvents.

The Eudragits are anionic polymers

containing methacrylic acid groups. They are copolymers of methacrylic acid and acrylic
acid derivatives. The cellulosic PPIs include HPMC, HPMC-AS, HPC, CMC, MC,
cellulose, acetate phthalate, alginic acid, HEC, NaCMC, and gum Arabic. The selection
of PPIs in the development of drug product not only depends on the properties of drug
but also depends on the properties of PPIs as well as the type of SDDS.9 For example,
PPIs with high glass transition temperatures including HPMC, PVP, and their derivatives
are commonly used in solid dispersions, whereas PPIs with low melting points such as
vitamin E TPGS and Cremophor RH40 are frequently used in lipid-based drug delivery
systems.
The inhibition of nucleation and crystal growth due to impurities and additives
has been studied extensively for non-pharmaceutical systems, especially for inorganic
salts.37,109-116

The

inhibitory

effects

of

1,2-dihydroxy-1,2-

bis(dihydroxyphosphonyl)ethane and Zn on the crystal growth of hydroxyapatite were
attributed to adsorption and, in turn, blocking of active growth sites on the hydroxyapatite
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seed crystals. The inhibitory effect of additives on crystal growth has been successfully
exploited to engineer crystals with a desired shape117-119 (crystal habit) and size.37,119 In
the case of pharmaceutical systems, several studies have been carried out to determine the
effect of PPIs on the precipitation of drugs.2,7,11,12,17,18,20,21,43,46,120-122 Some studies have
been aimed at understanding the effects of PIs on the growth of a specific crystal face, the
change in the crystal lattice energy, or the modification of the crystal habit of drugs.11,123
These PPIs are believed to be maintaining drug supersaturation by changing nucleation,
crystal growth, or both.108 As illustrated in Figure 2.5, the typical shape of the drug
concentration vs. time profile observed during the crystallization of drug in the presence
of PPIs depends on the mechanism of precipitation inhibition. For example, if a PPI
significantly inhibits nucleation then the supersaturated drug concentration is maintained
for a prolonged period of time followed by a decline in concentration due to the
nucleation and crystal growth of drug. However, if a PPI is selectively inhibiting crystal
growth then a significant drop in drug concentration is observed initially due to
nucleation followed by a slow decline in concentration due to the inhibition of crystal
growth.
Recent studies have shown that the inhibitory effects of PPIs on nucleation,
crystal growth, or both vary significantly from drug molecule to drug molecule. Ozaki et
al.108 showed that, unlike Eudragit, HPMC and PVP significantly inhibited the nucleation
and crystal growth of griseofulvin and danazol. While HPMC was a more effective
nucleation inhibitor of griseofulvin, it significantly inhibited the nucleation and crystal
growth of danazol. Lindfors et al.20 observed that PVP was a better crystal growth
inhibitor than a nucleation inhibitor of bicalutamide. Vandecruys et al.43 observed that
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PPIs such as PVP & HPMC were more effective at prolonging supersaturation than
providing higher degrees of supersaturation, whereas the PPIs such as surfactants and
cyclodextrins provided higher degrees of supersaturation. These observations clearly
indicate that the inhibition of nucleation and crystal growth of drugs by PPIs is complex,
involving multiple mechanisms that could vary depending on the drug-PPI combination.
The effects of PPIs on the inhibition of nucleation are mainly associated with the
interactions of PPIs with drug molecules in the bulk solution.13-16 For example, the
effectiveness of PPIs in inhibiting the formation of carbamazepine dihydrate was related
to the intermolecular hydrogen bonding and hydrophobic interactions between PPIs and
carbamazepine. However, their relative impact on the effectiveness of a given PPI could
not be determined due to experimental limitations.14 The superiority of HPMC-AS HF
over HPMC-AS LF, two different grades of HPMC-AS containing different ratios of
acetate and succinate substituents, in inhibiting the precipitation of carbamazepine from
supersaturated aqueous solutions was attributed to stronger hydrophobic interactions
between HPMC-AS HF and carbamazepine in the bulk solution.13 Similarly, the
inhibitory effects of cellulosic PPIs on the nucleation of three model drugs, celecoxib,
efavirenz, and ritonavir, from supersaturated aqueous solutions correlated well with the
hydrophobicity of the cellulosic PPI relative to that of the model drugs.15
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Figure 2.5. Schematic diagram illustrating desupersaturation profiles in the presence of
PPIs as nucleation or crystal growth inhibitors.
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The inhibitory effects of PPIs on the crystal growth of a drug have been
associated with the adsorption of PPIs on the growing crystal surface.4,12,17-24 The
adsorption of polymers9 or impurities124 on the growing crystal surface has been linked to
their crystal growth inhibitory effects. The inhibitory effect of PVP on the crystal growth
of bicalutamide was attributed to the adsorption of PVP onto bicalutamide crystals.20 The
habit modification of hydrocortisone acetate crystal by HPMC was attributed to the
preferential adsorption of HPMC to the crystal faces.12 It has been proposed that the
adsorbed polymer could inhibit crystal growth by blocking the active growth site,
increasing the diffusive barrier at the solid-liquid interface, or both.12,21 Raghavan et al.12
proposed that the inhibition of hydrocortisone acetate crystal growth by HPMC could be
attributed to: (1) an increase in the diffusional barrier in the hydrodynamic boundary
layer by HPMC, and (2) the adsorption of HPMC on the growing crystal surface. The
inhibition of the crystal growth of sulfathiazole by PVP was attributed to the formation of
a possible net like structure on the crystal surface by the adsorbed PVP. It was proposed
that the pore size of the net like structure would be smaller when the relative transport
rate of PVP to sulfathiazole is higher, which in turn would provide greater inhibition of
the crystal growth.18
The adsorption of PPIs on the growing surface could be attributed to the
intermolecular interactions such as hydrogen bonding, and hydrophobic interactions
between the PPI and surface.4,10-12 Raghavan et al12 proposed that the stronger inhibitory
effects of HPMC as compared to PVP and PEG 400 on the crystal growth of
hydrocortisone acetate may be attributed to hydrogen bonding interactions between
HPMC and the drug. Moreover, the extent of HPMC adsorption was correlated with the
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hydrogen bonding capacity of different faces of the HA crystal.12 Ilevbare et al.22 found
that cellulosic polymers with moderate levels of hydrophobicity, semi-rigid structure, and
amphiphilic nature were more effective crystal growth inhibitors of a highly lipophilic
and poorly water soluble drug, ritonavir, in aqueous suspensions. It was proposed that
these properties of PPIs could likely promote adsorption onto the crystal surface of
ritonavir.10 Gao et al.4 observed that HPMC was a better PPI than PVP for AMG 517, a
poorly water soluble drug candidate, which was attributed to the greater hydrophobicity
of HPMC than that of PVP. Tian et al.14 observed that both the hydrogen bonding and
hydrophobicity of PPIs were important for the inhibition of the form conversion of
carbamazepine anhydrous to carbamazepine dihydrate. However, a complete inhibition
of carbamazepine dehydrate formation was achieved only with more hydrophobic
polymers such as HPMC, methylcellulose (MC), and hydroxypropyl cellulose (HPC) and
not with less hydrophobic polymers such as HEC indicating that hydrogen bonding
interactions between the drug and polymers did not play a significant role here as all the
above-mentioned polymers had a similar cellulosic backbone.
The mobility of the functional group of PPIs involved in the interaction with the
surface and, in turn, the adsorption process also affects the precipitation inhibitory effects
of PPIs.19,125 The crystal growth inhibitory effects of PPIs have been associated with the
molecular weight and chain length of PPIs as both PPI properties could influence the
ability of PPI to make greater number of contacts with the crystalline surface and, in turn,
reduce the mobility of the adsorbed PPI.9,107,125 Unlike PVA and PEG, the stronger
crystallization inhibitory effect of PVP for acetaminophen was attributed to the lower
flexibility of PVP chains as compared to PVA and PEG chains.19 In a molecular
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dynamics simulation study, the superior inhibitory effect of PVP as compared to HPMC
on the crystal growth of salbutamol sulfate was attributed to the higher interaction energy
and greater number of contacts with the salbutamol sulfate crystal by PVP as compared to
HPMC, which in turn reduced the movement of PVP chains.125 Gift et al.107 determined
that, unlike hydroxyl group containing small molecules such as glycerol, glucose, adipic
acid, and methanol, only polymers such as PVA and PAA were able to inhibit the
precipitation of caffeine indicating that the hydrogen bond formation was not enough to
inhibit caffeine precipitation. The inhibitory effect of PPI on caffeine precipitation was
greater at higher molecular weights of PPI, which was attributed to probably a greater
number of hydrogen bonding interactions provided by higher molecular weight PPIs.
While a few recent studies1,20,43 have attempted to discern the mechanism of
action for PPIs, the supersaturation maintenance effects of PPIs are still not well
understood due in part to a paucity of systematic and quantitative explorations.104,108
Most of the existing literature studies on the inhibition of drug precipitation are of
screening types where the PPIs are rank ordered based on their inhibitory
effects.2,17,43,46,122 The proposed mechanisms of PPI effects including the adsorption of
PPI on the growing crystal surface are rarely correlated with the sub-processes of drug
precipitation (i.e., nucleation and crystal growth) and their specific mechanisms such as
bulk diffusion or surface integration.

Specifically, the mechanism of the inhibitory

effects of PPIs on drug crystal growth is seldom proven directly and/or correlated with
the adsorption of PPIs in a quantitative manner. Consequently, the nature of the adsorbed
PPI layer as well as the key physicochemical properties of PPIs and drugs such as
molecular weight, hydrogen bonding capability and hydrophobicity that could influence
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the adsorbed PPI layer and, in turn, the effectiveness of PPI are not well understood. A
thorough understanding of the correlation between the adsorption of a given PPI and its
crystal growth inhibitory effect is still required. The identification of a specific
mechanism such as the blocking of growth sites or the diffusional resistance for drug
molecules underpinning the effectiveness of PPI is absent in many previous studies. The
knowledge of the adsorption behavior of PPIs would help in exploring the mechanisms of
crystal growth inhibition by PPIs. A thorough understanding of how the adsorbed PPIs
inhibit the crystal growth of poorly water soluble drugs would be essential in a rationale
selection of PPIs for the development SDDS.
Finally, the overall lack of thorough understanding of the effects of PIs on drug
supersaturation maintenance makes a priori predictions of their beneficial effects very
challenging. The mechanism by which a given PPI achieves its beneficial effect is
unknown and what combination of properties of the drug and PPI provides an optimal
benefit is unclear. In general, good correlations between the effects of PPIs and the
physico-chemical properties of PPIs as well as drugs have not been established. The
supersaturation maintenance effects of PPIs vary extensively between drug molecules
rendering the development of predictive tools for a rational and efficient PPI selection
process more difficult. There are no reliable quantitative models that would allow a
formulator to predict a priori the most suitable PPIs and the amounts that should be used
for a given dose of a new poorly water soluble drug candidate to achieve the desired
prolongation in supersaturation. It is currently impossible to rapidly select (without
performing screening studies for each drug candidate) suitable PPIs that can inhibit
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precipitation to improve oral absorption and, in turn, oral bioavailability of poorly water
soluble drugs.
4.

Indomethacin, a Model Poorly Water Soluble Drug
Indomethacin is an anti-inflammatory, antipyretic, and analgesic drug.126

Indomethacin was chosen as the model compound in the present study due to its low
intrinsic solubility (~1 µg/mL) and the availability of physical characterization data in the
existing literature.127-129

It is a suitable model compound for the studies aimed at

understanding the abilities of certain excipients or PIs to prolong drug supersaturation
after oral administration of drug products that produce supersaturated solutions in the GI
tract. The physicochemical properties of indomethacin including stability,130,131 physical
forms,126 and solubility132,133 in aqueous solutions have been characterized previously.
Indomethacin decomposes in aqueous solutions by hydrolysis.130 The rate of hydrolysis
is significantly slower at low pH.131
Indomethacin exists in several polymorphic forms including the γ, α, and δ
forms.128,134 The two major polymorphs of indomethacin are the γ and α polymorphs.
The γ-form used in these crystal growth studies is thermodynamically most stable.126 The
metastable α-form of indomethacin has a lower heat of fusion and lower melting point.135
The melting points of γ and α polymorphs are 160°C and 154°C, respectively.127 While it
is metastable, the α-form has remained stable for longer than 18 months at room
temperature.128 The experimental densities of the γ and α polymorphs are 1.38 g/cm3 and
1.40 g/cm3, respectively.134

The unit cell of the α-polymorph consists of three

indomethacin molecules, whereas the unit cell of the γ-polymorph has two molecules
forming a dimer.126

The unit cell of α-polymorph provides more conformational
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arrangements as compared to the same for the γ-polymorph.126 A recent study found that
the amorphous form of indomethacin had lower dissolution rate as compared to the
crystalline γ and α polymorphs, which was in contrast to the thermodynamic
predictions.126 The α polymorph showed the highest rate of dissolution amongst the
amorphous and crystalline γ polymorph.126 Hancock et al.132 reported the solubility of γindomethacin in deionized water at 25ºC as ~5 µg/mL (~1.4 × 10-5 M). Wassvik et al.133
reported an intrinsic solubility of 1.12 ± 0.03 × 10-6 M for γ-indomethacin. The higher
indomethacin solubility reported by Hancock et al. is in accordance with the solubility
enhancement provided by indomethacin ionization at higher pH (>pKa) that would result
from dissolution in deionized water.

Copyright © Dhaval D. Patel 2015
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Chapter Three
Maintenance of supersaturation: 1. Indomethacin crystal growth kinetic Modeling
using an online second derivative UV spectroscopic method
INTRODUCTION
The risk of clinical failure associated with poorly water soluble drug candidates
due to their low and variable oral bioavailability remains a significant concern in current
drug development. For poorly water soluble drugs, oral bioavailability enhancement may
be possible by achieving and maintaining supersaturated drug concentrations in the
gastrointestinal (GI) tract.1-6 Salts,48 cyclodextrin complexes,7,43 lipid-based delivery
systems,4,5,136 high energy amorphous solid dispersions,3 and nanoparticles6,137 are among
the types of strategies that may produce high, supersaturated drug concentrations in the
GI tract facilitated by the local GI environment, which is constantly changing in pH, food
effects, and natural surfactant concentrations.

However, prolonged maintenance of

supersaturation in the GI tract may be difficult to achieve due to the inherent
thermodynamic instability of the supersaturated state, which may lead to precipitation or
crystallization (nucleation and crystal growth) of poorly water soluble drugs and variable,
sub-optimal oral bioavailability.
Formulation excipients can play an important role in maintaining supersaturation
and may provide better control from patient to patient independent of variability in the
local GI environment.

Literature studies have shown that excipients such as

cyclodextrins,7,43 polyethylene glycol (PEG) and PEG containing derivatives,2,4,43 as well
as other polymers such as hydroxypropylmethyl cellulose (HPMC)4,5,12,43,138 and
polyvinylpyrrolidone

(PVP)4,12,18,42,43,138

have

the

potential

to

prolong

drug

supersaturation to varying degrees depending on the properties of the drug and excipient.
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The effectiveness of such excipients in maintaining supersaturation may be attributable to
their ability to inhibit nucleation, crystal growth, or both.
Inhibition of nucleation and crystal growth due to the presence of impurities or
additives has been widely studied for non-pharmaceutical systems,37,110,112,113,115117,119,139,140

especially for inorganic salts,37,110,112,113,115,116 and in some cases the kinetics

and mechanisms of nucleation and crystal growth inhibition have been rationalized. For
example, based on the kinetics observed, the crystal growth of hydroxyapatite was
attributed to a surface controlled spiral growth mechanism.113 The inhibitory effects of
1,2-dihydroxy-1,2-bis(dihydroxyphosphonyl)ethane and Zn on the crystal growth of
hydroxyapatite were attributed to adsorption and, in turn, blocking of active growth sites
on the hydroxyapatite seed crystals. The inhibitory effect of additives on crystal growth
has been successfully exploited to engineer crystals with a desired shape117-119 (crystal
habit) and size.37,119 Effects of additives on polymorphic transformation141,142 and lattice
energy139,143 have also been determined. Several studies have also been carried out to
determine the effects of excipients on drug crystallization.1-6,12,17-20,42,43,138,144

The

inhibitory effect of polymers on drug crystallization has been attributed to their
adsorption on to the crystal surface.12,17-19 Raghavan et al.12 proposed that the inhibition
of hydrocortisone acetate crystal growth by PVP could be attributed to an increase in the
diffusional barrier around the growing crystal due to the presence of high molecular
weight PVP and its adsorption on the growing crystal surface. However, most of the
above-mentioned studies on drug crystallization have been screening studies in which the
excipients were simply rank ordered based on their inhibitory effects. Generally, the
mechanism by which a given excipient achieves its beneficial effect is unknown and what
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combination of properties of the drug and excipient molecules provides an optimal
benefit is unclear. Consequently, there are no reliable quantitative models that would
allow a formulator to predict a priori the most suitable excipient(s) and the amounts that
should be used for a given dose of a new poorly water soluble drug candidate to achieve
the desired prolongation in supersaturation.
Undoubtedly, understanding the effect of excipients on precipitation kinetics will
require quantitative models describing both nucleation and crystal growth. One of the
reasons for the deficiency of such quantitative models could be the lack of simple, robust,
and reliable techniques to separately quantify the kinetics of nucleation and crystal
growth that influence the maintenance of supersaturation. The aims of this study were
twofold: (1) to develop and test a non-invasive (online) technique to measure crystal
growth kinetics using second derivative UV spectroscopy; and (2) to use this technique to
determine the reaction order and rate-limiting step for the crystal growth kinetics of a
model poorly water soluble drug, indomethacin (Figure 3.1). Indomethacin appears to be
a suitable model compound for future studies aimed at understanding the abilities of
certain excipients to prolong supersaturation after oral administration of drug products
that produce supersaturated solutions in the GI tract.
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Figure 3.1. Chemical structure of indomethacin.
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THEORY

Classical Diffusion-Reaction Model for Crystal Growth
Crystal growth processes are classically described by a two-step diffusionreaction model (Figure 2.3)24,26,92,93,101 involving (1) solute diffusion from the bulk
solution to the crystal/solution interface and (2) a surface integration reaction whereby
the solute is incorporated into the crystal lattice. These two processes are assumed to
occur in series. The equation for solute diffusion to the crystal/solution interface is:

−

dcb
= k d A(cb − ci )
dt

(3.1)

where kd is the coefficient of mass transfer by diffusion, A is the crystalline surface
area per unit volume of the bulk medium, cb is the solute concentration in the bulk
medium, and ci is the solute concentration in solution at the crystal-solution interface.
The second step is the surface integration step:

−

dci
r
= k r A(ci − c s ) + k d A(cb − ci )
dt

(3.2)

where kr is a rate coefficient for surface integration, r is the order of the surface
integration process, and cs is the solute concentration in solution at equilibrium (i.e., the
saturation solubility).
Since ci is generally not obtainable experimentally, a simplified empirical crystal
growth model is often employed that assumes the overall driving force to be equal to the
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difference between the bulk concentration and the equilibrium solubility, (cb - cs), as in
Eq. (3.3):

−

dcb
g
= k G A(cb − c s )
dt

(3.3)

where kG is an apparent crystal growth rate coefficient, A, cb, and cs are as defined
previously, and g is the apparent order of the crystal growth process. If g = 1, then kG can
be expressed as

1
1
1
=
+
kG k d k r

(3.4)

When kd « kr, the crystal growth kinetics are bulk diffusion rate-limited and kG ≈ kd,
whereas when kr « kd, the crystal growth kinetics are surface integration (or reaction) ratelimited and kG ≈ kr.

Classical Diffusion Layer Model for Drug Dissolution
The rate of dissolution of drug particles in aqueous media is generally treated as a
bulk diffusion controlled process wherein the rate-limiting step is the diffusion of solute
molecules through an aqueous boundary layer surrounding the solid particles.24 Noyes &
Whitney145 as well as Nernst146 & Brunner147 modeled the bulk diffusion controlled
dissolution process from planar surfaces using Eq. 3.5:

dcb DAt
(cs − cb )
=
dt Vb h
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(3.5)

where D is the diffusion coefficient of solute, h is the thickness of the diffusion layer,
At is the total surface area of dissolving solid, Vb is the volume of bulk medium, cs is the
equilibrium solubility of solute, and cb is the solute concentration in the bulk medium at
time t. The quantity D/h in Eq. 3.5 is analogous to the coefficient of mass transfer (kd) in
Eq. 3.1.

Mass-Balance Relationship in Crystal Growth Processes
A mass balance relationship can be used to predict the change in seed crystal size
upon crystal growth at a specific degree of supersaturation.

The mass-balance

relationship24,92,93 assumes that the change in bulk solution concentration is proportional
to the mass deposition on seed crystals, i.e., dm = -VbdCb. Here, m is the mass of seed
crystals (moles), Vb is the volume of bulk medium in liters, and cb is the molar solute
concentration in the bulk medium. The relationship between the apparent crystal growth
rate or mass deposition rate, RG (moles/cm2time), and the apparent linear growth rate, G
(cm/time), can be expressed as:

RG =

V dc
 3αρ c  dL  3αρ c 
1 dm
g


 =
= − b b = k G (cb − c s ) = G
At dt
At dt
 β  dt  β 

(3.6)

where At is the total surface area (cm2) of seed crystals, kG is the apparent crystal
growth rate coefficient, g is the apparent order of crystal growth, α and β are the volume
and surface shape factors of seed crystals, respectively, ρc is the seed crystal density, L is
the characteristic size of seed crystals (e.g., volume based diameter), and t is time. The
change in seed crystal diameter, ΔL, can be expressed as:
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∆L =

M F1 / 3 − M B1 / 3
(αρ c N )1 / 3

(3.7)

where MB and MF are the mass of seed crystals before and after growth, respectively,
and N is the total number of seed crystals.
For a population of seed crystals with a specific size distribution, the entire
population can be divided into size classes containing collections of particles in a size
range represented by each class. A change in size distribution after growth for the entire
seed crystal population can be determined from the changes in the number of particles in
each size class. When crystal growth is bulk diffusion controlled, kG and g in Eq. 3.6 are
equal to D/h and 1, respectively. Consequently, the mass of the seed crystals in the ith
size class after bulk diffusion controlled crystal growth (MFi) can be predicted using Eq.
3.6 as follows:

RG = −

Vb dcb
1 dmi
D
=∑
= ∑ (cb − cs )
At dt
i Ai dt
i hi

(3.8)

where mi, Ai, and hi are the mass, total surface area, and thickness of the diffusion
layer for the seed crystals in the ith size class using a characteristic size Li. The change in
diameter (ΔLi) for the seed crystals in the ith size class can be described as

∆Li =

M F1i/ 3 − M B1 /i 3
(αρ c ni )1 / 3

(3.9)

where MBi and ni are the mass (before growth) and number of seed crystals in the ith
size class. Therefore, the apparent crystal growth rate (RG) and the surface area Ai can be
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used to estimate the change in seed crystal diameter (ΔLi) for each i, and in turn the size
distribution of an entire seed crystal population after growth.
MATERIALS AND METHODS

Materials
Indomethacin

(1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic

acid,

99+%, γ-polymorph, molecular weight =357.8 g/mole, pKa=4.17148) was purchased from
Sigma-Aldrich, Inc. (St. Louis, MO, USA). Nylon net filters (30 µ) and polycarbonate
membrane filters (3 µ) were purchased from Millipore Inc., (Milford, MA, USA). Nylon
membrane filters (0.2 µ) and 13 mm PTFE syringe filters (0.45 µ) were purchased from
Whatman Int. Ltd. (Maidstone, England). Deionized water was obtained from a Milli-Q
water purification apparatus (Milli-Q Synthesis, Millipore Inc., Milford, MA, USA) and
pre-filtered through a 0.22 µ filter (Millipak Express 20, Millipore Inc., Milford, MA,
USA). All other reagents and materials were of an analytical grade.

Preparation of Indomethacin Seed Crystal Suspension
A technique to obtain a narrow and unimodal size distribution of indomethacin
seed crystals was developed. A pre-weighed quantity of indomethacin solid powder was
dispersed (0.1% w/w) in 50 mM phosphate buffer (pH 2.15, ionic strength of 0.1 M using
NaCl) in a glass bottle with a polypropylene cap. The mixture was vigorously mixed for
about 2 minutes using a vortex mixer to ensure a uniform dispersion. The suspension
was equilibrated for about 72 hours at 25ºC in a shaker water bath to ensure complete
saturation of indomethacin. The saturated suspension was vacuum filtered through a 30
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µ nylon net filter using a stainless steel vacuum filtration device containing a stainless
steel mesh to support the filter followed by a second filtration through a 3 µ
polycarbonate filter.

The seed crystals retained on the top of the 3 µ filters were

redispersed in a saturated solution of indomethacin in a glass bottle. The final suspension
was stored at 25ºC before being used in a crystal growth experiment. The particle size
distribution, total surface area, and the mass median diameter of indomethacin seed
crystals were determined before their use in a crystal growth experiment.

UV Spectroscopic Analysis
Indomethacin concentrations in clear solutions as well as in suspension samples
were determined using 1-cm matched quartz cells (Starna Cells Inc., Atascadero, CA,
USA) and a dual beam UV-Visible spectrophotometer (Lambda 40P, Perkin-Elmer Inc.,
USA). The indomethacin concentration in clear solutions was determined from the
absorbance at 321 nm. The indomethacin concentration in suspensions was measured
from the second derivative absorbance (d2A/dλ2 or A”) at 295 nm. The second derivative
UV absorbance was obtained by taking a second derivative of the original indomethacin
UV absorption spectrum (wavelength range: 400 to 210 nm) with respect to the
absorption wavelength. More detailed results obtained during the development of this
method are provided in the Results section.

Indomethacin Phase Solubility Study
The intrinsic solubility of indomethacin was determined using the phase solubility
method described by Higuchi and Connors.149 An amount of indomethacin solid powder
in excess of its saturation solubility was added to a glass vial with a PTFE lined screw
cap containing pH 2.15 phosphate buffer to produce a 0.1% w/w suspension.
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The

mixture was shaken end-to-end at 25ºC in a rotary shaker. An aliquot (~9 mL) of the
suspension was withdrawn at regular time intervals (1, 2, 3, and 5 days) and filtered
through a 0.45 µ PTFE syringe filter, discarding the initial ~6 mL of filtrate to ensure
saturation of the filter.
spectrophotometry.

Indomethacin concentration was determined by UV

All measurements were determined at least in triplicate.

The

experiment was repeated using a higher suspension concentration (0.2% w/w) to
determine the effect of amount of excess solid on the indomethacin intrinsic solubility
value.

Indomethacin Seed Crystal Particle Size Distribution and Number Concentration
The particle size distribution of indomethacin seed crystals in suspensions was
determined using a Coulter counter (Multisizer Z2, Beckman Coulter Inc., Miami, FL,
USA) fitted with a 50 µ glass aperture tube and filled with clear indomethacin saturated
solution, obtained by filtering the indomethacin saturated suspension through a 0.2 µ
nylon membrane filter. Since the coincidence error in the Coulter counter measurement
depended on the seed crystal concentration, the indomethacin seed crystal suspension
samples were diluted as needed using the clear indomethacin saturated solution to
maintain the coincidence error in the manufacturer recommended optimum range (~ 5%).
The raw data obtained from the Coulter counter included the number of particles (per 1
mL of suspension) in 256 different size classes. Each size class contains a collection of
particles in a size range represented by that class. The indomethacin seed crystal size
distribution in the size range of 2 to 25 µ was determined by obtaining two Coulter
counter measurements (each with 256 size classes) in the size ranges of 2 to 8 and 8 to 25
µ for each suspension sample. The seed crystal number concentration (# of seed crystals
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per mL of suspension) was calculated by summing the number of particles in each size
class in the range of 2 to 25 µ. Each size class represented the volume based diameter of
the representative indomethacin seed crystal. Calibration of the Coulter counter was
performed using 3 and 10 µ particle size standards (Beckman Coulter Inc., Miami, FL,
USA).

Physical Form of Indomethacin Seed Crystals
Powder X-ray diffraction (PXRD) was used to determine the physical form of
indomethacin seed crystals before and after crystal growth. Indomethacin seed crystal
suspensions (before and after growth) were centrifuged for about 5 minutes at 12000
RPM. The clear supernatant solution was discarded and the solid collected in the bottom
of the centrifuge tubes was air dried before PXRD analysis.

PXRD patterns were

obtained using an X-ray diffractometer (Bruker D8 Advance, Bruker AXS, Inc.,
Madison, WI, USA). The X-ray copper anode (1.54A) was operated at 40 kV and 40
mA. The scans were performed from 3 to 35º 2θ with 0.05° step size and 4 or 0.6
seconds step time.

Microscopic Evaluation of Indomethacin Seed Crystals
The shape and size of the indomethacin seed crystals were also characterized
using a scanning electron microscope (Hitachi S4300) and a polarized light microscope.
For scanning electron microscopy (SEM), the samples were prepared by filtering the
indomethacin seed crystal suspension through a 0.2 µ nylon membrane filter. The seed
crystals retained on the filter were air dried. A section of the filter membrane was cut and
mounted on a scanning electron microscopy sample holder using graphite tape. In the
case of polarized light microscopic analysis (PLM), the slide sample was prepared by
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placing a small aliquot of indomethacin seed crystal suspension between a glass slide and
a glass cover slip.

Indomethacin Crystal Growth Rate Measurement
Indomethacin crystal growth kinetics was measured at 25ºC in aqueous
supersaturated suspensions of indomethacin seed crystals (pH 2.15) by determining the
decline in indomethacin concentration (desupersaturation) at different time intervals
online in a UV spectrophotometer (Figure 3.2). Supersaturation was attained by the
controlled addition of approximately 100-150 µl of freshly prepared, highly concentrated
(~120 µg/mL), high pH (6.8) indomethacin solution to 3 mL of the low pH indomethacin
saturated suspension (pH 2.15) using a micro-syringe pump at an addition rate of 150
µl/min. The high pH indomethacin solution was in 50 mM phosphate buffer (pH 6.8,
ionic strength of 0.1 M using NaCl). The bulk pH of the supersaturated indomethacin
suspensions after the addition of a small amount of high pH (6.8) indomethacin solution
remained below pH 2.2. The higher pH indomethacin stock solution was held in a gas
tight syringe and the tip of the tubing from the syringe was immersed in the suspension to
minimize possible entry of carbon dioxide into the high pH solution during its addition,
thereby avoiding micro-bubble formation. The change in indomethacin concentration at
different time intervals was measured by taking a second derivative of the original UV
absorbance spectrum with respect to the absorption wavelength between 210 to 400 nm
(λmax =295 nm) to minimize the variability in indomethacin solution concentration
measurements by removing the error from UV light scattering by indomethacin seed
crystals in the sample. The homogeneity of the indomethacin concentration in the bulk
solution was maintained via magnetic stirring using a pivoted rod-shaped magnetic stir
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bar (400 RPM).

Indomethacin crystal growth rates were measured at a degree of

supersaturation (S) of 6, where S, also known as the supersaturation ratio, is defined by
Eq. 3.10.

S=

C
Cs

(3.10)

where c is indomethacin concentration immediately after supersaturation and cs is the
equilibrium solubility of indomethacin.

Indomethacin Dissolution Rate Measurement
Indomethacin seed crystal dissolution rates were measured to determine
indomethacin mass transfer (diffusion) rate coefficients.

The mass transfer rate

coefficient from indomethacin dissolution was compared with the same from
indomethacin crystal growth at a high degree of supersaturation (S=6) to verify the ratelimiting step in the indomethacin crystal growth process. Indomethacin seed crystal
dissolution experiments were performed at 25ºC by two different experimental methods
to compare their hydrodynamic conditions: (1) the USP Dissolution Apparatus II; and (2)
the online UV assembly with a quartz cuvette and magnetic stirring. In both cases, a
specific amount of indomethacin solid powder was added to the dissolution medium (50
mM phosphate buffer, pH 5.8, 130 RPM). The volumes of the bulk dissolution medium
for method (1) and (2) were 250 mL and 3 mL, respectively. For method (1), ~3 mL of
sample suspension was withdrawn at regular time intervals to measure indomethacin
concentration using second derivative UV spectroscopy.

For method (2), online

measurements of indomethacin concentrations were obtained at regular time intervals.
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Subsequently, indomethacin dissolution rates and, in turn, the mass transfer coefficients
(Eq. 3.5) were also measured at pH 2.15 and 6.5 using method (2) at ~400 RPM. Here,
dissolution was initiated by diluting indomethacin seed crystal suspensions (pH 2.15)
with a specific volume of either pH 2.15 phosphate buffer or 0.1N NaOH to attain the
final pH of 2.15 or 6.5, respectively. The final volume of the bulk dissolution medium
was 3 mL.

Data Analyses
Non-linear least-squares analyses were performed using a software program,
Scientist (Micromath Inc., St. Louis, MO, USA). The other statistical tests including the
Student t-test and ANOVA were performed using Microsoft Excel. The lack-of-fit test
analysis was performed using Scientist and Microsoft Excel.
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Quartz cuvette with a screw cap
Micro syringe pump
UV cuvette holder
with water jacket
Pivoted stir bar
PTP 1 temperature controller

Computer
Magnetic stirrer controller

Figure 3.2. Schematic diagram describing the typical experimental assembly for the
newly developed non-invasive (online) UV method to determine crystal growth
kinetics of poorly water soluble drugs using second derivative UV spectroscopy and
a crystal seeding technique.
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RESULTS

Development of a Second Derivative UV Spectroscopic Method
Indomethacin crystal growth kinetics was determined by monitoring the change in
indomethacin concentration (i.e., desupersaturation) versus time from its supersaturated
seed crystal suspensions.

While the precise measurement of indomethacin solution

concentration was essential for obtaining reliable crystal growth rates, the presence of
seed crystals in the supersaturated suspensions caused scattering of the incident UV light
which in turn introduced variability in indomethacin concentration measurements.
Second derivative UV spectroscopy was employed to alleviate the undesirable effect of
the spectral interference on indomethacin concentration measurements. Figure 3.3 shows
a representative spectrum of the indomethacin UV absorbance between 400 to 210 nm
(λmax = 321 nm) and its second derivative with respect to the wavelength (λmax = 295 nm).
Representative second derivative UV spectra of indomethacin at various concentrations
are also shown in Figure 3.3 (inset). Effectiveness of the second-derivative UV method
was tested by comparing indomethacin standard curves obtained from two different
indomethacin standard solutions at varying concentrations: (1) clear indomethacin
standard solutions, and (2) indomethacin standard solutions with added polystyrene latex
particles (4.0 × 104 particles/mL). As shown in Figure 3.3, linear standard curves with
correlation coefficients of 0.995 and 0.999 were obtained for indomethacin standard
solutions with and without the scattering effect of polystyrene latex particles,
respectively. The indomethacin response factors determined from the slopes of the linear
standard curves (with and without scattering effect) were 42.4 and 43 (abs×nm-2×M-1),
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respectively. This clearly indicated that the second derivative UV technique successfully
eliminated the spectral interference (i.e., UV light scattering) caused by the presence of
solid polystyrene latex spheres.
The robustness of the second derivative method was further validated by comparing
the second derivative UV response factors obtained from the indomethacin standard
curves containing varying concentrations of indomethacin seed crystals.

Figure 3.3

(inset) the second derivative UV response factors at four different indomethacin seed
crystal concentrations. The response factors were similar at different indomethacin seed
crystal concentrations, which is indicative of the robustness of the method within the
given range of solid particle concentrations.

Indomethacin Phase Solubility Study
The indomethacin intrinsic equilibrium solubility at 25ºC (pH 2.15; ionic strength: 0.1
M using NaCl) was determined to be 3.4 ± 0.1 × 10-6 M (95% CI). The equilibration
time (i.e., time to attain saturation solubility) was determined by statistically comparing
indomethacin concentrations of the samples drawn at 24, 48, 72, and 120 hour time
intervals. As shown in Figure 3.4, the equilibration time for the indomethacin intrinsic
solubility was 72 hours or 3 days (p < 0.05). At earlier time intervals (24 and 48 hours),
samples with a higher amount of excess solid had higher indomethacin concentrations.
However, the effect of the amount of excess solid on indomethacin intrinsic solubility
was not statistically significant at the 72 and 120 hour time intervals (p < 0.1).
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Figure 3.3. Representative indomethacin UV absorption spectra before and after
second derivatization of absorbance with respect to wavelength.

Inset:

Representative indomethacin second derivative UV spectra at varying indomethacin
concentrations.
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Figure 3.4. Second derivative UV absorbance standard curves of indomethacin
clear solutions (Δ) and (♦) with added polystyrene latex spheres.

Inset:

Indomethacin second derivative response factors at different seed crystal
concentrations.
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Figure 3.5.

Effect of the amount of excess solid on indomethacin intrinsic

equilibrium solubility. Error bars represent 95% confidence intervals (CI).
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Indomethacin Seed Crystal Suspension Characterization Before and After Crystal
Growth
Indomethacin seed crystal suspensions were characterized before and after crystal
growth by determining their physical characteristics including size distribution, number
concentration, morphology, and physical form.

Raw particle size distribution data

(number of particles in each volume based diameter size class) obtained from a Coulter
counter measurement were converted into total volume of seed crystals in each size class.
Indomethacin seed crystals were assumed to be spherical, and hence the values of the
surface shape factor (β) and the volume shape factor (α) were chosen to be equal to π and
π/6, respectively. Typical indomethacin seed crystal size distribution profiles (% volume
vs. seed crystal diameter) are shown in Figure 3.6. The mass-median diameter (Dm) of
indomethacin seed crystals was calculated using Eq. 3.11.

Dm =

∑n d
∑n d
i

i

3
i
2
i

(3.11)

where ni is the number of seed crystals in the ith size class using a volume based
diameter d. The typical mass median diameter of the indomethacin seed crystals was
11.1 ± 0.3 (95% CI) µ. The surface area of indomethacin seed crystals per unit volume
(mL) of suspension was calculated using Eq. 3.12.

S t = β ∑ ni d i2

(3.12)

where β is the surface shape factor (3.14 based on the spherical shape assumption).
The typical surface area of indomethacin seed crystals was 4.5 ± 0.3× 10-2 (95% CI) cm2
per mL of suspension.

The number of indomethacin seed crystals per mL of
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indomethacin suspension was 4.1 ± 0.6 × 104 (95% CI). The typical seed crystal density
in indomethacin suspension samples was ~50 µg/mL.

In a typical crystal growth

experiment (S=6), ~24 µg of indomethacin was deposited on the surface of ~160 µg of
indomethacin seed crystals upon the completion of crystal growth.
A significant change in indomethacin seed crystal size characteristics including
total surface area, total volume, and the mass median diameter could change the
indomethacin crystal growth rate. Since the suspensions were mixed by magnetic stirring
during crystal growth studies, the effect of magnetic stirring (e.g., attrition or
agglomeration) on indomethacin seed crystal size distributions was evaluated by mixing
the suspensions in the same manner as that employed in a typical growth study. As
shown in Figure 3.6, the indomethacin seed crystal size distribution profiles before
growth and after magnetic stirring with no growth were similar.

There were no

significant differences (p < 0.05) between the seed crystal size characteristics of the two
indomethacin suspensions before growth vs. after magnetic stirring with no growth
including total surface area (4.6 ± 0.8 × 10-2 vs. 4.7 ± 0.2 × 10-2 cm2/mL), total volume
(8.9 ± 1.9 × 10-6 vs. 8.7 ± 0.6 × 10-6 cm3/mL), mass median diameter (11.3 ± 0.6 vs. 11.1
± 0.7 µ), and the seed crystal concentration (4.1 ± 0.6 × 104 vs. 4.6 ± 1.1 × 104 seed
crystals/mL of suspension).
A comparison of the indomethacin seed crystal size distribution and seed crystal
concentration

after crystal growth (S=6) with those before growth indicated no

significant change in the size distribution (Figure 3.6) or the seed crystal concentration
after growth (4.1 ± 0.6 × 104 vs. 4.6 ± 0.2 × 104 seed crystals/mL of suspension).
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Figure 3.6. Representative indomethacin seed crystal particle size distributions
from suspension samples before growth (Δ), only mixing by magnetic stirring with
no growth ( ○) and after growth (□) as well as the predicted size distribution
(broken line) after crystal growth (S=6) using the mass balance relationship (Eq. 3.8
& 3.9). Error bars represent SEM (n=3). Inset: A representative polarized optical
micrograph of indomethacin seed crystals.
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The absence of a significant difference between the seed crystal concentration
before and after growth (p < 0.05) seems to rule out significant primary nucleation of
indomethacin seed crystals.
The shape characteristics of indomethacin seed crystals were analyzed by
microscopy (PLM & SEM). Representative micrographs of indomethacin seed crystals
from PLM and SEM are shown in Figure 3.6 (inset) and Figure 3.7, respectively. The
polarized light micrograph qualitatively confirmed the crystalline nature of indomethacin
seed crystals. The SEM analysis of indomethacin seed crystals indicated that the crystals
were of cuboid shape. Furthermore, no particles with significantly different geometry
(e.g., needles) could be detected from comparisons of several SEM micrographs of
indomethacin seed crystals before and after crystal growth, which again suggests the
absence of primary nucleation of different indomethacin forms.
The physical form of indomethacin seed crystals before and after crystal growth was
determined by PXRD.

PXRD patterns of three different indomethacin seed crystal

samples including original indomethacin powder as received (γ polymorph) and
indomethacin seed crystals before and after growth are shown in Figure 3.8. The PXRD
patterns of indomethacin seed crystals before and after crystal growth matched the PXRD
patterns of original indomethacin powder, indicating that no change in the crystalline
nature or polymorphic form of indomethacin seed crystals could be detected after crystal
growth.
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Figure 3.7. Representative scanning electron micrographs of indomethacin seed
crystals before and after crystal growth (inset).
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(3)
(2)
(1)

Figure 3.8. Comparison of PXRD patterns of various indomethacin seed crystals
samples: (1) indomethacin powder (as received), (2) indomethacin seed crystals
before crystal growth, and (3) indomethacin seed crystals after crystal growth.
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Indomethacin Crystal Growth Kinetic Modeling
Representative indomethacin desupersaturation kinetic profiles (n=5) at the
degree of supersaturation of 6 are shown in Figure 3.9 (solid circles).

The

desupersaturation kinetic profiles were fitted to the empirical crystal growth kinetic
model (Eq. 3.3) with the apparent order of crystal growth (g) set equal to 1. The apparent
crystal growth rate coefficient (kG) and the equilibrium solubility (cs) were used as fitting
parameters. As shown in Figure 3.9 (solid line), the crystal growth profiles were fit well
using the first order empirical crystal growth kinetic model. The apparent equilibrium
solubility after crystal growth, henceforth defined as the apparent solubility, was 5.2 ±
0.6 × 10-6 M (95% CI). The apparent solubility of indomethacin seed crystals after
crystal growth was significantly higher (p < 0.05) than the equilibrium solubility before
growth (3.4 ± 0.2 × 10-6 M). Here, the equilibrium solubility before growth represents
the indomethacin concentration in saturated indomethacin seed crystal suspensions before
their use in crystal growth experiments. It should also be noted that the solubility before
growth was similar to the indomethacin equilibrium solubility determined from the phase
solubility studies (3.4 ± 0.1 × 10-6 M).

80

2.0E-05

Indomethacin Concentration (M)

Crystal Growth (S=6)
No Growth (Mixing)

1.5E-05

First Order Model Fit with Apparent Solubility
First Order Model Fit with Equilibrium
Solubility

1.0E-05

5.0E-06

0.0E+00
0

10000

20000

30000

40000

50000

60000

70000

Time (sec)

Figure 3.9.

A representative desupersaturation profile (●) from indomethacin

crystal growth experiments (S=6).

The broken line represents the first order

empirical crystal growth model (Eq. 3.3) fit using the initial equilibrium solubility
value measured before crystal growth; the solid line represents the first order
empirical crystal growth model fit using the apparent equilibrium solubility value
measured after crystal growth. The open squares (□) represent the effect of only
mixing (magnetic stirring) without any crystal growth on indomethacin equilibrium
solubility. Error bars represent 95% confidence intervals.
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Indomethacin Apparent Solubility and the Apparent Order of the Crystal Growth
Process
The apparent indomethacin solubility after crystal growth was about 55% higher
than the equilibrium solubility before growth. The value chosen for the equilibrium
solubility can affect the kinetic model that best fits the desupersaturation profiles.

As

shown in Figure 3.9 (solid line), the crystal growth kinetic profiles were fit well by a first
order crystal growth model when the value of solubility at infinity was fixed at the higher
apparent solubility found after crystal growth. However, the first order model gave a
poor fit (Figure 3.9; dashed line) when the equilibrium solubility before growth was
selected. The kinetic profiles were re-analyzed using the same model but with the
apparent order of crystal growth process (g) included as a fitted parameter.

This

approach provided a value for g of 1 when the higher apparent solubility was employed
whereas the value of g increased from 1 to 1.5 when the equilibrium solubility before
growth was selected. These results clearly indicated that the apparent order of the crystal
growth process depends critically on the indomethacin solubility value employed.
Hence, additional experiments were conducted to verify the change in indomethacin
solubility after crystal growth.
During the crystal growth experiment, the homogeneity of indomethacin
concentration in the bulk solution was maintained by magnetic stirring. One hypothesis
for the change in indomethacin solubility considered was that the surface energy of the
indomethacin seed crystals could be altered by the mechanical shear forces created by
magnetic stirring during crystal growth experiments. The higher surface energy could in
turn provide a higher apparent solubility after crystal growth. Hence, the effect of
magnetic stirring on indomethacin solubility was determined by measuring indomethacin
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concentration in stirred suspensions over time.

The results indicated that magnetic

stirring did not change the solubility (Figure 3.9, open squares). The solubility measured
from this study (3.2 ± 0.1 × 10-6 M) was similar to the solubility obtained from the phasesolubility studies (3.4 ± 0.1 × 10-6 M). This clearly indicated that magnetic stirring
during a crystal growth experiment does not produce the higher apparent solubility values
of indomethacin observed after crystal growth.
Since the indomethacin apparent solubility after approximately 0.67 day (16-hour)
crystal growth experiments (Figure 3.9, solid circle) was ~55% higher than the
equilibrium solubility before growth, it was essential to explore the length of time this
higher apparent solubility remained constant after growth.

Multiple crystal growth

experiments with durations of greater than 0.67 day were performed. A representative
desupersaturation profile from a 7 day long crystal growth experiment is shown in Figure
3.10 indicating that the higher apparent solubility remained constant at around 5 µM even
after 7 days. A comparison of indomethacin apparent solubility after 0.67, 1, 3, 5, and 7
day long crystal growth experiments is shown in Figure 3.10 (inset). The apparent
indomethacin solubility after 0.67 day was similar to those obtained after 1, 3, 5 and 7
days indicating that the crystal growth process had reached an equilibrium (or pseudoequilibrium) concentration after 0.67 day (16 hours) of crystal growth.
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Figure 3.10. Indomethacin concentration vs. time (day) profile from a 7-day long
indomethacin crystal growth study to verify the apparent indomethacin solubility
after

crystal

growth.

Inset:

Comparison

of

indomethacin

equilibrium

concentrations after crystal growth at different time intervals to verify the apparent
indomethacin solubility after crystal growth.

84

After verifying the long-term stability of the higher indomethacin apparent
solubility after crystal growth, the apparent order of the overall indomethacin crystal
growth process at higher degrees of supersaturation (S=6) was determined by conducting
a lack-of-fit analysis using different values of g. The crystal growth kinetic profiles were
fit to the empirical crystal growth model (Eq. 3.3) with varying apparent order of the
crystal growth process (g = 0, 1, 2, and 3). A statistical lack-of-fit test analysis was
performed for the model fits and the results from the analysis are shown in Table 3.1.
The calculated F value was the smallest for the first order model (g = 1). The rank
ordering of the models based on their calculated F values was first order < second order <
third order < zero order. The rank ordering clearly indicated that the first order model
provided the best fit for indomethacin crystal growth profiles at a degree of
supersaturation of S = 6. Moreover, only the first order model successfully met the
requirements of the lack-of-fit test analysis (p < 0.05) out of all four kinetic models.

Indomethacin Crystal Growth Rate-limiting Step
After determining the apparent order (g = 1) from the indomethacin crystal
growth kinetics, the indomethacin mass transfer coefficients from its crystal growth and
dissolution were compared using similar conditions including similar seed crystal
suspensions.

The hypothesis was that in the case of bulk diffusion rate limited

indomethacin crystal growth, the mass transfer coefficients determined from
indomethacin crystal growth would be similar to the same obtained from its dissolution,
which is known to reflect a bulk diffusion rate limited process.150
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Table 3.1. Statistical (Lack-of-Fit) Analysis of Fitting of Indomethacin Crystal Growth Kinetic Data using Empirical Crystal
Growth Model (Eq. 3.3) with Varying Apparent Order of Crystal Growth Process.

Apparent Order
of Crystal Growth
Process (g)

Sum of
Squares
(Residual)

Sum of
Squares
(Lack of Fit)

F value
(Calculated)

1.88×10-09

1.87×10-09

320

1

2.27×10-11

9.28×10-12

1.59

2

8.33×10-11

6.99×10-11

12

3

2.39×10-10

2.25×10-10

39

(Critical; α=0.05)

86

0

F value

1.72

The indomethacin mass transfer coefficient from powder dissolution was
determined using the online UV method that included a quartz cuvette and magnetic
stirring. Since the hydrodynamic conditions were not pre-defined for the online UV
method, the indomethacin dissolution profile from the online UV method was compared
with that from the standardized USP Dissolution Apparatus II method, which uses well
defined hydrodynamic conditions. The dissolution profiles (pH 5.8) generated by the two
different methods using the same indomethacin seed crystal suspension were similar
(Figure 3.11 (inset)), indicating that the hydrodynamic conditions in both methods are
similar. Subsequently, indomethacin dissolution profiles at two different pH values (2.15
and 6.5) were determined using the online UV method. A representative indomethacin
dissolution kinetic profile at pH 6.5 is shown in Figure 3.11. The indomethacin mass
transfer coefficients (kd) were estimated from fitting the dissolution profile to the
diffusion layer model (Eq. 3.5). The indomethacin mass transfer coefficients determined
from the dissolution (pH 6.5 and 2.15) of indomethacin (Table 3.2) indicate that the bulk
pH of the dissolution medium did not affect the indomethacin mass transfer coefficient
significantly. This was attributed to the presence of 50 mM phosphate buffer in the
dissolution medium at pH 2.15 as well as 6.5, which resisted the formation of pH
gradients in the diffusion layer. Moreover, the mass transfer coefficients determined
from indomethacin crystal growth kinetic profiles (pH 2.15) at a degree of
supersaturation of S = 6 were similar to the same obtained from indomethacin dissolution
(Table 3.2), a further indication that indomethacin crystal growth at this degree of
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supersaturation is a bulk diffusion rate limited process. As shown in Eq. 3.5, from the
indomethacin mass transfer coefficients, the diffusion layer thickness for the
indomethacin seed crystals was estimated. The diffusion coefficient of indomethacin
used in the calculation was 5.6 × 10-6 cm2/sec.148

The diffusion layer thicknesses

estimated from indomethacin dissolution and crystal growth were 11.5 ± 4.0 and 11.5 ±
2.1 (95% CI) µ, respectively. The estimated diffusion layer thicknesses were similar to
the mass median diameter of the indomethacin seed crystals (11.1 ± 0.3 (95% CI) µ) used
in the dissolution and crystal growth experiments. This was in good agreement with
previously published measurements of the diffusion layer thickness from bulk diffusion
controlled dissolution studies.151,152

Prediction of Seed Crystal Size Distribution after Growth
The change in indomethacin seed crystal size distribution upon crystal growth at a
high degree of supersaturation of S=6 was predicted using the mass balance relationship
(Eq. 3.8 & 3.9) for bulk diffusion controlled crystal growth of a population of seed
crystals. In the size prediction modeling, the diffusion layer thickness (hi) of the seed
crystals in the ith size class was assumed to equal the mass-median diameter (Dmi). The
seed crystal density (ρc) of indomethacin135 was 1.37 g/cm3. The size predictions using
Eq. 3.8 & 3.9 were obtained from the numerical simulations provided by the software
program, Scientist.
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Figure 3.11. A representative indomethacin powder dissolution kinetic profile (bulk
pH 6.5). The solid line represents the first-order diffusion layer (or thin layer)
model fit (Eq. 3.5).

Inset: A comparison of indomethacin dissolution profiles

determined using the USP Dissolution Apparatus II method as well as the online UV
method (quartz cuvette and magnetic stirring).

89

Table 3.2. Comparison of Mass Transfer Coefficients (± 95% CI) Determined from
Indomethacin Dissolution and Crystal Growth (S = 6) Studies.
Mass Transfer Coefficient (cm/sec)
pH
Dissolution (kd)

Crystal Growth (kG)

pH 2.15

4.6 ± 2.0 × 10-03

4.7 ± 0.7 × 10-03

pH 6.5

4.8 ± 1.7 × 10-03
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As shown in Figure 3.6, the size predictions in the larger particle size range (>15
µ) were in excellent agreement with the experimentally measured sizes but there was
overall a greater increase in particle volume predicted than obtained. The predicted sizes
after growth for the smaller seed crystals (<15 µ) were larger than those measured. These
differences were mainly attributed to the fact that sample dilutions for the Coulter counter
size measurements employed diluent solutions that were saturated using the “before”
growth indomethacin crystals.

Indomethacin concentrations of the after growth

suspension and the saturated diluent were 5.2 ± 0.6 × 10-6 M (95% CI) and 3.4 ± 0.1 × 106

M, respectively. This indomethacin concentration difference provided a driving force

for some re-dissolution, which would have preferentially re-dissolved seed crystals in the
smaller size range.
DISCUSSION

Development of Techniques to Study Indomethacin Crystal Growth Kinetics
Supersaturation of poorly water soluble compounds can be prolonged by the
presence of suitable excipients in the system. The beneficial effects of excipients on the
maintenance of supersaturation may be attributable either to the inhibition of nucleation
or crystal growth or both. To develop a quantitative and mechanistic understanding of
excipient effects on the maintenance of supersaturation by nucleation or crystal growth
inhibition, it is essential to determine the parameters that govern nucleation or crystal
growth kinetics of poorly water soluble compounds.

Previous kinetic studies have

monitored solute concentration vs. time (i.e., desupersaturation) profiles during
nucleation or crystal growth.2-6,42,43 However, some of the sampling methods including
syringe filtration and centrifugation used to determine solute concentrations in
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supersaturated systems could easily lead to erroneous results mainly due to unwanted loss
of solute concentration during sampling. When supersaturated samples come into contact
with solid surfaces such as syringes, filter membranes, and centrifuge tubes nucleation
and/or solute adsorption may occur.

Recently, non-invasive and online methods

consisting of spectroscopic techniques such as ATR-FTIR,144 Raman,17 and
fluorescence20 have been employed to measure desupersaturation profiles without the risk
of sampling errors.

The present study describes an online second derivative UV

spectroscopic method to monitor crystal growth kinetics of the poorly water soluble drug
indomethacin. The second derivative technique provided robust measurements at varying
seed crystal concentrations (4.41 × 104 - 1.76 × 105 particles/mL).
The newly developed online UV assembly utilized magnetic stirring.

The

development and validation of the seeding method involved not only the steps to obtain
narrow, unimodal seed size distributions but also the determination of any change in seed
size and number upon mixing by magnetic stirring. A pivoted magnetic stir bar was
selected from a range of stir bars with different shapes and characteristics to minimize
any effect of stirring on seed crystal size distribution (data not shown).

Since

desupersaturation can occur due to primary nucleation at high degrees of supersaturation,
a fine balance existed between the number of seed crystals (i.e., total available surface
area for growth) and the highest possible degree of supersaturation that could be
achieved. The seed crystal concentration range was limited by the ability of the second
derivative technique to reliably measure indomethacin concentrations near its intrinsic
solubility range, whereas higher degrees of supersaturation were limited by spontaneous
primary nucleation manifested by a sharp increase (close to an order of magnitude) in
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seed crystal concentrations. The prevention of primary nucleation using the seeding
technique was tested by comparing the seed crystal concentrations before and after a
crystal growth experiment. In a systematic study (data not shown), the optimum range of
seed crystal concentrations and the degree of supersaturation was determined.

The

maximum achievable degree of supersaturation without any primary nucleation was
about 6 for the seed crystal concentration range of 4.41 × 104 - 1.76 × 105 particles/mL.
Therefore, the crystal growth experiments were conducted at an S of 6 or below.

Indomethacin Phase Solubility Study
Indomethacin was chosen as the model compound in the present study due to its
low intrinsic solubility (~1 µg/mL) and the availability of physical characterization data
in the existing literature.

Indomethacin physicochemical properties including

solubility132,133 and stability130 in aqueous solutions have been characterized previously.
Indomethacin decomposes in aqueous solution by hydrolysis.

Since indomethacin

hydrolysis is significantly slower at low pH and the degradation half life is significantly
longer than the equilibration time for solubility and crystal growth experiments, its effect
on indomethacin intrinsic solubility and crystal growth rate determinations at pH 2.15
was considered negligible. The intrinsic solubility of indomethacin determined in the
present study is 3.4 ± 0.1 × 10-6 (95% CI) M. Hancock et al.132 reported the solubility of
indomethacin in deionized water at 25ºC as ~5 µg/mL (~1.4 × 10-5 M). Wassvik et al.133
reported an intrinsic solubility of 1.12 ± 0.03 × 10-6 M.

The higher indomethacin

solubility reported by Hancock et al. is in accordance with the solubility enhancement
provided by indomethacin ionization at the higher pH (>pKa) that would result from
dissolution in deionized water. The lower indomethacin solubility reported by Wassvik
93

et al.133 reflects a lower equilibration temperature (21ºC) and shorter equilibration time
(24 hr) as compared to the present study.

Relationship between Indomethacin Crystal Growth Kinetics and its Equilibrium
Solubility
Several methods have been described in the crystal growth literature24,92,93 for
crystal growth rate measurement including the use of a single crystal vs. a population of
crystals (multiparticulate), growth rate determination from the change in crystal
properties (e.g., mass or size) vs. change in solution properties (e.g., solution
concentration), and isothermal vs. non-isothermal conditions. Each technique has its own
advantages and limitations. For example, the single crystal measurement technique is
advantageous in terms of measuring the growth rate of a specific crystal face of interest.
However, the availability of a very small surface area limits the ability to achieve high
degrees of supersaturation in comparison to multiparticulate systems and results in a
higher sensitivity to the presence of impurities (even at very low concentrations). The
advantages of the multiparticulate method, also known as batch crystallization, chosen
for this study are: (1) its relevance to the in-vivo GI conditions in terms of maintaining
supersaturation after primary nucleation, (2) its simplicity, and (3) a low sensitivity to
small differences in crystal shapes or to non-uniformity of the number of dislocations on
crystal surfaces. A limitation of this method is that it gives an average of crystal growth
rates from individual faces of the crystal.93
The apparent solubility of indomethacin after crystal growth was approximately
55% higher as compared to before growth. Since the solubility of a solute defines its
thermodynamic activity at the solid-liquid interface in a crystal growth process, it is
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essential to know its exact value to determine the true thermodynamic driving force for a
crystal growth process (Figure 2.3). An array of validation studies confirmed that the
equilibrium solubility was altered after crystal growth.

Possibly, the apparent

equilibrium after crystal growth reflects a metastable state and after a long equilibration
time the system would re-establish a true equilibrium (same as before growth). However,
a comparison of indomethacin equilibrium concentrations after 0.67, 1, 3, 5, and 7 day
crystal growth experiments showed that the apparent equilibrium concentration did not
change significantly indicating that the crystal growth process had reached an apparent
equilibrium (or pseudo-equilibrium). It was therefore hypothesized that the newly grown
surface could be of higher energy either due to the presence of higher disorder (i.e.,
higher density of high energy sites such as kinks) or due to the secondary nucleation of a
metastable polymorph such as the α-polymorph of indomethacin on the existing seed
crystals of the more stable γ-polymorph. While the absence of a change in the seed
crystal polymorphic form detected by PXRD indicated that the primary nucleation of any
new indomethacin polymorph did not occur during crystal growth, the inability of the
PXRD technique to detect small crystal packing or conformational differences at the
surfaces of seed crystals before and after growth is worth noting. The diffraction pattern
measured by the PXRD technique is dominated by the signal from the core or bulk of the
material, and hence the contributions from small differences on the surface are
undetectable.139,153,154

Theoretical calculations, described below, were performed to

explore the possibility that the α polymorph formed on the surface of seed crystals.
As mentioned earlier, the two major polymorphs of indomethacin are the γ and α
polymorphs. The γ-polymorph used in these crystal growth studies is thermodynamically
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more stable. The metastable α-polymorph of indomethacin has a lower heat of fusion and
lower melting point135. The heat of fusion (ΔHm) and the melting point (Tm) of the two
polymorphs were obtained from the literature127,132,135,155 and are compared in Table 3.3.
The ideal solubility of indomethacin at 25 ºC can be calculated using the following ideal
solubility equation (Eq. 3.13).156

ln X = −

∆H m (Tm − T ) ∆C p
+
RTTm
R

Tm 
 (Tm − T )
+
ln
 T
T 


(3.13)

where X is the ideal mole fraction solubility, ∆Cp is the heat capacity difference
between the liquid and solid phases of the solute and T is temperature. If it is assumed
that the heat capacity for both phases is similar, the following equation can be derived
from Eq. 3.13:

ln X = −

∆H m (Tm − T )
RTTm

(3.14)

In the above equation, the calculation of the free energy difference between two
phases (i.e., solid and liquid) assumes that the enthalpy and entropy differences are
temperature independent and equal to ΔHm and ΔHm/Tm, respectively. Eq. 3.14 is more
suitable for calculating the mole fraction solubility at higher temperatures close to Tm.
Alternatively, an extended form of Eq. 3.14 was derived by Hoffman157 (Eq. 3.15) to
predict solubility at temperatures well below Tm.

ln X = −
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∆H m (Tm − T )
RTm2

(3.15)

Using Eq. 3.14 and 3.15, the mole fraction solubilities of the two indomethacin
polymorphs were calculated at 25ºC (Table 3.4). Since the values of the heat of fusion
and melting point of indomethacin polymorphs, especially for α-polymorph, varied
significantly in the literature (Table 3.3), averages of the predicted solubilities with 95%
CI are shown in Table 3.4. The Hoffman equation (Eq. 3.15) predicted significantly
higher solubilities for indomethacin polymorphs as compared to the ideal solubility
equation (Eq. 3.14). Ratios of the calculated solubilities (α-polymorph/ γ-polymorph)
were compared with the ratio of experimentally determined solubilities of indomethacin
seed crystals after and before crystal growth (Table 3.4). There was no significant
difference between the two theoretical solubility ratios and the experimental solubility
ratio. Moreover, the experimental solubility ratio was very similar to the theoretically
predicted solubility ratio using the Hoffman equation (Eq. 3.15). These results suggest
that a metastable α-polymorph may be growing on the seed crystals of γ-polymorph
during indomethacin crystal growth, which in turn could explain the higher apparent
solubility

of

indomethacin

seed
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crystals

after

crystal

growth.

Table 3.3. Heat of Fusion and Melting Point of Indomethacin Polymorphs
Literature
Reference
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a
b

36.5 kJ/mol
35.4 kJ/mol

Heat of Fusion (ΔHm, J/g)

Melting Point (Tm, °C)

γ-polymorph

α-polymorph

γ-polymorph

α-polymorph

Legendre et al.127

103

92

159.1

153

Andronis et al.135

110

91

161

155

Hancock et al.132

102

101

162

156

Urakami et al.155

102a

98.9b

163

157

Table 3.4.

Comparison of Theoretical Solubility (± 95% CI) of Indomethacin

Polymorphs with Experimental Indomethacin Solubility (Before and After Crystal
Growth, ± 95% CI)
Indomethacin Solid Form

Solubilitya,b

γ-polymorphc

9.0 ± 1.4a × 10-3

α-polymorphc

1.5 ± 0.4a × 10-2

γ-polymorphd

3.9 ± 0.4a × 10-2

α-polymorphd

5.4 ± 0.9a × 10-2

Seed crystal before growth

3.4 ± 0.2b × 10-6

Seed crystals after growth (S = 6)

5.2 ± 0.6b × 10-6

a

Solubility
Ratio

1.8 ± 0.7

1.4 ± 0.4

1.5 ± 0.1

Mole fraction
Moles/liter
c
An average of indomethacin solubilities calculated using the ideal solubility equation (Eq.
3.14) and the physical property values listed in Table 3.3
d
An average of indomethacin solubilities calculated using the Hoffman equation (Eq. 3.15)
and the physical property values listed in Table 3.3
b
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As shown in Figure 3.9, the first order empirical crystal growth model did not fit
the indomethacin crystal growth kinetic experimental data when the driving force was
calculated using the original indomethacin equilibrium solubility.

A value for the

apparent order of crystal growth process as high as 1.5 was required to fit the data. Since
the saturated indomethacin seed crystal suspension reached a different equilibrium
concentration after a crystal growth experiment, it is obvious that assuming the original
indomethacin equilibrium solubility throughout the experiment could lead to an
overestimation of the driving force for crystal growth. The first-order empirical crystal
growth kinetic model fit the experimental data well when the apparent (or observed)
equilibrium solubility value was used to determine the driving force for crystal growth.

Rate-limiting Step of Indomethacin Crystal Growth Kinetics at a High Degree of
Supersaturation
The similarity between the indomethacin mass transfer coefficients from its
crystal growth and dissolution indicated that the crystal growth of indomethacin at a high
degree of supersaturation of S=6 was a bulk diffusion rate limited process.

The

indomethacin mass transfer coefficients were initially determined at higher pH (~6.5) as
the higher indomethacin solubility at pH 6.5 would provide higher driving force, and in
turn, faster dissolution. However, the pH at the dissolving solid surface may be lower
than the bulk pH during the dissolution of weak acids in higher pH (> pKa) dissolution
media.148,158 Since a pH gradient in the diffusion layer could result in an overestimated
mass transfer coefficient if not taken into account, the pH at the dissolving solid surface
of indomethacin (pKa148 4.17) particles was estimated using the reactive diffusion layer
model described in detail by Mooney et al.148 and Ozturk et al.158 These calculations
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gave a solid surface pH of 6.44, not significantly different from the measured bulk pH
(6.46). This lack of difference was attributed to the presence of 50 mM phosphate buffer
in the dissolution medium.

Moreover, the similarity between the mass transfer

coefficients determined at pH 6.5 and 2.15 confirmed the absence of pH gradient effects
(at pH 2.15, which is below the pKa of indomethacin, one would not expect a pH
gradient in the diffusion layer since indomethacin would not ionize upon dissolution).
Therefore, the mass transfer coefficient, and in turn, the thickness of the diffusion layer
were calculated by fitting the experimental dissolution profiles (pH 6.5) to the diffusion
layer model (Eq. 3.5). The value for the diffusion coefficient of indomethacin used in the
calculation of the diffusion layer thickness was 5.6 × 10-6 cm2/sec.148 Mooney et al.148
compared indomethacin diffusivity values that were derived from various sources
including the Levich plot (dissolution by the rotating disc method at 25ºC, pH 2, µ 0.5),
the Stokes-Einstein equation, and the square root of molecular weight relationship. The
indomethacin diffusivity values from these sources were 5.6 × 10-6, 4.8 × 10-6, and 5.6 ×
10-6 cm2/sec, respectively. The similarity between the estimated diffusion layer thickness
and the mass median diameter of indomethacin seed crystals was in good agreement with
the widely accepted tenet in the dissolution literature stating that the diffusion layer
thickness of spherical particles below a specific size is generally equal to the particle
mass median diameter or radius.150-152,159

In earlier studies, investigators including

Hixson and Crowell160 as well as Higuchi and Hiestand150 assumed that diffusion layer
thickness correlated with particle size for all size ranges. For example, Higuchi and
Hiestand150 employed the diffusion layer thickness as approximately equal to or larger
than the particle radius. Later, Hintz and Johnson161 introduced the concept of a diffusion
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layer thickness that matches the particle size for particles up to 30 µ, while remaining
constant at 30 µ for larger particles. Recently, De Almeida et al.151 have shown that the
thickness of the diffusion layer for ibuprofen particles below 22 µ was linearly
proportional to the particle diameter. Simoes et al.162 found the diffusion layer thickness
equal to the particle diameter from the dissolution of 5-15 µ indomethacin particles.
Galli152 reported diffusion layer thicknesses of 0.3 to 8.5 µ for particles with diameters in
the range of 0.5 to 5.9 µ. Sheng et al.159 determined the diffusion layer thickness from
fenofibrate powder dissolution to be equal to 1.71 and 1.59 times the particle radius for
particles below 37.7 µ (50 RPM) and 23.7 µ (100 RPM), respectively. The similarity
between the estimated thickness of the diffusion layer and the mass median diameter of
indomethacin seed crystals in the present study also verified that the indomethacin crystal
growth kinetics at higher degrees of supersaturation were bulk diffusion rate controlled.
CONCLUSIONS
A non-invasive, online, simple and reliable method to determine crystal growth
rates using a batch crystallization technique and second derivative UV spectroscopy has
been developed.

The second derivative UV spectroscopy successfully removed the

spectral interference due to the presence of seed crystals in the crystal growth samples
during indomethacin concentration measurements.

The presence of seed crystals

obviated primary nucleation of indomethacin at higher degrees of supersaturation during
crystal growth. The apparent equilibrium solubility of indomethacin after crystal growth
was about 55% higher than its equilibrium solubility, which could be attributed to the
growth of a higher energy indomethacin form on seed crystals of the thermodynamically
most stable form. The first order desupersaturation kinetic profiles and the similarity
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between the mass transfer coefficients determined from indomethacin powder dissolution
and crystal growth clearly indicated that the indomethacin crystal growth at a high degree
of supersaturation of S=6 is bulk diffusion rate limited. Currently, studies are underway
to determine the effect of model excipients on bulk diffusion rate limited indomethacin
crystal growth using the techniques and models developed in this study. The long term
goal of this project is to develop a quantitative and mechanistic understanding of model
excipient effects on the maintenance of supersaturation by crystal growth inhibition of
poorly water soluble drugs after the administration of drug products that produce
supersaturated solutions. The long term impact of this project would be the creation of a
framework for rational and efficient decision making leading to the rapid selection of
excipient(s) or excipient combinations specific to the drug candidate under evaluation
that provide high oral bioavailability for compounds that otherwise might exhibit
solubility-limited absorption or undergo extensive precipitation/recrystallization after
dissolution.

Copyright © Dhaval D. Patel 2015
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Chapter Four
Maintenance of Supersaturation II: Indomethacin Crystal Growth Kinetics Versus
Degree of Supersaturation
INTRODUCTION
The success of certain types of high energy formulations (e.g., amorphous
dispersions) in promoting higher and less variable oral bioavailability of poorly water
soluble drugs has often been attributed to the generation and stabilization of
supersaturated solutions in the gastrointestinal tract.1

The abilities of various

pharmaceutical excipients to prolong supersaturation of poorly water soluble drug may be
linked to their effects on nucleation and/or crystal growth of these compounds.4,20
Quantitative, mechanistic studies of drug nucleation and crystal growth are therefore
needed to fully understand how to most effectively utilize pharmaceutical excipients to
maintain drug supersaturation.
Because supersaturated solutions are thermodynamically unstable, processes such
as nucleation and crystal growth allow them to reach a more stable equilibrium state
(Figure 2.1).92 The nucleation process consists of the formation of stable nuclei, which
are also known as critical nuclei.93,95,96 The critical nuclei grow in size to form larger
crystals during the crystal growth process.24 The crystal growth process is a multistep
process involving several mechanisms. According to the diffusion-reaction theory, the
major steps in the crystal growth process are96: (1) diffusion of the solute molecules from
bulk to the growing interface, and (2) incorporation of the solute into the crystal
lattice.24,92 The latter step is generally defined as a “surface integration” or “surface
reaction” step.
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The surface integration process could be divided into several sub-steps.26 Desolvation of
the solute occurs at the solid-liquid interface followed by the adsorption of the solute on
the growing crystal surface.9

The adsorbed solute molecules diffuse on the crystal

surface until active growth sites such as defects, kinks, or steps are encountered upon
which the molecules get incorporated into the lattice.101 Rapid and continuous crystal
growth continues until all the active growth sites are occupied and a molecularly smooth
crystal surface is created. The crystal growth rates from molecularly smooth surfaces are
slow, which require two-dimensional nucleation to occur on the smooth surface.96
Alternatively, crystal growth could occur through the spiral growth mechanism where
screw dislocations are formed that allow continuous and faster crystal growth.25 This
process does not lead to the formation of molecularly smooth crystal surfaces upon
crystal growth which, in turn, provides continuous crystal growth without the need for
two-dimensional nucleation.9
The diffusion-reaction theory of crystal growth assumes that the two major steps
of the crystal growth process occur in series.24,26,92,93,101 The driving force for the first
step (i.e., bulk diffusion) is determined from the difference between the solute
concentration in the bulk medium and the solute concentration in solution at the crystalsolution interface (ci). The surface integration rate is a function of the driving force
defined as the difference between ci and the solute concentration at the solid surface (i.e.,
the saturation solubility). Since ci is generally not obtainable experimentally, a simplified
empirical crystal growth model is often employed that assumes the overall driving force
to be equal to the difference between the bulk concentration and the equilibrium
solubility.24,104
105

Knowledge of the fundamental relationships between the mechanisms of
crystallization (i.e. nucleation and crystal growth) and the variables that govern the
crystallization rate including pH, temperature, agitation, and the number of active growth
sites on the growing surface would be essential for understanding the effects of
pharmaceutical excipients on the crystallization rate and, in turn, the maintenance of
supersaturation. Additionally, the relationship between the nucleation and crystal growth
rates and the degree of supersaturation could be further employed in modeling the effects
of excipients in maintaining supersaturation. Quantitative and mechanistic explorations
of nucleation and crystal growth of poorly water soluble drug candidates in aqueous
systems have, in general, suffered due to the lack of simple and robust experimental
techniques. Recently, we have developed a non-invasive (online) method to study crystal
growth of poorly water soluble compounds from supersaturated aqueous suspensions
using second derivative UV spectroscopy and a controlled seeding technique.104 Using
this method, the crystal growth kinetics of indomethacin, a poorly water soluble model
drug, were found to follow bulk diffusion controlled first-order kinetics at a high degree
of supersaturation (S~6). The aim of this study was to determine indomethacin crystal
growth kinetics in aqueous suspensions over a wide range of S to compare to the
previously determined indomethacin crystal growth kinetics at high S. This kinetic
information may be useful in quantitative and mechanistic treatments of indomethacin
crystal growth inhibition and in turn, supersaturation maintenance by pharmaceutical
excipients.
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MATERIALS AND METHODS

Materials
The γ-polymorph of indomethacin (99+ %) was obtained from Sigma-Aldrich,
Inc. (St. Louis, MO, USA). The chemical name of indomethacin is 1-(p-chlorobenzoyl)5-methoxy-2-methylindole-3-acetic acid. The molecular weight and pKa of indomethacin
are 357.8 g/mole and 4.17,148 respectively. Filters including 30 µm nylon net filters and 3
µm polycarbonate membrane filters were acquired from Millipore Inc. (Milford, MA,
USA) whereas 0.2 µm nylon membrane filters and 0.45 µm (13 mm) PTFE syringe filters
were purchased from Whatman Int. Ltd. (Maidstone, England).

A MilliQ water

purification apparatus (Milli-Q Synthesis, Millipore Inc., Milford, MA, USA) with a 0.22
µm pre-filter (Millipak Express 20, Millipore Inc., Milford, MA, USA) was used to
obtain deionized water. All other reagents were of an analytical grade.

Preparation of Indomethacin Seed Crystal Suspensions
Indomethacin seed crystal suspensions were prepared using a previously
published method.104 Briefly, indomethacin powder (~0.1% w/w) was mixed with 50
mM phosphate buffer (pH 2.15) for about 3 days using a mechanical shaker. The
temperature was controlled at 25°C using a water bath. The equilibrated suspensions
were first passed through 30 µm nylon filters, and filtrates from this step were further
filtered through 3 µm filters. The solids retained on the 3 µm filters were re-suspended in
saturated indomethacin solutions (pH 2.15) to obtain final suspensions with a narrow and
unimodal particle size distribution.
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Indomethacin Crystal Growth Rate Measurement
1. Batch Method (S>1.6)
Indomethacin crystal growth rates at different S between 2 and 9 were measured
using a previously published second derivative online UV method.104

Briefly,

indomethacin crystal growth rate coefficients were estimated from indomethacin
desupersaturation (concentration vs. time) profiles. Indomethacin concentration vs. time
profiles were determined using the second derivative UV spectroscopic method
(wavelength range: 210 to 400 nm, λmax =295 nm). The suspensions were supersaturated
by adding 100-150 µl of a highly concentrated (~120 µg/mL) indomethacin solution (pH
6.8) at a specific addition rate using a micro-syringe pump.
supersaturated indomethacin suspensions was below 2.2.

The final pH of

During desupersaturation,

indomethacin suspensions (pH 2.15) were mixed in 1-cm matched UV quartz cells using
pivoted magnetic stirrers at 400 RPM.
2. Infusion Method (S<1.6)
Indomethacin solution (5 µg/mL, pH 6.8) was infused into 3 ml of indomethacin
seed crystal suspension (pH 2.15) for about 4 hours at 2.5 µl/min infusion rate using a
micro-syringe pump. The total infusion volume of the indomethacin solution added was
about 0.6 ml. The pH of the final supersaturated suspension after infusion remained
below 2.8. Indomethacin concentrations were measured at regular time intervals using
the second derivative UV method. The infusion was stopped after about 4 hours and the
supersaturated indomethacin suspension (S~1.4) was allowed to reach a stable
equilibrium state. Indomethacin apparent solubility after crystal growth was determined
after around 24 hours using the same method as described in an earlier section.
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3. High Energy Seed Crystals
Indomethacin crystal growth rates at low S (< 6) were also measured using high
energy indomethacin seed crystals. High energy indomethacin seed crystals, unlike the
low energy seed crystals, had higher energy surface that, in turn, provided higher
apparent solubility.104

Specifically, the low energy seed crystals from saturated

indomethacin suspensions at pH 2.15 were converted into the high energy seed crystals
by depositing higher energy thin surface layers of indomethacin on the low energy seed
crystals. The deposition of high energy thin surface layers of indomethacin was achieved
using a typical crystal growth experiment at high S (S~6). The indomethacin suspensions
containing higher energy seed crystals were then utilized to determine indomethacin
crystal growth rates by the batch method described in an earlier section.

Indomethacin Solubility Measurements (Before and After Crystal Growth)
The intrinsic solubility of indomethacin before crystal growth was measured using
a method described previously.104

Briefly, indomethacin was mixed with 50 mM

phosphate buffer (pH 2.15) in a rotary shaker. The temperature was maintained at 25ºC
using a water bath.

At regular time intervals, indomethacin concentrations were

measured using syringe filtration (0.45 µ PTFE syringe filter) and an UV
spectrophotometer (λmax =321 nm). The method for determining indomethacin apparent
solubility after crystal growth, henceforth defined as the apparent solubility, was
described in detail in a previous publication.104 Briefly, the apparently solubility was
measured

from

equilibrated

indomethacin

suspensions

after

crystal

growth.

Indomethacin concentrations from these suspensions were measured by UV
spectrophotometry in two different ways: (1) online concentration measurements from
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indomethacin suspensions using the second derivative UV spectroscopic method (λmax
=295 nm), and (2) off-line concentration measurements from clear indomethacin
solutions by regular UV spectroscopy (λmax =321 nm). The clear solutions were obtained
by filtration of indomethacin suspensions through a 0.45 µ PTFE syringe filter.

Indomethacin Seed Crystal Characterization
Indomethacin seed crystals were characterized for their number and size
distributions, mass median diameter, total surface area, morphology, and crystalline
polymorphic form before and after crystal growth. The methods used in characterizing
indomethacin seed crystals were described previously.104

The number and size

distributions per unit volume of indomethacin suspension were determined using a
Coulter counter ((Multisizer Z2, Beckman Coulter Inc., Miami, FL, USA). The Coulter
counter measurements were made in two size ranges: (1) 2-8 µm and 8-25 µm. Powder
X-ray diffraction (PXRD) profiles were obtained using an X-ray diffractometer (Bruker
D8 Advance, Bruker AXS, Inc., Madison, WI, USA). The scan settings were 3 to 35º 2θ
with 0.05° step size and 4 or 0.6 seconds step time (operating conditions for the x-ray
copper anode (1.54A): 40 kV and 40 mA).

Analyses of the shape and size of

indomethacin seed crystals utilized a polarized light microscope (PLM) and a scanning
electron microscope (SEM, Hitachi S4300).

Statistical Analyses
Scientist® software (Micromath Inc., St. Louis, MO, USA) was used to perform
non-linear least-squares analyses of indomethacin concentration vs. time profiles.
Microsoft Excel was used to conduct the Student t-test and ANOVA.
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RESULTS

Indomethacin Seed Crystal Characterization Before and After Crystal Growth
Indomethacin seed crystals were characterized in suspensions before and after
crystal growth by determining their physical characteristics including size distribution,
number concentration, morphology, and physical form.

The typical mass median

diameter of the indomethacin seed crystals was 11.1 ± 0.3 (95% CI) µm. The typical
surface area of indomethacin seed crystals was 4.5 ± 0.3 × 10-2 (95% CI) cm2 per mL of
suspension.

The number of indomethacin seed crystals per mL of indomethacin

suspension was 4.1 ± 0.6 × 104 (95% CI). The shape characteristics of indomethacin seed
crystals were analyzed by PLM & SEM (data not shown). The crystalline nature of the
indomethacin seed crystals was confirmed by polarized light microscopy. The SEM
analysis of indomethacin seed crystals indicated that the crystals were cuboidal, a
characteristic morphology of the γ-polymorph of indomethacin.128

Furthermore, no

particles with significantly different geometry (e.g., long needles or spherulites
characteristic of the α-polymorph of indomethacin128) could be detected from
comparisons of several SEM micrographs of indomethacin seed crystals before and after
crystal growth, which again indicated the absence of primary nucleation of other
indomethacin forms.128 The physical form of indomethacin seed crystals before and after
crystal growth was determined by PXRD. The PXRD patterns of indomethacin seed
crystals before and after crystal growth matched the PXRD patterns of original
indomethacin powder, indicating that there was no significant change in crystallinity or
polymorphic form of the indomethacin seed crystals after crystal growth that could be
detected by PXRD (data not shown). The theoretically estimated thicknesses of the
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newly grown indomethacin surface layer after crystal growth at S values of 6 and 2 were
approximately 0.3 µm and 0.9 µm, respectively. Considering the very small thicknesses
of the newly grown surface layers, it is unlikely that surface changes on the seed crystals
would have been detected by PXRD.104,139,153,154

Indomethacin Solubility Before and After Crystal Growth
The intrinsic solubility of indomethacin (before crystal growth) was determined
previously as 3.4 ± 0.1 × 10-6 M (pH 2.15; 0.1 M ionic strength, 25ºC).104 In the same
earlier study,104 we showed that the apparent solubility of indomethacin after crystal
growth at a high S of 6 was about 55% higher than its equilibrium solubility (Table 4.1).
The higher apparent solubility was attributed to the deposition of a thin surface layer of
higher energy on the existing lower energy indomethacin seed crystal surfaces. One of
the objectives of this study was to compare indomethacin apparent solubilities after
crystal growth at a wide range of S and, in turn, determine if the higher energy surface
was also formed after crystal growth at low S. Indomethacin apparent solubilities after
crystal growth were determined at various S ranging from 2 to 9.

Representative

indomethacin apparent solubilities after crystal growth at a high S of 6 and a low S of 2
are compared in Table 4.1. The indomethacin apparent solubilities after crystal growth at
different S from 2 to 9 were significantly higher than the indomethacin equilibrium
solubility (p <0.05). For example, the apparent solubility of indomethacin after crystal
growth at an S of 9 was 5.3 ± 0.3 × 10-6 M whereas the equilibrium solubility of
indomethacin was 3.4 ± 0.2 × 10-6 M. Moreover, there was no significant difference
between the apparent solubilities after growth at low (2 < S < 6) and high S (6 ≤ S ≤ 9) (p
<0.05). Finally, the higher apparent solubility observed after crystal growth at high and
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low S clearly indicated that the higher energy surface was formed on indomethacin seed
crystals after crystal growth (Refer to the “Discussion” section in this report for more
details on this topic).30,104

Indomethacin Crystal Growth Kinetics at High & Low Degrees of Supersaturation
Indomethacin crystal growth kinetic (or desupersaturation) profiles were obtained
at different degrees of supersaturation between 2 and 9. Representative indomethacin
desupersaturation profiles determined at high (S=6) and low (S=3) degrees of
supersaturation using seed crystals with similar surface areas are shown in Figure 4.1.
The indomethacin desupersaturation rate was much slower when the desupersaturation
was initiated at a low S of 3 as compared to that at a high S of 6. To compare the
indomethacin crystal growth rate coefficients (kG) at a high and low S, the kGs at various
S were determined by fitting indomethacin desupersaturation profiles to an empirical
crystal growth model (Eq. 4.1).24 More detailed discussion on the derivation of this
model can be found elsewhere.104

−

dcb
g
= k G A(cb − cs )
dt

(4.1)

where cb is the solute concentration in the bulk medium, kG is an apparent crystal
growth rate coefficient, A is the crystalline surface area per unit volume of the bulk
medium, cs is the solute concentration in solution at equilibrium (i.e., the saturation
solubility), and g is the apparent order of the crystal growth process. In our previous
study,104 we had determined that the value of g for indomethacin crystal growth kinetics
(S=6) from its supersaturated aqueous suspension was equal to 1. This determination
was carried out by comparing the empirical crystal growth model (Eq. 4.1) fits of
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indomethacin desupersaturation profiles using three different values of g (i.e., 0, 1, 2, and
3) and the lack of fit test. The lack of fit analysis clearly showed that the crystal growth
model with g=1 (Eq. 4.1) fit the indomethacin desupersaturation profiles (S=6) best.
Here, the driving force for crystal growth was calculated as the difference between cb and
the apparent solubility i.e. 5.2 ± 0.6 × 10-6 M (Table 4.1). Since the objective of the
present study was to compare indomethacin crystal growth rate coefficients (kG) at
different S including the previously studied high S of 6, we further evaluated the
application of the first-order empirical crystal growth kinetic model at different S. As
shown in Figure 4.1, the first-order crystal growth model fit the indomethacin
desupersaturation profiles at high and low S very well and hence the first-order model
was used in the present study to determine kGs at different S. It should also be noted that
since g is an empirical parameter, the value of g used in Eq. 4.1 may not have any
fundamental significance.24
Indomethacin crystal growth rate coefficients (kG) were determined at various S
between 2 and 9 (Figure 4.2). The kGs were significantly smaller at low S as compared to
those at high S indicating much slower crystal growth rates at low S. For example, as
shown in Table 4.1, indomethacin kGs at S=6 and S=2 were 5.0 ± 0.7 × 10-3 cm/sec and
5.5 ± 1.3 × 10-4 cm/sec, respectively. The indomethacin kG increased with S between 2
and 6, while between S values of 6 and 9, the kG did not change significantly and
appeared to be reaching a plateau. The indomethacin kG between the S= 6-9 was similar
to the theoretically predicted kG (Figure 4.2, broken line) assuming bulk diffusion
controlled crystal growth (5.0 ± 0.3 × 10-3 cm/sec (±95% CI)).104 This indicated that the
crystal growth kinetics of indomethacin is bulk diffusion controlled for S>6.
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The

indomethacin kGs at S <6 were significantly smaller than the theoretically predicted (bulk
diffusion controlled) indomethacin kG (Figure 4.2, broken line). The indomethacin kG at
a low S of 2 was approximately nine times smaller than the theoretically predicted kG
assuming bulk diffusion control. This could indicate a change in the rate limiting step for
indomethacin crystal growth with decreasing values of S from bulk diffusion controlled
crystal growth kinetics at S>6 to surface integration control at lower S values.

Indomethacin Crystal Growth Kinetics using High Energy Seed Crystals
To determine the relationship between indomethacin seed crystal surface energetics
and its crystal growth kinetics (growth rates and rate limiting steps), indomethacin
crystal growth rates were measured at a low S of 2 using high and low energy
indomethacin seed crystals. The high energy indomethacin seed crystals were obtained
from previously completed indomethacin crystal growth experiments in supersaturated
aqueous suspensions at high S (6 ≤ S ≤ 9). As shown in Table 4.1, the indomethacin
crystal growth rate coefficient determined at a low S of 2 using high energy seed crystals
was 5.6 ± 0.7 × 10-3 cm/sec, which was approximately ten times higher than the kG
determined at the low S of 2 using low energy seed crystals (5.5 ± 1.3 × 10-4 cm/sec).
Moreover, the kG determined from high energy seed crystals at low S was similar to the
theoretically predicted kG assuming bulk-diffusion controlled crystal growth (5.0 ± 0.3 ×
10-3 cm/sec). This indicated that the surface energetics of indomethacin seed crystals
clearly influenced the indomethacin crystal growth rate and, in turn, its rate limiting step.
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Table 4.1. Effects of degree of supersaturation and seed crystal surface energetics
on indomethacin solubility and crystal growth rate coefficient (± 95% CI)

Indomethacin
Seed Crystals

Before Crystal
Growth

After Crystal
Growth

Degree of
Supersaturation
(S)

Equilibrium/
Apparent
Solubility (M)

Indomethacin
Crystal Growth
Rate Coefficient, kG
(cm/sec)

6

3.4 ± 0.2 × 10-6

5.0 ± 0.7 × 10-3

2

3.4 ± 0.2 × 10-6

5.5 ± 1.3 × 10-4

<1.6

3.4 ± 0.2 × 10-6

6.4 ± 1.8 × 10-4

6

5.2 ± 0.6 × 10-6

-

2

6.3 ± 0.7 × 10-6

5.6 ± 0.7 × 10-3

<1.6

3.9 ± 0.5 × 10-6

-
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Figure 4.1. Representative indomethacin crystal growth kinetic profiles at high
(S=6, □) and low (S=3, ●) degrees of supersaturation (S). The lines represent firstorder empirical crystal growth model (Eq. 4.1) fits. Error bars represent 95%
confidence intervals (CI).
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Figure 4.2. Effect of the degree of supersaturation (S) on indomethacin crystal
growth rate coefficients (kG). The broken line represents theoretically predicted
indomethacin kG for bulk diffusion controlled crystal growth. Error bars represent
95% confidence intervals (CI).
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Indomethacin Crystal Growth using the Infusion Method (S<1.6)
Indomethacin crystal growth experiments at S < 1.6 were carried out using an
infusion method. The purpose of this experiment was to measure indomethacin crystal
growth rates at very low S without converting the initial lower energy indomethacin seed
crystal surface to a higher energy surface. It was assumed that if the crystal growth of
indomethacin occurred at S below the indomethacin apparent solubility (i.e., S < 1.6)
then the higher energy surface would not be formed on the initial low energy seed crystal
surface. Therefore, indomethacin crystal growth rates measured at S < 1.6 could be
directly attributed to deposition on the lower energy indomethacin seed crystal surface.
The batch method used to study crystal growth at S between 2 and 9 was limited by
severe difficulties in achieving and maintaining very low degrees of supersaturation (S <
1.6). A modified crystal growth measurement method was therefore developed using an
infusion technique. A detailed description of this method is provided in the Materials and
Methods section.
A representative indomethacin crystal growth profile determined using the
infusion method is shown in Figure 4.3.

The open squares denote experimentally

measured indomethacin concentrations at regular time intervals.

The infusion was

continued for about 4 hours after which the supersaturated indomethacin suspension was
allowed to equilibrate for about 24 hours. The apparent solubility of indomethacin after
crystal growth at S< 1.6 (3.9 ± 0.5 × 10-6 M) was similar to its equilibrium solubility (3.4
± 0.2 × 10-6 M) (Table 4.1). This indicated that the higher energy surface did not form on
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the initial lower energy seed crystal surface after crystal growth at very low S <1.6. The
indomethacin crystal growth profile was fit to an infusion-based crystal growth model
(Eq. 4.2), which was derived from the first-order empirical crystal growth model (Eq.
4.1).

cb =

R + k app cs
k app

(1 − e

−kappτ

)e

−kapp t

(

+ cs 1 − e

−kapp t

)

(4.2)

Here, the rate constant, kapp= kG × A where kG is an apparent crystal growth rate
coefficient, A is the crystalline surface area per unit volume of the bulk medium, R is the
indomethacin infusion rate (moles.liter-1.sec-1), τ is the total duration of infusion (sec), cb
is the indomethacin concentration in the bulk at time t (moles.liter-1), and cs is the
indomethacin concentration at the crystal surface (i.e., the equilibrium solubility of
indomethacin). The experimentally measured indomethacin crystal growth profile using
the infusion method was in good agreement with the predicted profile (solid line, Figure
4.3). The broken line (Figure 4.3) represents the predicted indomethacin concentrations
assuming no crystal growth had occurred during the entire infusion period.

The

indomethacin crystal growth rate coefficient (kG) estimated from the infusion method
using Eq. 4.2 was 6.4 ± 1.8 × 10-4 cm/sec. This was in good agreement with the
indomethacin kG (5.7 ± 0.7 × 10-4 cm/sec) previously estimated from the crystal growth
experiments at a low S of 2 (Table 4.1), indicating that the slower indomethacin crystal
growth at low S (<6) could be associated with the low energy seed crystal surface
available for growth.
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A representative indomethacin desupersaturation profile from an

infusion-based crystal growth experiment at a degree of supersaturation (S) below
1.6. (Legends: □ bulk concentration, ―•—•― equilibrium solubility line, ……
apparent solubility line, ─ ─ ─ predicted bulk concentration in the absence of
crystal growth, ——— infusion-based crystal growth model fit (Eq. 4.2))
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DISCUSSION

Indomethacin Apparent Solubility after Crystal Growth
The apparent solubility of indomethacin after crystal growth at a low S of 2 was
higher than the saturation solubility before growth (Table 4.1). Similar observations were
made for the apparent solubilities after growth at S between 2 and 9 (data not shown).
We have previously shown that the apparent solubility could be different from the
equilibrium solubility depending on the nature of the newly grown surface layer.104 If the
newly grown layer is of higher energy, then the apparent solubility would be higher than
the equilibrium solubility before growth.32 Similar to our previous observation for
indomethacin crystal growth at S=6,104 we found in the present study that a higher energy
indomethacin crystal surface was also formed after crystal growth at low S (2 < S < 6).
The higher energy of the newly grown surface layer could be attributed to higher
disorder30 or the growth of a higher energy polymorphic form (e.g., the α-form of
indomethacin).104 The higher disorder could range from smaller lattice defects to larger
amorphous regions depending on the degree of disorder.29 Several previous studies have
linked a higher apparent solubility or dissolution rate to higher disorder (higher energy
sites) of the solid surface.29,30,32
Since the higher energy indomethacin surface provided an apparent solubility that
was approximately 1.6 times higher than the equilibrium solubility, we determined the
apparent solubility at S < 1.6. It was reasoned that if the S remained below 1.6 during
crystal growth then the higher energy surface would not be formed. This would result in
similar indomethacin solubilities before and after crystal growth. Here the equilibrium
solubility represented the lower energy surface of indomethacin seed crystals.
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The

apparent solubility of indomethacin after growth at S < 1.6 was similar to the equilibrium
solubility (Table 4.1), indicating that the lower energy indomethacin seed crystal surface
was retained after growth at low S < 1.6.

Indomethacin Crystal Growth Kinetic Modeling at High & Low Degrees of
Supersaturation
Several external (e.g., degree of supersaturation, impurities, and excipients) and
internal (structure, bonds, and defects or disorder) factors influence the kinetics of a
typical crystal growth process.25,26 The degree of supersaturation, being the driving force
for the crystal growth process, could significantly change the crystal growth kinetics and
related growth parameters such as the crystal growth rate coefficient (kG) and the order of
the crystal growth process (g) (Eq. 4.1). As mentioned earlier, the term g used in
crystallization studies (Eq. 4.1) is an empirical parameter, which is different from the
“reaction order” term used in chemical kinetics. It does not illustrate the number of
species involved in the crystal growth process and hence it may have no fundamental
significance.24 Nevertheless, several empirical correlations have been made between the
value of g and the mechanism of crystal growth.24,103,163 A g value of 1 is associated with
high energy (high disorder or roughness) surface-based continuous growth at high and
low S as well as screw dislocation or spiral growth mechanisms at high S.24,103 A g value
of 2 is associated with the screw dislocation mechanism-based growth at low S, whereas
a g > 2.5 is associated with two-dimensional nucleation mechanism-based growth.103 Li
and Rodriguez-Hornedo103 experimentally determined the values of g for two different
faces of the glycine crystal. The values of g were 1.3 ± 0.2 and 1.5 ± 0.2 for 010 and 011
faces, respectively. Based on the values of g, the growth of 010 and 011 faces of glycine
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was attributed to the screw dislocation mechanism. Moreno et al.163 observed that the
values of g were erratic and higher than 1 at low degrees of supersaturation during the
crystal growth of hydroxyapatite. In our previous study,104 we observed that when the
indomethacin desupersaturation profiles were fitted to the empirical crystal growth model
(Eq. 4.1) where the driving force was calculated as the difference between indomethacin
bulk concentration and the apparent solubility, the value of g was 1. However, when the
driving force for crystal growth was calculated using the equilibrium indomethacin
solubility (~55% lower than the apparent solubility), the value of g increased from 1 to
approximately 1.5. Since the higher apparent indomethacin solubility was stable up to 7
days as described in our previous study,104 it was used to calculate the driving force for
crystal growth. In the present study, we used the same method to calculate the driving
force for crystal growth. As shown in Figure 4.1, the first-order empirical crystal growth
model fit the desupersaturation profiles very well when the driving force was calculated
using the apparent solubility. This indicated that the indomethacin crystal growth could
be associated with the high energy (high disorder or roughness) surface-based continuous
growth mechanism at high and low S.
The indomethacin crystal growth rate coefficient in aqueous supersaturated
suspensions increased with S between 2 and 6 whereas it reached a plateau at S>6. Since
the faster indomethacin crystal growth at S ≥ 6 was bulk diffusion controlled,104 the
slower crystal growth at S<6 was associated with a change in rate limiting step from bulk
diffusion to surface integration. The rate limiting steps of crystal growth have previously
been correlated with the degree of supersaturation.37 Scholl et al.44 observed that the
crystal growth rate of PDI 747, a phosphodiesterase type 4 inhibitor, was at least one
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order of magnitude slower than the theoretically predicted diffusion-limited growth rates
at low S between 2 and 3. The slower growth of PDI 747 was determined to be surface
integration controlled. Nancollas et al.111 observed that the crystal growth of calcium
sulfate dehydrate in aqueous solutions was also surface integration controlled at low S.

Relationship between Indomethacin Crystal Surface Energetics and the Rate Limiting
Steps of Indomethacin Crystal Growth
Highly disordered or molecularly smooth surfaces could be formed during crystal
growth depending on high or low degrees of supersaturation, respectively.9 Properties of
the newly grown surface such as the degree of surface disorder or defects or roughness
(i.e., surface energetics) significantly influence the rate limiting step of the crystal growth
process. Besides surface energetics, the rate limiting step of a crystal growth process also
depends on factors such as degree of supersaturation, solvent type, temperature, and the
nature of the growing crystal surface.25 The crystal surface with higher energy due to
higher active growth sites such as defects or kinks is associated with faster crystal growth
rates.24,30 When the growing surface is molecularly smooth (e.g., perfect crystals), the
crystal growth is significantly slower. While the bulk diffusion controlled crystal growth
rate coefficient has been directly correlated with the diffusion coefficient of the solute
and the diffusion layer thickness,104 the relationship between the degree of
supersaturation and surface integration rate depends on the nature of the growing crystal
surface.96
The higher indomethacin apparent solubility at low S (2 < S < 6) indicated that the
higher energy seed crystal surface was formed when the growth was initiated at low S.
However, despite the formation of a higher energy surface, the indomethacin crystal
125

growth rate coefficient was significantly smaller indicating surface integration control.
Hence it was hypothesized that a longer lag time existed for the conversion of the initial
low energy seed crystal surface to a high energy surface when crystal growth occurred at
low S (Figure 4.4). The longer lag time and, in turn, slower rate of conversion from the
initial lower energy seed crystal surface to the higher energy surface at low S could be
attributed to the smaller thermodynamic driving force available for crystal growth at low
S. To confirm this hypothesis, the indomethacin crystal growth rate was determined at
very low S < 1.6 using the infusion method. It was expected that the higher energy
surface would not be formed at S < 1.6, which was later experimentally confirmed from
the indomethacin apparent solubility measurements after crystal growth at S < 1.6. The
indomethacin crystal growth rate coefficient measured at low S < 1.6 was similar to that
measured at low S of 2 confirming the fact that the slower indomethacin crystal growth
rate was associated with the lower energy surface (Table 4.1). The effect of seed crystal
surface energetics on the indomethacin crystal growth rate at low S was further studied
using the high energy seed crystals. Since the slower indomethacin crystal growth rate at
low S was associated with the lower energy seed crystal surface, it was assumed that
indomethacin crystal growth at low S would be faster when higher energy seed crystals
were used. As shown in Table 4.1, the indomethacin crystal growth rate coefficient (kG)
measured at S=2 using the higher energy seed crystals was about 10 times higher than
that obtained using the lower energy seed crystals at the same S. This result further
supported the hypothesis that the slower indomethacin crystal growth rate at low S was
associated with the lower energy surface of the seed crystals.

Finally, the faster

indomethacin crystal growth k at S between 6 and 9 was bulk diffusion controlled
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whereas the slower crystal growth at S < 6 could be surface integration controlled. The
change in the rate limiting step from bulk diffusion to surface integration for
indomethacin crystal growth at low S could be attributed to the lower energy seed crystal
surface and the longer lag time for its conversion to higher energy surface.
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Low energy seed crystals
High energy seed crystals

Concentration

Crystal growth experiment (High S)
Crystal growth experiment (Low S)
Infusion-based crystal growth experiment (Low S)

Higher Apparent solubility
Lower equilibrium solubility

Time

Figure 4.4.

Schematic diagram illustrating a proposed hypothesis for varying

indomethacin seed crystal surface energetics at different degrees of supersaturation
(S) during crystal growth from supersaturated aqueous suspensions.
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CONCLUSIONS
Indomethacin crystal growth kinetics from supersaturated aqueous suspensions was
compared at varying degrees of supersaturation (2 ≤ S ≤ 9). The higher indomethacin
apparent solubility after crystal growth at S between 2 and 9 indicated that a higher
energy surface was formed on the seed crystals initially having a lower energy surface.
The indomethacin crystal growth rate coefficient (kG) increased with S between an S of
2-6. At high S (6 ≤ S ≤ 9), the kG reached a plateau value that was similar to the
theoretically predicted kG assuming bulk diffusion controlled crystal growth.

The

indomethacin kG at a low S of 2 was ~10 times smaller than the theoretically predicted kG
assuming bulk diffusion controlled crystal growth. The smaller indomethacin kG at S=2
could be due to a change in the rate limiting step from bulk diffusion to surface
integration. The change in rate-limiting step from bulk diffusion to surface integration
for the indomethacin crystal growth at a low S of 2 was attributed to a longer lag time for
the conversion of initial lower energy indomethacin seed crystal surface to a high energy
surface due to reduced thermodynamic driving force for crystal growth at the low S of 2.
The kG determined at a low S of 2 using higher energy seed crystals was similar to that
predicted assuming bulk diffusion controlled crystal growth. This result further verified
the hypothesis that the higher energy surface provided faster bulk diffusion controlled
crystal growth. Using an infusion-based method, the indomethacin kG at very low S
(<1.6) was determined without transforming the initial lower energy surface to the higher
energy surface. The indomethacin apparent solubility after crystal growth at S<1.6 was
lower and similar to the equilibrium solubility indicating that crystal growth at S below
the higher indomethacin apparent solubility (i.e., S < 1.6) did not form the higher energy
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surface. The kG at S < 1.6 was similar to that determined at an S of 2 supporting the
hypothesis that the smaller kG at low S could be attributed to the lower energy
indomethacin seed crystal surface. Finally, the higher energy surface provided faster,
bulk diffusion controlled indomethacin crystal growth at high and low S, whereas the
lower energy surface was associated with significantly slower surface integration
controlled crystal growth rate at low S. The quantitative mechanistic understanding
derived from the indomethacin crystal growth kinetics at high and low S may be useful in
exploring the inhibitory effects of model pharmaceutical excipients on indomethacin
crystal growth and, in turn, on its supersaturation maintenance.

Copyright © Dhaval D. Patel 2015
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Chapter Five
Effect of Precipitation Inhibitors on Indomethacin Supersaturation Maintenance:
Mechanisms & Modeling
INTRODUCTION
Supersaturation is commonly encountered when high energy drug delivery
technologies such as amorphous solid dispersions,3 lipid-based delivery systems,50 and
nanoparticles1 are utilized to enhance bioavailability of poorly water soluble drugs.
Supersaturation in the solid-state can be attributed to higher drug loadings in drug
delivery system matrices than the equilibrium solubilities in the same matrices.53
Solution-state (e.g., aqueous) supersaturation could be produced in vivo after the
administration of high energy drug delivery technologies to patients.91 The in vivo
aqueous supersaturation generally occurs due to higher apparent solubilities provided by
the high energy states of drugs in biological media.
While the solid-state supersaturation has been an active topic of research for the
past several decades, a thorough understanding of the solution-state (or aqueous)
supersaturation and its maintenance is also critical for the development of robust drug
delivery technologies for two main reasons: (1) the solution-state understanding could
serve as a foundation for understanding supersaturation in the solid-state with the aim of
improving physical stability of drugs in high energy formulations and (2) optimal in vivo
supersaturation maintenance could provide higher & less variable bioavailability,1,91
which in turn could reduce the requirements of higher and frequent dosing as well as
wider safety margins for drug candidates under clinical development. Pharmaceutical
polymeric precipitation inhibitors (PPIs) such as cyclodextrins,7 surfactants,43
polyvinylpyrrolidone (PVP),108,164 and hydroxypropyl methylcellulose (HPMC)108,164
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have effectively maintained aqueous supersaturation of a number of pharmaceutical
compounds. The supersaturation maintenance effect of these PPIs varies extensively
depending on the drug, rendering the development of predictive tools for a rational and
efficient pharmaceutical PPI selection process more difficult. For example, Vandecruys
et al.43 observed in a recent screening study with several drug candidates that PPIs such
as PVP & HPMC were more effective at prolonging supersaturation than providing
higher degrees of supersaturation, whereas PPIs such as surfactants and cyclodextrins
provided higher degrees of supersaturation.

These PPIs are believed to maintain

supersaturation by inhibiting drug nucleation, crystal growth, or both.1,108 Lindfors et al.20
recently determined that PVP was more effective at inhibiting the crystal growth of
bicalutamide than its nucleation. The inhibitory effects of polymers such as PVP and
HPMC were attributed to their adsorption on to the growing crystal surface. Moreover, it
was proposed that the adsorbed polymer could inhibit the crystal growth process by
blocking the active growth site, increasing the diffusive barrier at the solid-liquid
interface, or both.12,21 While a few recent studies1,20,43 have attempted to discern the
mechanisms of action for the above-mentioned PPIs, the supersaturation maintenance
effects of these PPIs are still not well understood due in part to a paucity of systematic
and quantitative explorations. Moreover, the proposed mechanisms of PPIs’ actions are
rarely correlated with the sub-processes of amorphous precipitation or crystallization
processes including nucleation and crystal growth and their specific mechanisms such as
bulk diffusion or surface integration. The overall lack of a thorough understanding of
PPIs’ effects on aqueous supersaturation maintenance also makes a priori predictions of
their beneficial effects very challenging.
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The objective of this study was to develop a quantitative approach to explore the
crystal growth inhibition and, in turn, maintenance of supersaturation of indomethacin, a
model poorly water soluble drug, by three model PPIs including hydroxypropyl βcyclodextrin (HP-β-CD), PVP, and HPMC and to begin the process of understanding
these effects mechanistically (Figure 5.1). In this report, using a recently developed
second-derivative UV spectroscopy method,104 we have shown that PVP and HPMC have
more dramatic effects than HP-β-CD on the crystal growth of indomethacin, particularly
at high degrees of supersaturation. HP-β-CD is a better indomethacin crystal growth
inhibitor at low (S<3) than at high (S>3) degrees of supersaturation. A mathematical
model based on reactive diffusion theory has been developed to rationalize the modest
effect of HP-β-CD on indomethacin crystal growth at high S.
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A

B

C

D

Figure 5.1. Chemical structures of indomethacin (A) and model pharmaceutical
PPIs:

(B)

hydroxypropyl

β-cyclodextrin

(HP-β-CD),

methylcellulose (HPMC), and (D) polyvinylpyrrolidone (PVP).
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(C)

hydroxypropyl

THEORY

Reactive Diffusion Layer Theory
The effect of HP-β-CD on indomethacin crystal growth kinetics was modeled
using the classical reactive diffusion layer theory. The theory assumes complexation
between indomethacin (HA) and HP-β-CD (CD) in the diffusion layer during crystal
growth, as described below.165
The following equilibrium will exist when HA and HA-CD, the complex of HA
and CD, are diffusing through the diffusion layer from the supersaturated bulk to the
crystal solid surface during crystal growth.
K 1:1

HA + CD ←→
HA − CD

K 1:1 =

[ HA − CD ]
[ HA][CD ]

(5.1)

(5.2)

where K1:1 is the equilibrium or stability constant for the 1:1 complex of HA and CD,
HA-CD. The concentration gradients of various solution species across the diffusion
layer during indomethacin crystal growth in a low pH supersaturated solution containing
HP-β-CD are schematically described in Figure 5.2. Here, the subscripts “b” and “s”
represent bulk and surface, respectively. HB and B- represent the concentrations of
unionized and ionized species of a buffer. The thickness of the diffusion layer is h.
Since the mass transfer occurs from the bulk to the solid-solution interface, the value for
X (space variable) is assumed to be equal to zero at the bulk end of the diffusion layer and
equal to h at the solid-solution interface.
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Drug
crystal

Diffusion layer

Bulk medium

Adsorption
layer

X=h

X=0

Drug
B-b

B-s
HBs

HBb
[HA-CD]b
HAb

Cyclodextrin
Drug-cyclodextrin
complex

[HA-CD]s
HAs
A -s

Figure 5.2.

A -b

Schematic diagram describing concentration gradients of solution

species across the diffusion layer during crystal growth of a model weak acid drug
(HA) in supersaturated suspensions containing drug seed crystals, a complexing
agent (CD or HP-β-CD) and a buffer (HB).
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Mass balance of the species at any point X in the diffusion layer must take into
account both diffusion and reaction. The reaction rate component is expressed as Φ. At
steady state, the concentration change of each species with time can be expressed by the
following equations:
∂[HA]
∂ 2 [HA]
= D HA
+ Φ1 = 0
∂t
∂x 2

(5.3)

∂[CD ]
∂ 2 [CD ]
= DCD
+ Φ2 = 0
∂t
∂x 2

(5.4)

∂[HA − CD ]
∂ 2 [HA − CD ]
= D HA−CD
+ Φ3 = 0
∂t
∂x 2

(5.5)

where, DHA, DHA-CD, and DCD are the diffusion coefficients of HA, HA-CD, and CD,
respectively. According to the mass balance relationships,

D HA

∂ 2 [HA]
∂ 2 [HA − CD ]
=
−
D
HA
−
CD
∂x 2
∂x 2

(5.6)

DCD

∂ 2 [CD ]
∂ 2 [HA − CD ]
=
−
D
HA−CD
∂x 2
∂x 2

(5.7)

Integrating the above equations yields

DHA

∂[HA]
∂[HA − CD ]
= C1
+ DHA−CD
∂x
∂x

(5.8)

DCD

∂[CD ]
∂[HA − CD ]
+ D HA−CD
= C2
∂x
∂x

(5.9)
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where, C1 and C2 are the integration constants. Upon the second integration of the
above equations one obtains

DHA[ HA] + DHA− CD [ HA − CD] = C1 X + C3
DCD [CD ] + DHA−CD [ HA − CD ] = C 2 X + C 4

(5.10)

(5.11)

The following boundary conditions can be applied to determine the integration
constants:
At X=0 (bulk):
[HA] b=from total drug concentration
[HA-CD] b= from total drug concentration
[CD] b=known
At X=h (solid surface):
[HA] s=indomethacin intrinsic solubility
[HA-CD] s=unknown
[CD] s=unknown
∂[CD ] ∂[HA − CD ]
=
= 0; Since their fluxes at the solid boundary will be equal to
∂x
∂x

zero.
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From Eq. 5.9 and the boundary condition at X=h

DCD

∂[CD ]
∂[HA − CD ]
+ DHA−CD
= C2 = 0
∂x
∂x

(5.12)

From Eq. 5.11 and the boundary conditions at X=0 and h

DCD [CD]b + DHA−CD [ HA − CD]b = C 4

DCD [CD] s + DHA−CD [ HA − CD] s = C 2 h + C 4

(5.13)

(5.14)

Combining Eqs. 5.12, 5.13 and 5.14 one obtains

DCD [CD ]b + DHA−CD [ HA − CD ]b = DCD [CD ] s + DHA−CD [ HA − CD] s

(5.15)

By substituting from Eq. 5.4,

[CD] s =

DCD [CD]b + DHA−CD [ HA − CD]b
DCD + DHA−CD K1:1 [ HA] s

(5.16)

[CD]s can be calculated from Eq. 5.16. Furthermore, [HA-CD]s can be estimated using
[CD]s and Eq. 5.2. The indomethacin bulk diffusion controlled crystal growth rate or
mass deposition rate, J (moles cm-2 time-1), in the presence of a complexing agent such as
HP-β-CD can be defined as
1 dm
1
= J = [DHA ([ HA]b − [ HA] s ) + DHA−CD ([ HA − CD ]b − [ HA − CD ] s )]
A dt
h
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(5.17)

where A is the surface area of seed crystals in cm2, m is the mass of indomethacin in
moles, and t is time. The bulk diffusion controlled crystal growth rate of indomethacin
without any complexing agent, J0, can be defined as

J0 =

where

[HA]total
b

and

[HA]total
s

[ (

1
total
total
DHA [HA]b − [HA]s
h

)]

(5.18)

are total concentrations of ionized and unionized

indomethacin in the bulk and at the solid-liquid interface, respectively.

The

indomethacin crystal growth inhibition factor (R) was defined as

R = J / J0

(5.19)

where J and J0 are indomethacin crystal growth rates with and without a model PPI such
as HP-β-CD.
MATERIALS AND METHODS

Materials
Indomethacin

(1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic

acid,

99+%, γ-polymorph, molecular weight =357.8 g/mole, pKa=4.17148) and PVP (PVP
K29-32, molecular weight: ~40,000 g/mole) were obtained from Sigma-Aldrich, Inc. (St.
Louis, MO, USA). HP-β-CD (Cavitron 32005, molecular weight =1297 g/mole, degree
of substitution: 0.4) was received from Cargill Food and Pharma Specialties (Cedar
Rapids, IA). HPMC (Methocel E5, molecular weight =10,000 g/mole) was obtained
from Dow Chemical Company (Midland, MI).

Nylon net filters (30 µ) and

polycarbonate membrane filters (3 µ) were purchased from Millipore Inc., (Milford, MA,
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USA). Nylon membrane filters (0.2 µ) and 13 mm PTFE syringe filters (0.45 µ) were
purchased from Whatman Int. Ltd. (Maidstone, England). Deionized water was obtained
from a MilliQ water purification apparatus (Milli-Q Synthesis, Millipore Inc., Milford,
MA, USA) and pre-filtered through a 0.22 µ filter (Millipak Express 20, Millipore Inc.,
Milford, MA, USA). All other reagents and materials were of an analytical grade.

Preparation of Indomethacin Seed Crystal Suspension
The indomethacin seed crystal suspension preparation method has been
previously described in detail.104 Briefly, the suspension was prepared by dispersing
~0.1% w/w indomethacin in 50 mM phosphate buffer at 25ºC for about 3 days using a
shaker water bath. The pH and ionic strength were maintained at 2.15 and 0.1 M (using
NaCl), respectively. The desired size distribution of the seed crystals was obtained by
first passing the equilibrated suspension through a 30 µ filter followed by another pass
through a 3 µ filter. The seed crystals retained on the 3 µ filter were re-suspended in
saturated indomethacin solution. The saturated indomethacin suspension was stored at
25ºC prior use.

Indomethacin Equilibrium & Apparent Solubility with Model PPIs
The equilibrium solubility of indomethacin in the presence of model PPIs was
measured using the same method that was used previously to determine its intrinsic
solubility.104 Briefly, a specific amount of indomethacin in excess of its saturation
solubility was shaken end-to-end in the model PPI solution (pH 2.15) using a rotary
shaker. Samples were withdrawn at 1, 2, 3 and 5-day time intervals and filtered through
a 0.45 µ PTFE syringe filter while ensuring its saturation. The filtrates were assayed for
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indomethacin using UV spectrophotometry (Lambda 40P, Perkin-Elmer Inc., USA) and
1-cm matched quartz cells (Starna Cells Inc., Atascadero, CA, USA) at 321 nm.
The indomethacin solubility after crystal growth in the presence of model PPIs,
henceforth referred to as the indomethacin apparent solubility, was measured using the
previously described method.104,166 Briefly, the indomethacin apparent solubility was
determined from the equilibrated suspensions of indomethacin after crystal growth from
supersaturated concentrations in the presence of model PPIs.

Indomethacin

concentrations were measured directly in the suspensions using second-derivative UV
spectroscopy as well as in clear solutions obtained by filtering the suspensions through a
0.45 µ syringe filter.

Viscosity Determination of Model PPI Solutions
The viscosity of model PPI solutions was measured using a programmable
cone/plate rheometer (Brookfield DV-III LV; Brookfield Engineering, Stoughton, MA).
The measurements were taken at 25°C using a CPE-40 spindle. The sample volume and
RPM were 0.5 mL and 100, respectively.

Indomethacin Crystal Growth Rate Measurement in the Presence of Model PPIs
The method to measure indomethacin crystal growth rates in the absence of model
PPIs has been described in detail in our previous publication.104 Using the same method,
indomethacin crystal growth rates in the presence of model PPIs were determined from
the decline in indomethacin concentration versus time from a supersaturated
concentration to a lower equilibrium concentration at 25ºC using an online secondderivative UV spectroscopic method. A more detailed description of the development
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and validation of the second-derivative UV method is provided elsewhere.104

The

second-derivative UV absorbance of indomethacin was measured at 295 nm after taking
the second-derivative of the original indomethacin UV spectrum (210 to 400 nm).
Suspensions containing defined quantities of seed crystals at pH 2.15 were supersaturated
by adding a highly concentrated indomethacin solution (pH 6.8) containing specific
amounts of model PPIs using a micro-syringe pump.

Both, the crystal growth

suspensions and the highly concentrated indomethacin-model PPI solutions were in 50
mM phosphate buffer having an ionic strength of 0.1 M using NaCl. The suspensions
were stirred using a pivoted magnetic stirrer at 400 RPM to ensure homogeneity.

Indomethacin Seed Crystal Characterization
Indomethacin seed crystals, before and after crystal growth, were characterized
for their size, shape and physical form. The mean size, number concentration and the
size distribution were obtained using a Coulter counter (Multisizer Z2, Beckman Coulter
Inc., Miami, FL, USA). A 50 µ glass aperture tube was used, which provided size
distribution data between 2 and 25 µ. The Coulter counter was calibrated using 3 and 10
µ particle size standards (Beckman Coulter Inc., Miami, FL, USA). The seed crystals
were characterized for any morphological changes before and after growth using
polarized light microscopy (PLM). The physical form of the indomethacin seed crystals
was verified before and after growth using powder X-ray diffraction (PXRD).
Indomethacin seed crystals were separated from suspension by filtration.

The seed

crystals were air dried for about 24 hours before being analyzed using an X-ray
diffractometer (Bruker D8 Advance, Bruker AXS, Inc., Madison, WI, USA). The X-ray
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copper anode (1.54A) was operated at 40 kV and 40 mA. The scans were performed
from 3 to 35º 2θ with 0.05° step size and 4 or 0.6 seconds step time.

Data Analyses
Linear and non-linear least-squares analyses were performed using a software
program (Scientist, Micromath Inc., St. Louis, MO, USA). The other statistical tests
including the Student’s t-test and ANOVA were performed using Microsoft Excel.
RESULTS

Model PPI Effects on Indomethacin Equilibrium & Apparent Solubility
The intrinsic solubility of indomethacin was determined previously to be 3.4 ± 0.1 ×
10-6 M (95% CI).104 The effects of model PPIs including HP-β-CD, PVP and HPMC on
the equilibrium solubility were determined at 0 to 1% w/w PPI concentrations. As shown
in Figure 5.3, HP-β-CD significantly increased the equilibrium solubility of
indomethacin. For example, at 1% w/w HP-β-CD, indomethacin solubility increased by
more than 100-fold from 3.4 ± 0.1 × 10-6 M to 3.9 ± 0.2 × 10-5 M (25 ºC, pH 2.15 at 0.1
M ionic strength using NaCl).

The effects of PVP and HPMC on the equilibrium

solubility of indomethacin were markedly less. The equilibrium solubilities of
indomethacin were 7.7 ± 0.7 × 10-6 M and 6.9 ± 0.2 × 10-6 M in 1% w/w PVP and
HPMC, respectively. These solubilities were approximately 50-fold lower than that
observed with 1% w/w HP-β-CD.
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Figure 5.3.

(A) Model PPI Effects on indomethacin equilibrium solubility. (B)

Effect of HP-β-CD on indomethacin apparent solubility after crystal growth. The
solid lines represent the model fit using Eq. 5.20. The broken line represents the
predicted indomethacin apparent solubility after crystal growth using the
indomethacin- HP-β-CD complexation constant before growth (1340 M-1) and Eq.
5.20.
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A linear relationship was observed for the effect of HP-β-CD concentration on the
equilibrium solubility of indomethacin (Figure 5.3). The equilibrium constant (K1:1) for
1:1 indomethacin:HP-β-CD complexation was estimated by fitting the indomethacin
solubility profile as a function of HP-β-CD concentration to Eq. 5.20.

S T = [ HA] +

K 1:1 [ HA][CDT ]
1 + K 1:1 [ HA]

(5.20)

where ST is the equilibrium solubility of indomethacin in the presence of HP-β-CD,
[HA] is the intrinsic solubility of indomethacin, and CDT is the total concentration of HPβ-CD. The model fit the solubility profile very well (Figure 5.3, solid line). The
estimated indomethacin:HP-β-CD complexation constant (K1:1) was 1340 ± 40 (95% CI)
M-1.
In a previous study,104 a significant difference between the solubilities of
indomethacin before and after crystal growth (with no PPI present) was observed. The
indomethacin solubility after crystal growth (i.e., indomethacin apparent solubility) was
about 55% higher (5.2 ± 0.6 × 10-6 M versus 3.4 ± 0.1 × 10-6 M) than the equilibrium
solubility before crystal growth. The higher apparent solubility of indomethacin after
crystal growth was attributed to the formation of a higher energy surface layer on the
existing indomethacin seed crystals.

As shown in Table 5.1 and Figure 5.3B, the

apparent solubilities of indomethacin after crystal growth in the presence of HP-β-CD (up
to 1% w/w) determined in the present study were higher than the equilibrium solubilities
before growth.

Moreover, it was observed that the higher indomethacin apparent

solubility was a function of HP-β-CD concentration. The apparent/equilibrium solubility
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ratios decreased as HP-β-CD concentration increased (Table 5.1).

At higher

concentrations, HP-β-CD may significantly influence the growth of the higher energy
surface layer on indomethacin seed crystals from supersaturated solutions or HP-β-CD
could enhance the rate of transformation of the higher energy form of indomethacin
deposited on the crystal surface to a lower energy form. This in turn could provide a
relatively lower indomethacin apparent solubility after crystal growth in the presence of
HP-β-CD than that predicted using the indomethacin-HP-β-CD complexation constant
and the higher apparent solubility obtained after crystal growth in the absence of HP-βCD (Figure 5.3B). This hypothesis was further verified by determining the apparent
solubility of indomethacin in the presence of 1% w/w HP-β-CD starting with seed
crystals containing the higher energy surface obtained after crystal growth. According to
the hypothesis, the experimental indomethacin apparent solubility should have been
lower than the theoretically predicted apparent solubility.

The experimental

indomethacin apparent solubility (4.5 ± 0.4 × 10-5 M) was lower than the theoretically
predicted solubility (5.9 ± 0.6 × 10-5 M), in accordance with the hypothesis. For PVP and
HPMC, the indomethacin apparent solubilities after crystal growth were similar to the
indomethacin equilibrium solubility indicating the absence of a higher energy surface
film after crystal growth in the presence of PVP and HPMC (data not shown).
The apparent solubility profile for indomethacin after crystal growth in the
presence of HP-β-CD (Table 5.1 and Figure 5.3B) was well described by Eq. 5.20 when a
higher value for the solubility [HA] than that used in Figure 5.3A was employed (i.e., 5.2
× 10-6 M vs. 3.4 × 10-6 M) along with an indomethacin:HP-β-CD complexation constant
(K’1:1) of 895 ± 16 (95% CI) M-1. These apparent parameter values were then utilized in
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modeling the inhibitory effect of HP-β-CD on the bulk diffusion controlled indomethacin
crystal growth at high S (Table 5.2).

Indomethacin Crystal Growth Rate Measurement in the Presence of Model PPIs
Representative indomethacin desupersaturation profiles (concentration versus
time) determined from supersaturated indomethacin seed crystal suspensions in the
presence and absence of model PPIs (HP-β-CD, PVP and HPMC) at high degrees of
supersaturation (S>3) are shown in Figure 5.4. The degree of supersaturation (S) is
defined by Eq. 5.21.

S=

C
Cs

(5.21)

where c is indomethacin concentration immediately after supersaturation and cs is the
equilibrium solubility of indomethacin. The desupersaturation profiles were fit to a first
order empirical crystal growth model104 using Eq. 5.22.

−

dcb k G A
(Cb − C s )
=
dt
Vb

(5.22)

where Cb is the solute concentration in the bulk medium, kG is an apparent crystal
growth rate coefficient, A/Vb is the crystalline surface area per unit volume of the bulk
medium, and Cs is the solution concentration of solute at equilibrium (i.e., the saturation
solubility).
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Table 5.1. Effect of HP-β-CD on Indomethacin Equilibrium & Apparent Solubility.
HP-β-CD
concentration
(% w/w)

Indomethacin Solubility (M)
Equilibrium
(Before Growth)

Apparent
(After Growth)

Solubility Ratio
(Apparent/Equilibrium)

0

3.4 ± 0.1 × 10-6

5.2 ± 0.6 × 10-6

1.5

0.05

4.7± 0.3 × 10-6

6.5± 0.4 × 10-6

1.4

0.25

1.2± 0.1 × 10-5

1.4± 0.5 × 10-5

1.2

0.5

2.0± 0.1 × 10-5

2.3± 0.3 × 10-5

1.2

1

3.9± 0.2 × 10-5

4.1± 0.4 × 10-5

1.1
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Table 5.2.

Model Parameters Employed in Predicting Effects of HP-β-CD on

Indomethacin Crystal Growth Kinetics at High Degrees of Supersaturation.
Parameters

Values

Diffusion coefficient of indomethacin (DHA)

5.6 × 10-6

cm2/sec

Diffusion coefficient of indomethacin:HP-β-CD
complex (DHA-CD)

3.0 × 10-6

cm2/sec

Diffusion layer thickness (h)

1.2 × 10-3

cm

Indomethacin apparent solubility

5.2 × 10-6

M

Stability constant of indomethacin:HP-β-CD
complex (K’1:1)

9.0 × 102

M-1
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Figure 5.4. Representative indomethacin crystal growth kinetic profiles (A) in the
presence and absence of model PPIs at high S and (B) in the presence of HP-β-CD at
high and low S (0.05% w/w). The solid lines represent fits to the first-order
empirical crystal growth model (Eq. 5.22).
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The driving force for crystal growth was calculated using the previously determined
indomethacin apparent solubilities either in the presence or absence of model PPIs. As
shown in Figure 5.4A (solid lines), the first-order empirical crystal growth model (Eq.
5.22) fit the indomethacin desupersaturation (or crystal growth kinetic) profiles in the
presence or absence of model PPIs at high S very well. Indomethacin crystal growth
rates measured from model fitting were further utilized to estimate an indomethacin
crystal growth inhibition factor (R) for each model PPI at high S using Eq. 5.19 and the
previously determined indomethacin crystal growth rate coefficient in the absence of any
PPI at high S (4.7 ± 0.7 × 10-3 cm/sec). The values of the indomethacin crystal growth
rate coefficient (kG) decreased from 4.0 ± 0.3 × 10-3 to 2.3 ± 0.4 × 10-3 cm/sec and R
decreased from 0.84 to 0.49 when the concentration of HP-β-CD was increased from 0.05
to 1% w/w (Table 5.3). The values of R at high S for 0.05, 0.2, 0.5 and 1% w/w HP-β-CD
were 0.84, 0.75, 0.65 and 0.49, respectively. The relationship between the concentration
of HP-β-CD and R was modeled using the reactive diffusion layer theory (Eq. 5.16 &
5.17). As shown in Figure 5.5, the predicted values of R using the reactive diffusion
layer model were in good agreement with the experimental values of R.
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The inhibitory effects of model PPIs on the crystal growth of indomethacin at
high S were further evaluated by comparing the values of kG and R for indomethacin
crystal growth in the presence of each model PPI (Table 5.3 & Figure 5.6). The kG
values for indomethacin crystal growth at high S in the presence of 0.05% w/w HP-β-CD,
HPMC, and PVP were 4.0 ± 0.3 × 10-3, 1.4 ± 0.6 × 10-4, 3.0 ± 1.9 × 10-5cm/sec,
respectively (Table 5.3). The values of R at high S for HP-β-CD, HPMC and PVP
(0.05% w/w) were 0.84, 0.03, and 0.006, respectively. Significantly smaller values of kG
and R for PVP and HPMC indicated that the indomethacin crystal growth inhibitory
effects of PVP and HPMC were significantly greater than those of HP-β-CD at high S.
Moreover, PVP was a better inhibitor of the crystal growth of indomethacin as compared
to HP-β-CD and HPMC. While the indomethacin crystal growth inhibitory effect of HPβ-CD increased as function of its concentration, no significant relationship was observed
between the crystal growth inhibitory effects of PVP and HPMC and their concentrations
at high S. This indicates that the mechanisms of action for the complexing agent HP-βCD and polymers such as PVP and HPMC were different at high S.
The model PPI effects on indomethacin crystal growth inhibition at low S (<3)
were also determined using the same method of measurement. The indomethacin crystal
growth kinetic profiles at low S in the presence of model PPIs were also modeled using
Eq.5.22. The model fit the profiles well (Figure 5.4B) and the indomethacin crystal
growth rate coefficients (kG) at low S in the presence of the model PPIs were estimated.
The kG values determined at high and low S in the presence of HP-β-CD, HPMC, and
PVP are compared in Table 5.3 and Figure 5.6. The kG for indomethacin crystal growth
at low S in the presence of 0.05% w/w HP-β-CD, HPMC, and PVP were 2.2 ± 0.3 × 10-4,
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1.6 ± 0.3 × 10-4, 1.6 ± 0.1 × 10-5cm/sec, respectively (Table 5.3). The rank order for the
effectiveness of the PPIs as inhibitors of indomethacin crystal growth changed from PVP
> HPMC > HP-β-CD at high S to PVP > HPMC ≈ HP-β-CD at low S.

Although the kG values at high and low S for PVP and HPMC were similar, their
inhibitory effects at high S were dramatic (Figure. 5.6). This is due to the fact that the
mechanism of crystal growth in the absence of these PPIs was diffusion controlled at high
S but was shifted to surface integration-controlled in the presence of PVP or HPMC. At
low S, indomethacin crystal growth became surface integration-controlled even in the
absence of PPIs and therefore the inhibition factors at low S (calculated relative to the
crystal growth rate of indomethacin at low S) were modest. This further indicated that
the mechanisms of crystal growth in the presence of PVP and HPMC were similar at high
and low S.

In contrast to the effects of PVP and HPMC, there was a significant

difference between the indomethacin kG at high and low S in the presence of HP-β-CD.
The value of R at low S was estimated using Eq. 5.19 and the previously determined
indomethacin kG at low S (5.5 ± 1.3 × 10-4 cm/sec) in the absence of any PPI. The R for
HP-β-CD at high and low S were 0.84 and 0.40 indicating that HP-β-CD showed a 2-fold
greater inhibitory effect on the crystal growth of indomethacin at low S as compared to
high S, which may suggest a possible change in the mechanism of action of HP-β-CD
between high and low S.
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Table 5.3. Comparison of Model PPI Effects on Indomethacin Crystal Growth Inhibition at High and Low Degrees of
Supersaturation (S).
High S (>3)
PPI Conc.
(% w/w)

PPI

kGb

Low S (<3)
Rc

(cm/sec)

kGb

Rc

(cm/sec)

--

4.7 ± 0.7 × 10-3

1.0 ± 0.1

5.5 ± 1.3 × 10-4

1.0 ± 0.2

HP-β-CD

0.05

4.0 ± 0.3 × 10-3

8.4 ± 0.3 × 10-1

2.2 ± 0.3 × 10-4

4.0 ± 0.6 × 10-1

0.2

3.5 ± 0.3 × 10-3

7.5 ± 0.7 × 10-1

--

--

0.5

3.0 ± 0.2 × 10-3

6.4 ± 0.5 × 10-1

--

--

1

2.3 ± 0.4 × 10-3

5.0 ± 0.9 × 10-1

--

--

0.05

3.0 ± 1.9 × 10-5

6.0 ± 4.0 × 10-3

1.6 ± 0.1 × 10-5

2.9 ± 0.2 × 10-2

0.2

3.2 ± 2.1 × 10-5

7.0 ± 4.0 × 10-3

--

--

0.05

1.4 ± 0.6 × 10-4

3.1 ± 1.0 × 10-2

1.6 ± 0.3 × 10-4

2.9 ± 0.6 × 10-1

0.2

9.0 ± 0.7 × 10-5

2.0 ± 1.0 × 10-2

--

--
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No PPI104,166

PVP

HPMC

a

Preliminary data(single runs) at selected PPI concentrations are reported in a conference proceedings25; b kG:
Indomethacin crystal growth rate coefficient (cm/sec); cR: Indomethacin crystal growth inhibition factor
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Figure 5.5. Inhibitory effects of HP-β-CD on the bulk diffusion controlled crystal
growth of indomethacin at high degrees of supersaturation. Error bars represent
95% confidence intervals.
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Indomethacin Crystal Growth Rate Coefficient
(kG, cm/sec)
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Low S (0.05%)
HPMC
PVP

Figure 5.6. Inhibitory effects of model PPIs on indomethacin crystal growth at high
and low degrees of supersaturation.
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Viscosity of Model PPI Solutions at Different Concentrations
Since the bulk viscosity of supersaturated indomethacin samples could change the
bulk-diffusion controlled rate of indomethacin crystal growth by affecting the diffusion
of indomethacin molecules from the bulk to the solid-liquid interface, viscosities of
model PPI solutions at different concentrations (0 to 3 % w/w) were measured. As
shown in Figure 5.7, the viscosity of HPMC solutions was significantly higher than that
of PVP and HP-β-CD solutions. The observed rank order for the viscosity of PPI
solutions at concentrations between 0 to 1% w/w was HPMC >PVP >HP-β-CD. The
viscosity of HPMC solutions increased significantly at higher HPMC concentrations (up
to 1% w/w), from 1 to 1.7 cP when the concentration was increased from 0.1 to 1% w/w,
respectively.

An almost linear relationship was observed for the effect of HPMC

concentration on solution viscosity. While the viscosity of PVP solutions increased
moderately as a function of PVP concentration (up to 1% w/w), no significant change in
the viscosity of HP-β-CD solutions was observed up to 3% w/w concentration. Between
0 to 3% w/w concentrations, the viscosity of HP-β-CD solutions remained at
approximately 0.9 cP at 25°C, which was similar to the viscosity of the blank buffer
vehicle that was used to prepare the model PPI solutions. The viscosity of PVP solutions
increased from 0.9 to 1.2 cP when the concentration was increased from 0.25 to 1% w/w,
respectively. Below a 0.5% w/w PVP concentration, the viscosity remained constant at
~0.9 cP.
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Figure 5.7. Viscosity of model PPI solutions at different concentrations.
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7

Indomethacin Seed Crystal Suspension Characterization after Crystal Growth with
Model PPIs
Indomethacin seed crystals were characterized for their mean size, size
distribution and number concentration before and after crystal growth using a Coulter
counter. The seed crystals had a typical mass median diameter of ~11 micron and surface
area of ~0.04 cm2 per mL of suspension. The indomethacin seed crystal concentration (#
of seed crystals per mL) was approximately 41,000/mL, which amounted to
approximately 150 µg of indomethacin per 3 mL in a typical crystal growth experiment.
Additional details on the size distribution analysis of these seed crystals as well as a
typical indomethacin seed crystal size distribution profile can be found in an earlier
publication.104 The seed crystals after growth in the presence of model PPIs were also
characterized using PXRD. A comparison of the PXRD spectra of indomethacin crystals
(“as received”) and indomethacin seed crystals after growth in the presence of model
PPIs is shown in Figure 5.8. The PXRD analysis indicated that there was no significant
change in indomethacin crystalline form (γ-polymorph) upon crystal growth with model
PPIs, although this technique would not provide information on the nature of the thin film
deposited on the crystal surface during growth.

160

1
2
3
4

Figure 5.8. PXRD patterns of indomethacin seed crystals after growth with (1) no
PPI

(indomethacin

“as

received”),

(2)

hydroxypropyl

polyvinylpyrrolidone, and (4) hydroxypropyl methylcellulose.

161

β-cyclodextrin,

(3)

DISCUSSION

Comparison of Model PPI Effects on Indomethacin Crystal Growth Kinetics
With the growth in popularity of high energy dispersion formulations for drug
development, interest in factors that prolong supersaturation in both solids and solutions
has also grown in recent years.1,53

The physical instability of supersaturated drug

products still remains a major challenge for pharmaceutical scientists. Quantitative,
mechanistic modeling to assess the degree of stabilization of supersaturated systems
provided by PPIs would be beneficial in addressing this major challenge.
Cyclodextrins74 and polymers such as PVP108,164 and HPMC108,164 have been used
in drug product development to improve the stability of solid and solution based
supersaturated states. In the case of solution-state supersaturation, the beneficial effects
of these PPIs could be classified into three hypothetical case scenarios. Case (1): Higher
molecular weight PPIs could enhance viscosity, which would lower the diffusivity of
drugs. The lower diffusivity could inhibit drug nucleation and crystal growth (the two
major processes that affect the stability of the supersaturated state) and, in turn, maintain
supersaturation. Case (2): PPIs could form complexes with the drug, which would not
only enhance the equilibrium solubility of the drug but also reduce the driving force for
drug nucleation and crystal growth and, in turn, drug precipitation. Finally, Case (3):
PPIs act at the solid-solution interface to inhibit incorporation of molecules from solution
into the growing crystal lattice. The main objective of this study was to quantitatively
explore the inhibitory effects of some of the pharmaceutically relevant PPIs (HP-β-CD,
PVP & HPMC) on the crystal growth of indomethacin, a model poorly water soluble
drug and to classify these effects based on the scenarios described above. For this effort,
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we have utilized our recent understanding of the crystal growth kinetics of indomethacin
from a previous study where we employed a newly developed second-derivative UV
technique to determine the kinetic order and the rate limiting steps of indomethacin
crystal growth kinetics in the absence of PPIs.
All three model PPIs including HP-β-CD, PVP & HPMC inhibited indomethacin
crystal growth at high S (Table 5.3 & Figures 5.4, 5.5 & 5.6). While the inhibitory
effects of PVP and HPMC at high S were significantly higher than that of HP-β-CD, a
good correlation between the crystal growth inhibitory effects of HP-β-CD and its
concentration was observed (Table 5.3 & Figure 5.5). As described in Case 1, the higher
molecular weight model PPIs could increase the viscosity of indomethacin suspensions,
which in turn could inhibit the rate of bulk diffusion controlled crystal growth of
indomethacin at high S by increasing the diffusive barrier for indomethacin. To test this
hypothesis, the change in indomethacin diffusivity due to higher bulk viscosity was
theoretically calculated using the Stokes-Einstein equation as shown below.

D=

kT
6πηr

(5.23)

where D is the diffusion coefficient or diffusivity of the solute, k is Boltzmann's
constant, T is the absolute temperature, η is the viscosity of the bulk medium and r is the
radius of the solute. Using the estimated indomethacin diffusivity, indomethacin crystal
growth rates at high S were calculated using Eq. 5.22 for each model PPI. The bulk
viscosity-adjusted indomethacin crystal growth inhibitory factor (R) for each model PPI
was determined from the theoretically estimated bulk diffusion controlled indomethacin
crystal growth rates in the presence and absence of a model PPI at high S (Eq. 5.19). The
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bulk viscosity-adjusted R was compared with previously described (“Results” section)
experimental R for HP-β-CD, PVP, and HPMC at a 0.2% w/w model PPI concentration.
The values of the bulk viscosity-adjusted R for 0.2% w/w HP-β-CD, PVP, and HPMC
were 1, 0.97, and 0.85, respectively. The values of the experimental R for 0.2% w/w HPβ-CD, PVP, and HPMC were 0.75, 0.007, and 0.02, respectively. Since there was no
change in the bulk viscosity of indomethacin seed crystal suspensions in the presence of
0.2% w/w HP-β-CD, no significant effect of HP-β-CD on indomethacin crystal growth
inhibition due to viscosity effects was predicted as indicated by the theoretical R value of
1. However, at 0.2% w/w HP-β-CD, the theoretical R (i.e., 1) for indomethacin was
higher than the experimental R (i.e., 0.75). Similarly, the theoretical R values for PVP
and HPMC were significantly different from the experimental R values at high S. The
theoretical R values for PVP and HPMC at 0.2% were 0.97 and 0.85, respectively,
whereas the experimental R values were 0.007 and 0.02. These results clearly indicate
that Case 1, which invokes effects of model PPIs on bulk viscosity to account for their
crystal growth inhibitory effects, could not account for the PPI effects on indomethacin
crystal growth.

Modeling the Effects of HP-β-CD on Bulk Diffusion Controlled Crystal Growth
Kinetics of Indomethacin
Unlike PVP and HPMC, HP-β-CD has a significant effect on the equilibrium
solubility of indomethacin due to 1:1 complex formation between indomethacin and HPβ-CD (Figure 5.3). The Case 2 scenario, as mentioned earlier, was applied to explain the
inhibitory effects of HP-β-CD on indomethacin crystal growth at high S.

In

supersaturated systems, a complexing agent such as HP-β-CD changes the equilibrium
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solubility of the drug and reduces the driving force for crystal growth. The prediction of
the inhibitory effect of a complexing agent such as HP-β-CD on crystal growth would
depend on the way in which the degree of supersaturation (S) is calculated. If S is
calculated using the concentration of free drug species then the calculated R (Eq. 5.19)
would be equal to 1 indicating the absence of any expected inhibitory effect of the
complexing agent on drug crystal growth. However, if the R is calculated using the total
solution concentration then the predicted R would be less than 1 indicating significant
inhibitory effects of the complexing agent on drug crystal growth.
The reactive diffusion layer theory has been successfully used to predict the exact
nature of the driving force for drug dissolution under the influence of various bulk
medium variables including pH and buffer concentration.148,158,167,168

This theory

simultaneously accounts for the mass transfer and the reaction processes accompanying
diffusion and thereby precisely calculates the concentration gradients of various species
of interest in the sample under investigation.

In the present study, concentration

gradients of free and complexed indomethacin species were required to predict the
inhibitory effects of HP-β-CD on the bulk diffusion controlled crystal growth of
indomethacin at high S.

Therefore, the HP-β-CD concentration at the solid-liquid

interface ([CD]s) was estimated using Eq. 5.16 and other parameters listed in Table 5.2
for different HP-β-CD concentrations in the bulk ([CD]b). The estimated [CD]s was
about 3% higher than [CD]b at all HP-β-CD concentrations. This was attributed to the
fact that only the free indomethacin was being incorporated into the existing
indomethacin crystal lattice and therefore the free HP-β-CD was being recycled at the
solid:liquid interface. The other parameters used in the predictions (Table 5.2) including
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the apparent solubility of indomethacin and the thickness of the diffusion layer for
indomethacin seed crystals were experimentally determined earlier.104 The R for HP-βCD was predicted using Eq. 5.16, 5.17, 5.22 and the parameters listed in Table 5.2. The
predicted R values at a high S (>3) for 0.05, 0.2, 0.5 and 1% w/w HP-β-CD were 0.89,
0.71, 0.64 and 0.59. These were in good agreement with the experimental R values of
0.91, 0.78, 0.63 and 0.50 for 0.05, 0.2, 0.5 and 1% w/w HP-β-CD. The plot of predicted
R vs. HP-β-CD concentration is shown in Figure 5.5 which shows that the reactive
diffusion layer theory (i.e., complexation in the diffusion layer) predictions for the
indomethacin crystal growth inhibitory effects of HP-β-CD were in reasonable agreement
with the experimental values. The values of R for HP-β-CD decreased with increasing
HP-β-CD concentrations, which is indicative of greater inhibition of indomethacin crystal
growth at higher HP-β-CD concentration. A good agreement between the predicted and
experimental values of R for HP-β-CD indicated that the inhibitory effect of HP-β-CD on
the bulk diffusion controlled indomethacin crystal growth can be accounted for by
reversible complexation in the diffusion layer.

Effect of Model PPIs on Indomethacin Surface Integration at Higher Degrees of
Supersaturation
Since PVP and HPMC did not exhibit significant complexation with
indomethacin, the Case 2 scenario was not applicable.

Moreover, the significantly

greater inhibitory effects of PVP and HPMC at high S (Figure 5.6 and Table 5.3) could
not be explained by adjusting the indomethacin mass transfer rates to reflect changes in
bulk viscosity in the presence of PVP and HPMC. Hence, the Case 3 scenario was
considered to understand the crystal growth inhibitory effects PVP and HPMC.
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It was hypothesized that the significantly higher indomethacin crystal growth
inhibition factors of PVP and HPMC at high S could be attributed to their adsorption on
to the growing indomethacin crystal surface.

These polymers could adsorb to

indomethacin surfaces due to hydrophobic and hydrogen bonding type interactions12 thus
providing an interfacial barrier for crystal growth, which in turn could retard the surface
integration rate significantly.164 For example, adsorbed polymers could block the active
indomethacin growth sites. Since it is known from the literature92,99,101,103 and a previous
study from this laboratory166 that crystal growth kinetics at low S are generally surface
integration controlled, the above-mentioned hypothesis was tested by comparing the
indomethacin crystal growth rate coefficients (kG) at high S in the presence of PVP and
HPMC with kG at low S without any PPI (previously166 determined as 5.5 ± 1.3 × 10-4
cm/sec). As shown in Table 5.3, the kG values at high S in the presence of PVP and
HPMC were at least similar or even lower than 5.5 ± 1.3 × 10-4 cm/sec. This supports our
hypothesis that both polymers, HPMC and PVP, significantly inhibited indomethacin
crystal growth at high S by changing the rate limiting step from bulk diffusion to surface
integration. For both HPMC and PVP, the values of kG at high and low S were very
similar and indicative of their impact on the rate of surface integration of indomethacin.
The impact of PVP on the indomethacin surface integration rate was significantly greater
(20-30 fold) than that of HPMC (~4 fold) at 0.05%. This also indicated that the adsorbed
PVP polymer not only changed the rate limiting step at high S but also significantly
retarded indomethacin surface integration at both high and low S. In the case of HP-βCD (0.05% w/w), the indomethacin crystal growth inhibitory effect was ~2-fold greater
at low S as compared to high S. Similar to PVP and HPMC, the indomethacin crystal
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growth inhibition factor of HP-β-CD at low S is also attributed to its impact on the
surface integration rate, as that was established to be the mechanism for indomethacin
crystal growth at low S in the absence of PPIs.

Finally, the significantly higher

indomethacin crystal growth inhibition factors of the model PPIs PVP and HPMC at high
S could be attributed to their adsorption on to the growing indomethacin crystal surface,
resulting in a change in the indomethacin crystal growth rate limiting step from bulk
diffusion to surface integration.
CONCLUSIONS
HP-β-CD significantly increased indomethacin equilibrium solubility due to 1:1
complex formation between indomethacin and HP-β-CD.

PVP and HPMC did not

substantially alter the solubility of indomethacin. Viscosity of HPMC solutions increased
significantly as a function of HPMC concentration. The rank order of solution viscosity
at similar PPI concentrations was HPMC > PVP > HP-β-CD. PVP and HPMC were
better indomethacin crystal growth inhibitors than HP-β-CD at high degrees of
supersaturation (S), which was attributed their ability to change the indomethacin crystal
growth rate limiting step from bulk diffusion to surface integration. HP-β-CD’s crystal
growth inhibitory effects at high S increased with an increase in its concentration up to
1% w/w concentration. The inhibitory effect of HP-β-CD on bulk diffusion controlled
indomethacin crystal growth at high S could be rationalized by reversible complexation
between HP-β-CD and indomethacin in the diffusion layer. The crystal growth inhibition
factors of PVP and HPMC were dramatically greater at high S than that for HP-β-CD,
which indicated that both PPIs changed the rate limiting step of indomethacin crystal
growth at high S from bulk diffusion to surface integration.
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At low S, the crystal growth rate of indomethacin becomes surface integration
controlled even in the absence of PPIs. Under these conditions all PPIs exhibited only
modest inhibitory effects. For example, a twofold greater indomethacin crystal growth
inhibition factor was observed for HP-β-CD at low S than that at high S, reflecting its
effect on the rate of indomethacin surface integration at low S. The relative effects of the
model PPIs at low S may be attributable to their adsorption on to the growing crystal
surface and the effect of this adsorption on the rate of surface integration.
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Chapter Six
Adsorption of Polyvinylpyrrolidone and Its Impact on Maintenance of Aqueous
Supersaturation of Indomethacin via Crystal Growth Inhibition
INTRODUCTION
Polymeric precipitation inhibitors (PPIs) have been used to maintain aqueous
supersaturation of poorly water soluble drugs.9 PPIs including polyvinylpyrrolidone
(PVP), hydroxypropyl methylcellulose (HPMC), polyethylene glycol (PEG) as well as
their derivatives such as polyvinylpyrrolidone-co-polyvinyl acetate (PVP-VA),
hydroxypropyl

methylcellulose

acetate

succinate

(HPMC-AS),

d-α-tocopheryl

polyethylene glycol 1000 succinate (TPGS), and polysorbate 80 are frequently
incorporated into various supersaturating drug delivery systems (SDDS) including
amorphous solid dispersions and lipid-based drug delivery systems.1,8

Upon oral

administration of the SDDS, the PPIs maintain supersaturation by significantly inhibiting
the precipitation of drugs in the gastrointestinal (GI) tract.91
While some PPIs including surfactants such as TPGS and polysorbate 80 could
increase the thermodynamic equilibrium solubility of drugs, the precipitation inhibitory
effects of PPIs are generally kinetic in nature. The PPIs maintain supersaturation through
the inhibition of nucleation, crystal growth, or both.20,23,27,104,108,169 The inhibitory effects
of PPIs on nucleation, crystal growth, or both vary significantly with the specific drug
and PPI combination.

For example, HPMC and PVP significantly inhibited the

nucleation and crystal growth of two model drugs, griseofulvin and danazol, while
Eudragit® did not. Moreover, the selectivity of HPMC for the inhibition of nucleation or
crystal growth of the two model drugs varied. HPMC was a more effective inhibitor of
the nucleation of griseofulvin, but equally effective in inhibiting both the nucleation and
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crystal growth of danazol.108

PVP was a better inhibitor of the crystal growth as

compared to the nucleation of bicalutamide.20 These observations clearly indicate that
the inhibition of nucleation and crystal growth of drugs by PPIs is complex, involving
multiple mechanisms that could vary depending on the drug-PPI combination.
Drug nucleation and crystal growth may be influenced by the intermolecular
interactions between PPI and drug molecules in the bulk solution.13-16 For example, the
effectiveness of PPIs in inhibiting the formation of carbamazepine dihydrate was related
to the intermolecular hydrogen bonding and hydrophobic interactions between PPIs and
carbamazepine but their relative impact on the effectiveness of a given PPI could not be
determined due to experimental limitations.14 In another study, the superiority of HPMCAS HF over HPMC-AS LF, two different grades of HPMC-AS containing different ratios
of acetate and succinate substituents, in inhibiting the precipitation of carbamazepine
from an aqueous solution was attributed to stronger hydrophobic interactions between
HPMC-AS HF and carbamazepine in the bulk solution.13 Similarly, the inhibitory effect
of cellulosic PPIs on the nucleation of three model drugs, celecoxib, efavirenz, and
ritonavir, from their supersaturated aqueous solutions correlated well with the
hydrophobicity of the PPI relative to that of the drugs.15
Adsorption of PPIs on the surface of growing crystals could also influence the
crystal growth of drugs.4,12,17-24 The inhibition of crystal growth by the PPI is generally
attributed to its effect on either bulk diffusion or surface integration of drug
molecules.9,10,18,27 The inhibition of the crystal growth of sulfathiazole by PVP was
attributed to the formation of a possible net like structure on the crystal surface by the
adsorbed PVP. It was proposed that the pore size of the net like structure would be
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smaller when the relative transport rate of PVP to sulfathiazole is higher, which in turn
would provide greater inhibition of the crystal growth.18 Stronger inhibitory effects of
HPMC as compared to PVP and PEG 400 on the crystal growth of hydrocortisone acetate
(HA) were attributed to: (i) a greater diffusive barrier provided by HPMC in the
hydrodynamic boundary layer; and (ii) stronger adsorption of HPMC on the crystalline
surface of HA. The extent of HPMC adsorption correlated with the hydrogen bonding
capacity of different faces of the HA crystal.12 Cellulosic polymers with moderate levels
of hydrophobicity, semi-rigid structure, and amphiphilic nature were more effective in
inhibiting the crystal growth of ritonavir. It was proposed that these properties of PPIs
could likely promote adsorption on to the crystal surface of ritonavir.10 Despite the
above-mentioned studies, the adsorption of PPIs is seldom directly correlated with their
crystal growth inhibitory effect on poorly water soluble drugs. Consequently, the nature
of the adsorbed PPI layer as well as the key physicochemical properties of PPIs and drugs
such as molecular weight, hydrogen bonding capability and hydrophobicity that could
influence the adsorbed PPI layer and, in turn, the effectiveness of PPIs are not well
understood.

A thorough understanding of the correlation between the adsorption of a

given PPI and its crystal growth inhibitory effect is still required. Knowledge of the
adsorption behavior of PPIs on to drug surfaces would help in exploring the mechanisms
of crystal growth inhibition by PPIs such as the creation of a barrier for surface diffusion
of the adsorbed drug molecules or the blocking of active growth sites for the
incorporation of drug molecules into crystal lattices and thereby aid in the rational
selection of PPIs for the development of SDDS.

172

The main objectives of this study were: (i) to determine the factors that govern the
adsorption of the model PPI PVP on to the crystalline surface of indomethacin, a model
poorly water soluble drug; and (ii) to relate the adsorption behavior of PVP to its
effectiveness as a crystal growth inhibitor of indomethacin. This chapter discusses: (a)
the characterization of the adsorption of PVP polymers of different molecular weights
and their monomer, N-vinylpyrrolidone, on to indomethacin crystals dispersed in an
aqueous medium; and (b) the correlation of PVP adsorption with indomethacin crystal
growth inhibition as a function of PVP concentration and molecular weight.
MATERIALS AND METHODS

Materials
Polyvinylpyrrolidone (PVP) polymers with different weight average molecular
weights including PVP K12 (3500 g/mole), PVP K16-18 (8000 g/mole), and PVP K2932 (58000 g/mole) as well as their monomer (N-vinylpyrrolidone, 111 g/mole) were
purchased from Fisher Scientific Inc. Indomethacin (1-(p-chlorobenzoyl)-5-methoxy-2methylindole-3-acetic acid, 99+%, γ-polymorph, molecular weight =357.8 g/mole,
pKa=4.17148) was purchased from Sigma-Aldrich, Inc. (St. Louis, MO, USA). Nylon net
filters (30 µ) and polycarbonate membrane filters (3 µ) were purchased from Millipore
Inc., (Milford, MA, USA). Nylon membrane filters (0.2 µ) and 13 mm PTFE syringe
filters (0.45 µ) were purchased from Whatman Int. Ltd. (Maidstone, England). Deionized
water was obtained from a MilliQ water purification apparatus (Milli-Q Synthesis,
Millipore Inc., Milford, MA, USA) and pre-filtered through a 0.22 µ filter (Millipak
Express 20, Millipore Inc., Milford, MA, USA). All other reagents and materials were of
an analytical grade.
173

CH3

CH2COOH

O
N

O
N

A

C

O

N

CH3
O

*

*

n

B

Cl

C

Figure 6.1. Chemical structures of N-vinylpyrrolidone (A), polyvinylpyrrolidone
(B), chemical structure (C) and molecular packing (D) of indomethacin (Cambridge
Structural Database reference code INDMET).
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PVP Assay using Size Exclusion Chromatography
PVP (PVP K12, K16-18 and K29-32) and N-vinylpyrrolidone samples were
analyzed using size-exclusion chromatography (SEC). The SEC system consisted of a
Waters Alliance 2690 HPLC system with a photo-diode array absorbance detector. A
size exclusion chromatography column (Ultrahydrogel 500, 7.8 × 300 mm, Waters Inc.)
was used to resolve the chromatographic peaks of three PVP polymers and their
monomer (N-vinylpyrrolidone). The pore size of the Ultrahydrogel 500 was 500 Å. The
molecular weight cut off was 4 × 105. An isocratic HPLC method with a mobile phase
containing deionized water (0.01% TFA) and acetonitrile in a ratio of 80:20 was used to
resolve chromatographic peaks. The flow rate was maintained at 1 mL/min providing the
column pressure of approximately 333 psi. The injection volume was 50 µl and the UV
detection wavelength was set at 210 nm.

Sample compartment temperature was

maintained at 25°C whereas the column was kept at ambient room temperature. The
column was equilibrated for about 1-2 hours before analyzing PVP samples.

The

standard solutions for PVP polymers and their monomer were prepared in 50 mM
phosphate buffer (pH 2.15).
Measurement of PVP Adsorption on to Indomethacin Seed Crystals
Adsorption of PVP polymers and their monomer on indomethacin seed crystals
was measured using the solution depletion method. A specific quantity of indomethacin
powder was mixed with the solutions of either PVP polymers or their monomer in
scintillation glass vials.

The PVP (or its monomer) solutions containing different

amounts of PVP (or its monomer) were prepared using 50 mM phosphate buffer (pH 2.15
at 0.1M ionic strength using NaCl). The final mixture or dispersion was equilibrated at
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25°C for about 12 hrs using a shaker water bath. Samples were withdrawn at regular
time intervals and were filtered through a 0.45 µ PTFE syringe filter. The filtrate was
assayed for PVP (or its monomer) concentration using the SEC method.

Preparation and Characterization of Indomethacin Seed Crystal Suspension for
Crystal Growth
A previously reported method was used to prepare indomethacin seed crystal
suspensions. Briefly, approximately 0.1% w/w indomethacin was dispersed in 50 mM
phosphate buffer (pH 2.15). The dispersion was equilibrated for 72 hours at 25ºC in a
shaker water bath. The ionic strength was maintained at 0.1M using NaCl. A narrow and
unimodal size distribution was obtained by filtering the saturated suspension through a 30
μ nylon net filter.

The filtered suspension was further passed through a 3 μ

polycarbonate filter to collect the seed crystals retained on the top of the 3 μ filter. The
final indomethacin seed crystal suspension was prepared by redispersing the retained
seed crystals in a saturated solution of indomethacin.
The surface area of indomethacin crystals was measured using the BET
adsorption isotherm equation. The samples were degassed at 120 °C for about 4 hours
under nitrogen purge prior to analysis. The adsorption of nitrogen on to indomethacin
crystals was measured using Tristar 3000 automated adsorption apparatus (Micromeritics,
USA).
Indomethacin seed crystals, before and after growth, were characterized for
physical form, size, number, and morphology using Powder X-ray diffraction (PXRD)
technique, a Coulter counter and polarized light microscopy. A more detailed description
of these characterization methods can be found elsewhere.104 Briefly, the PXRD patterns
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of indomethacin crystals before and after crystal growth were obtained using an X-ray
diffractometer (Bruker D8 Advance, Bruker AXS, Inc., Madison, WI, USA) to
determine, any possible, change in the form of indomethacin from the most stable γ-form
to either an amorphous form or any other metastable form such as α-form. Additionally,
the polarized light microscope (Olympus, Tokyo, Japan) was used to characterize any
shape and size related changes. The number concentration and size distribution including
volume based diameter of indomethacin crystals in the seed crystal suspension were
measured using a Coulter counter (Multisizer Z2, Beckman Coulter Inc., Miami, FL,
USA) containing a 50 µ glass aperture tube that was filled with clear indomethacin
saturated solution.
Indomethacin Crystal Growth Rate Measurement in the Presence of PVP
The crystal growth rates of indomethacin in the presence of PVP polymers and
their monomer were measured using a previously published method.27,104

Briefly,

indomethacin desupersaturation profiles (i.e., the plots of concentration vs. time) were
determined from supersaturated suspensions containing PVP or N-vinylpyrrolidone at
25ºC.

Supersaturation was attained by the addition of 100-250 µl of concentrated

indomethacin solution (50 mM phosphate buffer, pH 6.8, ionic strength of 0.1M using
NaCl) containing a specific amount of PVP or N-vinylpyrrolidone to 3 mL of
indomethacin saturated suspension (50 mM phosphate buffer, pH 2.15, ionic strength of
0.1M using NaCl) using a micro-syringe pump (final pH < 2.2). The supersaturated
suspensions were magnetically stirred at about 400 RPM using a pivoted rod-shaped
magnetic stir bar. The concentration of indomethacin from its supersaturated suspensions
was measured using a second derivative online UV spectroscopy method. The second
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derivative UV absorbance at 295 nm, obtained from an indomethacin UV absorbance
spectrum from 210 to 400 nm wavelength, was used to determine indomethacin
concentration. Additional details on the second derivative UV method development and
validation are provided in a previous publication.104
Crystal Packing
The molecular packing of the γ-form shown in Figure 6.1D was obtained using
Mercury 3.5.1 (Cambridge Crystallographic Data Centre, Cambridge, UK) as well as the
single crystal structure parameters from the Cambridge Structural Database reference
code INDMET.170
Data Analyses
The Student t-test and ANOVA tests were carried out using Microsoft Excel
software program. Scientist software program (Micromath Inc., St. Louis, MO, USA)
was used to perform non-linear least-squares analyses and to obtain 95% S-plane
confidence intervals.
RESULTS

Indomethacin Seed Crystal Suspension Characterization Before and After Crystal
Growth
The surface area of indomethacin crystals determined using the BET method was
0.23 ± 0.05 (95% CI) m2/g. The seed crystal mass median diameter in suspension was
~11 µ. No significant change in suspension concentration and particle morphology was
observed by Coulter counting and optical microscopy before and after crystal growth
indicating the absence of significant primary nucleation during crystal growth (e.g., the
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seed crystal concentration/mL was 2.8 ± 0.8 × 104 before crystal growth and 3.0 ± 0.2 ×
104 crystals/mL after crystal growth in the presence of PVP K29-32). PXRD patterns
also showed no significant change upon crystal growth. Additional discussions on the
seed crystal characterization before and after crystal growth in the absence of PPIs are
provided in an earlier publication.104

Size Exclusion Chromatography Method for Polyvinylpyrrolidone
The size exclusion chromatography (SEC) assay successfully resolved the peaks
of N-vinylpyrrolidone, PVP K12, PVP K16-18, and PVP K29-32. A representative
chromatogram of PVP K12 with a major peak at the retention time of around ~10
minutes is shown in Figure 6.2.

Similar chromatograms were obtained for N-

vinylpyrrolidone, PVP K16-18, and PVP K29-32. The SEC retention times of PVP
polymers decreased with an increase in their molecular weight. The retention times of Nvinylpyrrolidone, PVP K12, K16-18, and K29-32 were 11.1, 10.2, 9.9, and 8.9 minutes,
respectively (Table 6.1). Plots of the SEC standard peak areas versus concentration were
linear for all three PVP polymers and N-vinylpyrrolidone over the concentration range of
interest (Figure 6.3), from which response factors (ratios of peak area to concentration)
were generated (Table 6.1) and utilized in determining unknown PVP polymer and Nvinylpyrrolidone concentrations in adsorption samples.
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Figure 6.2. Representative size exclusion chromatogram of a model
polyvinylpyrrolidone polymer (PVP K12).
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Table 6.1. Size-Exclusion Chromatography Parameters for Polyvinylpyrrolidone
(PVP) Polymers and Their Monomer (N-vinylpyrrolidone)

Retention Time
(min)
PVP K29-32
PVP K16-18
PVP K12
N-vinylpyrrolidone

8.9
9.9
10.2
11.1
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Average Response
Factor ± 95% CI
(area.mg.mL-1)
5.6 ± 0.1 × 107
6.3 ± 0.3 × 107
6.0 ± 0.2 × 107
4.3 ± 0.2 × 107

4e+8
N-Vinylpyrrolidone
PVP K12
PVP K16-18
PVP K29-32

Area

3e+8

2e+8

1e+8

0
0

1

2

3

4

5

6

Concentration (mg/mL)

Figure 6.3. Standard curves of polyvinylpyrrolidones (PVP K12, K16-18 & K29-32)
and N-vinylpyrrolidone using size exclusion chromatography.
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Characteristics of PVP Adsorption on to Indomethacin Seed Crystals
The kinetics of PVP adsorption on to indomethacin crystals was studied by
determining the amount of PVP adsorbed per unit surface area of indomethacin crystals
over time. Representative adsorption kinetic profiles for PVP K12 and PVP K29-32 are
shown in Figure 6.4. Similar profiles were obtained for N-vinylpyrrolidone and PVP
K16-18. The kinetic profiles clearly indicate that equilibrium was achieved within 2
hours. Adsorption isotherms were constructed by plotting the plateau values from the
adsorption kinetic profiles against the respective bulk concentrations of PVP or Nvinylpyrrolidone (Figure 6.5).

The adsorption isotherms of PVP polymers and N-

vinylpyrrolidone exhibit different plateau values above a critical polymer (or monomer)
concentration depending on molecular weight (Figure 6.5). The plateau values,
representing the maximum extent of PVP (or N-vinylpyrrolidone) adsorption on to
indomethacin crystals (Amax) were expressed using different units: 1) weight-basis (𝐴𝑊
𝑚𝑎𝑥 ,
2
mg/m2), 2) monomer mole-basis ( 𝐴𝑚𝑀
𝑚𝑎𝑥 , moles of monomer/m ), and 3) mole-basis
2
(𝐴𝑀
𝑚𝑎𝑥 , moles/m ).

The extent of PVP adsorption on to indomethacin crystals on a

2
monomer mole-basis (𝐴𝑚𝑀
𝑚𝑎𝑥 , moles of monomer/m ) was calculated by dividing the

2
extent of PVP adsorption on a weight basis (𝐴𝑊
𝑚𝑎𝑥 , mg/m ) by the molecular weight of

the PVP monomer (i.e., 111 g/mole).

The adsorption isotherms of PVP were modeled using the Langmuir adsorption
isotherm model (Eq. 6.1).171,172

A = Amax

Kc
1 + Kc
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(6.1)

where A is the amount of adsorbate (e.g., PVP) per unit surface area of the adsorbent
(e.g., indomethacin crystals) (mg/m2, moles of monomer/m2, or mole/m2) at a specific
adsorbate concentration, c (mg/mL, moles of monomer/mL, or moles/mL). K is the
Langmuir affinity constant (mL/mg, mL/mole of monomer or mL/mole). The extent of
adsorption (Amax) reflects the adsorption capacity of an adsorbent whereas the values of K
provide an insight into the affinity of an adsorbate for an adsorbent. The Langmuir
adsorption model fit the adsorption isotherms of PVP and N-vinylpyrrolidone well
(Figure 6.5). Values of the Langmuir constant (K ± 95% CI) determined from the
adsorption isotherms are listed in Table 6.2 using two different units: 1) weight-basis
(𝐾 𝑤 , mg/m2), and 2) mole-basis (𝐾 𝑀 , mg/m2). The affinity constant of PVP polymers for
indomethacin crystals is significantly higher (e.g., 23-fold higher for PVP 29-32) than
that of N-vinylpyrrolidone. The higher molecular weight PVP K29-32 polymer exhibits
a greater affinity for indomethacin crystals than the lower molecular weight PVP K12
and PVP K16-18 polymers.

The values of 𝐾 𝑤 for PVP K12 and PVP K16-18 are

similar, whereas the values of 𝐾 𝑀 for the same polymers suggest that the affinity of PVP
K16-18 is slightly higher than that of PVP K12.

As shown in Table 6.2, the polymeric PVPs have significantly higher 𝐴𝑤
𝑚𝑎𝑥 and

𝐴𝑚𝑀
𝑚𝑎𝑥 for indomethacin crystals as compared to N-vinylpyrrolidone, however the trend

reverses when the same comparison is made using 𝐴𝑚
𝑚𝑎𝑥 . These results clearly indicate

that the adsorption capacities of indomethacin crystals for polymeric PVPs and N-

vinylpyrrolidone differ significantly. Moreover, the adsorption capacity of indomethacin
crystals is a function of PVP molecular weight (Table 6.2 and Figure 6.6). The values of
𝑚𝑀
𝑚
𝐴𝑤
𝑚𝑎𝑥 and 𝐴𝑚𝑎𝑥 increase whereas the values of 𝐴𝑚𝑎𝑥 decrease with an increase in the
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molecular weight of PVP. The 𝐴𝑤
𝑚𝑎𝑥 for PVP K29-32 is ~9-fold, ~3-fold and ~2-fold

greater than those for N-vinylpyrrolidone, PVP K12 and PVP K16-18, respectively
(Table 6.2). The relationship between the molecular weight of PVP and the extent of
PVP adsorption on to indomethacin crystals (𝐴𝑤
max ) was further characterized by Eq.

6.2.173

𝛼
𝐴𝑤
max = 𝑏𝑀

(6.2)

where M is the molecular weight of PVP (g/mol) and b as well as α are constants.
The value of α is generally used to get an insight into the conformation of adsorbed
polymer at the solid-liquid interface.173 A linear relationship (R2 = 0.99) was observed
when the extent of PVP adsorption (𝐴𝑤
max ) was plotted against the molecular weight of

PVP on a logarithmic scale (Figure 6.6). The value of α of 0.36, derived from the slope
of this curve, suggests a random coil conformation for PVP adsorbed at the indomethacin
solid-liquid interface.173

Inhibitory Effects of PVP on the Crystal Growth of Indomethacin
To quantitatively explore the inhibitory effects of PVP on the crystal growth of
indomethacin, the crystal growth rates of indomethacin were measured at a high degree
of supersaturation (S~5) in the presence and absence of PVP or N-vinylpyrrolidone using
a previously established method.27,104,166 Briefly, desupersaturation profiles for the crystal
growth of indomethacin were generated by plotting the supersaturated concentration of
indomethacin against time.
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Figure 6.5. Adsorption isotherms of polyvinylpyrrolidone (PVP K12, K16-18 and
K29-32) and their monomer (N-vinylpyrrolidone) for indomethacin crystals. The
solid lines represent model fits using the Langmuir adsorption isotherm model (Eq.
6.2).
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Table 6.2. Langmuir Adsorption Isotherm Model Parameters (±95%CI) for Polyvinylpyrrolidone (PVP) Polymers and Nvinylpyrrolidone
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N-vinylpyrrolidone

Maximum
Amount
Adsorbed
-2
(𝑨𝒘
𝒎𝒂𝒙 , mg.m )
0.2 ± 0.1

Maximum Amount
Adsorbed
𝒎𝑴
(𝑨𝒎𝒂𝒙 , monomoles.m-2)
21 ± 5.4 × 10-7

Maximum
Amount
Adsorbed
-2
(𝑨𝑴
𝒎𝒂𝒙 , moles.m )
21 ± 5.4 × 10-7

PVP K12

0.8 ± 0.0

69 ± 0.3 × 10-7

PVP K16-18

0.9 ± 0.0

PVP K29-32

2.0 ± 0.1

Langmuir
Langmuir Constant
Constant
(𝑲𝑴 , moles-1.mL)
(𝑲𝒘 , mg-1.mL)
5.3 ± 4.7

5.9 ± 5.2 × 105

1.9 ± 0.08 × 10-7

73 ± 24

2900 ± 970 × 105

77 ± 0.9 × 10-7

1.1 ± 0.01 × 10-7

74 ± 21

5900 ± 1700 × 105

179 ± 5.4 × 10-7

0.34 ± 0.01 × 10-7

124 ± 28

72100 ± 16500 × 105

Amax

10

1

0.1
101

102

103

104

105

Molecular Weight

Figure 6.6. Relationship between the maximum amounts of PVP adsorbed on to
indomethacin crystals (Amax) and the molecular weight of PVP.
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The degree of supersaturation (S), also known as the supersaturation ratio, is defined as

S=

Cb
Cs

(6.3)

where Cb is the supersaturated concentration of indomethacin and Cs is the
equilibrium solubility of indomethacin.

The desupersaturation profiles of indomethacin were modeled using a first order
empirical crystal growth model104 as shown in Eq. 6.4.

−

dcb k G A
(Cb − C s )
=
dt
Vb

(6.4)

where kG is an apparent crystal growth rate coefficient, and A/Vb is the crystalline
surface area per unit volume of the bulk medium. The rates of indomethacin crystal
growth in the presence and absence of PVP were used to compare the inhibitory effects
of PVP on the crystal growth of indomethacin. The inhibitory effects of PVP on the
crystal growth of indomethacin were quantitatively expressed as an indomethacin crystal
growth inhibition factor (R). R is defined as the ratio of indomethacin crystal growth
rates with and without PVP.

R=

J
J0
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(6.5)

where J is the crystal growth rate (moles cm-2 time-1) of indomethacin in the presence
of inhibitor and J0 is the crystal growth rate of indomethacin in the absence of inhibitor.
As determined previously104, the indomethacin crystal growth rate coefficient (kG) in the
absence of any PPI at a high S (>3) is 4.7 ± 0.7 × 10-3 cm/sec. In the present study, the
indomethacin kG values determined at a high S (~5) in the presence of 0.05% w/w Nvinylpyrrolidone, PVP K12, K16-18, and K29-32 are 4.9 ± 0.4 × 10-3, 1.0 ± 0.2 × 10-4,
1.1 ± 0.6 × 10-4, and 3.0 ± 1.9 × 10-5 cm/sec, respectively (Figure 6.7). The R values at a
high S (~5) for 0.05% w/w N-vinylpyrrolidone, PVP K12, K16-18, and K29-32 are 1,
0.02, 0.02, and 0.006, respectively (Figure 6.7). PVP K29-32 is ~160-fold more effective
at inhibiting the crystal growth of indomethacin than N-vinylpyrrolidone and ~3-fold
more effective than PVP K12 and PVP K16-18 at 0.05% w/w concentrations. These
results indicate that the polymeric PVPs are better crystal growth inhibitors of
indomethacin than N-vinylpyrrolidone.

The higher molecular weight PVP K29-32

showed greater inhibition of the crystal growth of indomethacin as compared to the lower
molecular weight PVP K16-18 and PVP K12.
In addition to the molecular weight of PVP, the effect of PVP concentration on
the rate of indomethacin crystal growth was evaluated at different concentrations of PVP
K29-32 (0 to 0.2% w/w).

The indomethacin kG decreases significantly as the

concentration of PVP K29-32 increases indicating significantly greater crystal growth
inhibition at higher PVP K29-32 concentrations (Figure 6.8A). The indomethacin kG
reaches a plateau above ~0.05% w/w PVP K29-32 concentration. A comparison of the
three parameters including PVP K29-32 concentration, indomethacin kG, and the extent
2
of PVP adsorption ( 𝐴𝑤
𝑚𝑎𝑥 , mg/m ) indicates that PVP K29-32 is more effective at

191

inhibiting the crystal growth of indomethacin at higher extents of PVP adsorption (Figure
6.8A). The relationship between the extent of PVP K29-32 adsorption and the inhibition
of indomethacin crystal growth was further characterized by comparing the degree of
inhibition (1/R) to the fractional surface coverage (Sf) of indomethacin crystals by the
adsorbed PVP K29-32 (Figure 6.8B). The Sf of indomethacin crystals by PVP K29-32
was calculated using Eq. 6.6:

𝑆𝑓 = 𝐴𝑤

𝐴𝑤

𝑠𝑢𝑟𝑓𝑎𝑐𝑒

(6.6)

where 𝐴𝑤 (mg/m2) is the amount of PVP K29-32 adsorbed on to indomethacin crystal

2
per unit surface area at a specific concentration of PVP K29-32 and 𝐴𝑤
𝑠𝑢𝑟𝑓𝑎𝑐𝑒 (mg/m ) is

the calculated maximum amount of PVP K29-32 adsorbed on to indomethacin crystal per

unit surface area (i.e., ~1 mg/m2) based on the condensed monolayer adsorption of the
monomeric units of PVP having the estimated area of 0.2 nm2.174,175 The degree of
inhibition (1/R) of indomethacin crystal growth by PVP K29-32 increases as the
fractional surface coverage of indomethacin crystals by PVP K29-32 increases (Figure
6.8B). The degree of inhibition increases steadily at Sf ≤1 then more dramatically at Sf
>1. These results suggest that the inhibition of the crystal growth of indomethacin
becomes significant as the surface coverage by PVP K29-32 approaches 1. Moreover, a
higher extent of PVP adsorption beyond complete surface coverage (Sf >1) further
enhances the crystal growth inhibitory effect of PVP K29-32.
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Figure 6.7. Comparison of the effects of PVP polymers (0.05% w/w) and their
monomer (N-vinylpyrrolidone) on indomethacin crystal growth at a high degree of
supersaturation (S~5).
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Figure 6.8. (A) Relationship between the adsorption of PVP K29-32 and the crystal
growth inhibition of indomethacin at different concentrations of PVP K29-32 (S~5),
and (B) Effect of the fractional surface coverage of indomethacin crystals by PVP
K29-32 on its crystal growth inhibitory effect for indomethacin (S~5).
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DISCUSSION
To understand the inhibitory effect of PVP on the crystal growth of indomethacin
and, in turn, on the maintenance of supersaturation, we focused on two main aspects of
the interaction of PVP with indomethacin crystals: 1) the adsorption behavior and nature
of the adsorbed layer of PVP on to indomethacin crystals; and 2) the correlation between
PVP adsorption and crystal growth inhibitory effects for indomethacin.
Several adsorption isotherm models including Langmuir,172,176 Freundlich,172,177
Redlich-Peterson,178 and Hinz,178 have commonly been used to understand the
characteristics of adsorption equilibria. The Langmuir adsorption isotherm model was
utilized in the present study, which assumes an interaction between an adsorbate and free
adsorbent sites subject to the following assumptions: (1) the adsorbent has a limited
adsorption capacity and all adsorption sites are identical; and (2) each site retains one
adsorbate molecule (monolayer assumption). The parameters of the Langmuir adsorption
isotherm model including the Langmuir constant (K) and the maximum amount adsorbed
(Amax) describe the affinity of the adsorbate for a specific adsorbent and the adsorption
capacity of the adsorbent, respectively.
The polymer adsorption process depends on several factors including the nature
of the polymer, solvent, and the surface of the adsorbent.179-181 The adsorption behavior
of a polymer could be influenced by the adsorption energy and related intermolecular
polymer-solvent, solvent-surface, and polymer-surface interactions such as van der
Waals, electrostatic, hydrogen bonding, and hydrophobic interactions.9,182,183 The free
energy changes related to the interactions of a surface with both the polymer and solvent
are expressed by the adsorption energy parameter (χs). Adsorption only occurs when χs
195

exceeds a critical value (χsc), which accounts for the loss of configurational entropy of the
polymer chain upon surface adsorption. The polymer-solvent interactions are sometimes
described using the Flory interaction parameter (χ), which also describes the solvent
quality.

Decreasing solvent quality (i.e., higher χ) generally increases the adsorbed

amount.174

The adsorption of most pharmaceutical PPIs involves hydrophobic drug

surfaces such as indomethacin crystals dispersed in aqueous media where hydrophobic
interactions, driven mainly by the gain in water entropy, could also play an important role
along with the hydrogen bonding interactions.12,183-186
The adsorption of polymers also depends on the properties of polymers such as
molecular weight, chain length, chain conformation, and chain flexibility.182 The longer
chains of higher molecular weight polymers can interact at multiple sites of the surface
thus providing a greater number of interactions as well as higher stability of the adsorbed
polymer as compared to the shorter chains of lower molecular weight polymers and
monomers.19 Although the adsorption energy of an individual polymer subunit could be
as low as that of its monomer, it is higher for a polymer chain due to multiple synergistic
or cooperative interactions with the surface.

The polymer subunits involved in the

interaction with the adsorbent surface are locally constrained by neighboring sub-units
that are also bonded with the surface.19 This limits the distance by which a subunit may
be displaced from its original site of interaction during dynamic bond breakage and
reformation events and, in turn, enhances the binding affinity.19,187
Besides cooperative interactions, the effects of molecular weight and chain length
on the adsorption of polymers have also been associated with the conformation of the
adsorbed polymer chain characterized as trains, loops, and tails.188 The polymer chains
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are in direct contact with the surface in the train conformation, protruding out into the
solution in the loop conformation, and unattached at one end in the tail conformation.
While the different configurations attained by the loops and tails define the entropy of the
adsorbed chain, the enthalpy of adsorption is determined by the interaction energy
between trains and the surface.

The train conformation is more prevalent at high

adsorption energy, whereas loops and tails are common at low adsorption energies. In
most cases, higher chain length provides longer loops and tails and, in turn, a thicker
adsorbed layer. The adsorbed amount and surface coverage also increase with the chain
length up to a critical length beyond which the effect saturates due to lower diffusivity of
very long chains.174 However, a molecular weight effect on the fraction bound to the
surface (i.e., trains) could be absent at a very high adsorption energy. For example,
Kramarenko182 demonstrated using molecular dynamics simulations that the fraction of
adsorbed polymer in train conformations decreased as the chain length increased only at a
low adsorption energy. At higher adsorption energy, the chain length did not influence
the fraction of adsorbed polymer in a train conformation.
The polymer concentration significantly affects the structure of the adsorbed layer
mainly due to the competition for the limited number of adsorption sites at high polymer
concentrations. The adsorbed polymer is generally in a train conformation at low surface
coverage whereas it forms loops and tails at higher extents of adsorption.189,190 The
concentration range can be divided into three regions and related three secondary
polymer conformations including pancake, mushroom, and brush.181

The first

concentration region is the low polymer concentration region where no entanglement
occurs between the adsorbed polymer chains that are present in the pancake conformation
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containing loops, tails, and trains structures.

The second region is the moderate

concentration region where chain entanglement and overlapping occurs resulting in the
mushroom conformation. The third high concentration region is where chains are only
attached to the surface with either one end segment or a few segments while forming a
brush-like structure.

PVP: A Model PPI for Indomethacin Crystals
PVP was selected as a model PPI in this study due to several factors including the
amphiphilic nature of PVP owing to its structural features: (1) the pyrrolidone ring
containing a highly polar amide group, and (2) the ring and backbone containing nonpolar methylene and methine groups (Figure 6.1A).

The adsorption of PVP on to

indomethacin, a model pharmaceutically active adsorbent, could be driven by polar and
non-polar interactions (e.g., hydrogen bonding, Van der Waals, and hydrophobic
interactions) provided by the amide and methylene-methine groups, respectively.183
Recently, Wen et al.183 observed that Van der Waals interactions played a more
significant role than hydrogen bonding for the interactions between PVP and the model
drug acetaminophen.
Accurate and precise measurements of PVP concentrations are required to
construct the adsorption isotherms of PVP.

Several analytical methods including

differential refractometry, UV spectroscopy, and fluorescence spectroscopy have been
used to determine the concentrations of PVP in aqueous and non-aqueous
solutions.174,176,188

In the present study, we used SEC-HPLC to measure the

concentration of PVP due to its superior sensitivity at very low PVP concentrations
across different molecular weights. The PVP concentrations measured by the SEC198

HPLC method were further utilized in constructing the isotherms for PVP adsorption on
to indomethacin crystals.
The adsorption of PVP on to pharmaceutically inactive adsorbents including
polystyrene,176,188 graphite,191 silica,174,191 alumina,191 clay minerals,175,192 and titanium
dioxide193 has been studied previously, however very few studies183,194 have been carried
out to determine the absorption behavior of PVP onto pharmaceutically active
adsorbents.38,49 Additionally, a majority of the above-mentioned PVP adsorption studies
have used adsorbents that are either non-polar such as polystyrene and graphite or polar
with only hydrogen bond accepting capability such as silica and titanium dioxide. Since
PVP has no hydrogen bond donors, no significant hydrogen bonding interactions could
occur between PVP and these adsorbents. While PVP lacks hydrogen bond donors and
cannot form an extensive hydrogen bond network by itself, indomethacin has four
hydrogen bond acceptors and one hydrogen bond donor that could facilitate the formation
of hydrogen bonds between PVP and indomethacin.129 The selection of indomethacin as
an adsorbent in this study could provide additional understanding of the adsorption
behavior of PVP onto a pharmaceutically active adsorbent with hydrogen bond donating
capability.
The crystallographic analyses of indomethacin reveals that strongly hydrogen
bonded carboxylic dimers are present in the γ-form of indomethacin rendering higher
thermodynamic stability. The carboxylic groups as well as the hydrophobic phenyl and
indole rings are present on the faces of indomethacin. The density of these groups on
different faces of indomethacin varies. Chen et al195 suggested that the hydrogen bonded
carboxylic acid dimers are surrounded by more hydrophobic groups. Due to the shielding
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of carboxyl groups from all sides by hydrophobic groups, hydrogen bonding would not
be likely between the surface of the γ-form of indomethacin and PVP. It should also be
noted that unlike the dissolution process, the surface of indomethacin crystals during the
crystal growth process could change significantly in terms of the physical form of
indomethacin in the newly grown layer.104 Depending on the experimental conditions
such as pH, temperature and degree of supersaturation, a wide variety of indomethacin
forms ranging from an amorphous form to the meta-stable forms could grow in the newly
grown layer, which could provide different densities of certain functional groups on the
surface. This could significantly change the interactions of PPIs and the surface and, in
turn, the PPI adsorption profiles. A previous study showed that the surface of the γ-form
of indomethacin did not change during crystal growth in the presence of PVP and the
crystal growth was surface integration controlled at a high degree of supersaturation.27
However, in the absence of PVP and at high supersaturation, the crystal growth of
indomethacin was found to be bulk diffusion controlled due to the formation of a higher
energy surface layer on the growing crystal.104

Polymer Adsorption and Crystal Growth Inhibition
The crystal growth process is generally divided into two major steps: (1) diffusion
of molecules from bulk to the surface, and (2) integration of molecules into the surface.
The surface integration process can be further divided into two sub-steps: (1) surface
diffusion of the molecules in the adsorbed layer, and (2) incorporation of the adsorbed
molecules into the active growth sites such as kinks.104 PPIs could change the kinetics of
drug crystal growth by influencing several factors including viscosity, solubility, bulk
diffusion, surface diffusion, and incorporation of drug molecules into active growth
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sites.9,27 The adsorption of polymers9 or impurities124 on the growing crystal surface has
been linked to their crystal growth inhibitory effects. While the adsorption of PPI has
been linked with its crystal growth inhibitory effects, the detailed understanding of this
mechanism is still lacking. For example, it is not well understood if the blocking of the
active growth sites by the adsorbed PPI is the only primary mechanism of inhibition or
the barrier for surface diffusion provided by the adsorbed PPI is also equally important in
achieving higher inhibitory effects. The goal of this study was to provide better insight
into the nature of PVP adsorption onto indomethacin crystals and, in turn, enhance
understanding of the mechanisms of crystal growth inhibitory effects of PVP.

Adsorption and Crystal Growth Inhibition of Indomethacin by N-vinylpyrrolidone
The affinity of N-vinylpyrrolidone for indomethacin crystals, as expected, was
significantly lower than that of polymeric PVP, which was attributed to cooperative or
synergistic interactions between PVP and the indomethacin surface (Table 6.2). The
extent of adsorption, 𝐴𝑤
𝑚𝑎𝑥 , for N-vinylpyrrolidone was ~9-fold smaller than that for PVP
K29-32 (Table 6.2). Moreover, N-vinylpyrrolidone did not inhibit the crystal growth of

indomethacin whereas PVP K29-32 showed ~160-fold greater crystal growth inhibitory
effect as compared to N-vinylpyrrolidone (Figure 6.7).

This clearly indicated that

although N-vinylpyrrolidone and PVP K29-32 could have similar intermolecular
interactions with indomethacin in solution as well as at the surface, the surface
interactions of N-vinylpyrrolidone are dynamic and ineffective at providing higher extent
of adsorption as well as inhibiting the crystal growth of indomethacin. Due to the
dynamic nature of interactions, when the bond between the monomer, Nvinylpyrrolidone, and the crystal surface of indomethacin is broken, the monomer could
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displace to form a new bond at a new site leaving the original site open for further crystal
growth.

Additionally, the comparison between the experimentally observed and

2
theoretically predicted values of 𝐴𝑤
𝑚𝑎𝑥 for N-vinylpyrrolidone (0.2 vs. 1.0 mg/m )

indicated that a complete surface coverage of the indomethacin surface was not achieved

by N-vinylpyrrolidone. This also indicated that some of the active growth sites for the
crystal growth of indomethacin were not blocked by N-vinylpyrrolidone resulting in the
complete absence of the inhibition of indomethacin crystal growth. The equilibrium
solubility of indomethacin after crystal growth at high degree of supersaturation in the
presence of N-vinylpyrrolidone was higher than the equilibrium solubility measured
without any induced crystal growth, which indicated that a higher energy surface layer
was formed on the growing crystal.104 The lack of significant surface adsorption by the
monomer found in this study could also explain previously observed ineffectiveness of
non-polymeric molecules at inhibiting crystal growth.14,19,107,196

For example, 2-

pyrrolidinone did not shown any effect on the etching pattern, nucleation and crystal
growth of acetaminophen as compared to PVP K30.19 Unlike polymeric hydrogen bond
donors such as PVP and PVA, the small molecule hydrogen bond donors such as
glycerol, glucose, adipic acid, and methanol could not inhibit the crystal growth of
caffeine hydrate.107

Effect of Molecular Weight & Concentration of PVP on the Adsorption and Crystal
Growth Inhibition of Indomethacin
Adsorption isotherms of PVP for indomethacin show a high-affinity character
(Figure 6.5). Similar high-affinity isotherms have been observed for the adsorption of
PVP onto other surfaces including kaolinite,175 Na-montmorillonite,192 polystyrene,176,188
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graphite,191 silica,174,189,191 and titanium dioxide.193 However, the adsorption isotherm of
PVP for alumina showed a low-affinity character, which was attributed to the weak
interactions between PVP and alumina.191
The extent of adsorption ( 𝐴𝑊
𝑚𝑎𝑥 ) of PVP K29-32 for indomethacin crystals

dispersed in an aqueous medium is 1.99 mg/m2 (Table 6.2 and Figure 6.5), which was
similar to previously determined values of the 𝐴𝑊
𝑚𝑎𝑥 of PVP K29-32 or PVP K30
halofantrine (1.8 mg/m2)194 and polystyrene (2 mg/m2)188 dispersed in aqueous media.

2
However, the 𝐴𝑊
𝑚𝑎𝑥 of PVP K30 for kaolinite was slightly lower (i.e., 1.2 mg/m ) than

that for indomethacin crystals indicating a difference between the interaction of PVP with
the two surfaces.175 Additional previous studies176,189,191,192 have also reported the 𝐴𝑊
𝑚𝑎𝑥

of PVP on various surfaces, however the values of 𝐴𝑊
𝑚𝑎𝑥 are described in very specific
units such as the weight of adsorbed polymer per unit weight of adsorbent (e.g., mg/g or

g/g) instead of a more universal unit such as the weight of adsorbed polymer per unit
surface area (e.g., mg/m2), which makes the direct comparison of 𝐴𝑊
𝑚𝑎𝑥 values of PVP

across various studies very difficult.

The affinity and the extent of adsorption onto indomethacin crystals ( 𝐴𝑊
𝑚𝑎𝑥 ,

mg/m2) were greater for higher molecular weight PVP K29-32 as compared to those for
lower molecular weight PVP K12 and PVP K16-18 (Table 6.2 and Figure 6.6). The
higher affinity, as discussed earlier, could be attributed to cooperative interactions. It was
hypothesized that the greater 𝐴𝑊
𝑚𝑎𝑥 for higher molecular weight PVP could be attributed

to a change in conformation of the adsorbed PVP from trains to loops and tails at higher

molecular weight. To characterize the change in conformation of the adsorbed PVP with

203

molecular weight, the extent of PVP adsorption onto indomethacin crystals was analyzed
in multiple ways: (1) by comparing the Amax of PVP using different units, (2) by plotting
the Amax against the molecular weight of PVP, and (3) by comparing the experimental
and theoretical Amax of PVP.
The values of Amax of PVP were compared using different units: 1) weight-basis
2
2
𝑚𝑀
(𝐴𝑊
𝑚𝑎𝑥 , mg/m ), 2) monomer mole-basis ( 𝐴𝑚𝑎𝑥 , monomoles/m ), and 3) mole-basis

2
𝑊
𝑚𝑀
𝑀
(𝐴𝑀
𝑚𝑎𝑥 , moles/m ). 𝐴𝑚𝑎𝑥 and 𝐴𝑚𝑎𝑥 increased while 𝐴𝑚𝑎𝑥 decreased with the molecular

weight of PVP (Table 6.2 and Figure 6.6). Thus, for a given number of interaction sites,

fewer molecules of higher molecular weight PVP were adsorbed onto indomethacin
crystals. This could be attributed to the fact that the long chains of higher molecular
weight polymers would have cooperative or synergistic interactions at multiple sites on
the surface. However, this observation also poses a new question as to whether all subunits of a higher molecular weight polymer chain are interacting with the surface at same
time or, in other words, whether the fraction of monomers or sub-units attached to the
𝑚𝑀
surface (i.e., in train conformation) is 1. If this were to occur then 𝐴𝑊
𝑚𝑎𝑥 and 𝐴𝑚𝑎𝑥 would

be similar for different molecular weights of PVP as the number of sub-units bonded with
the surface would be similar across the molecular weight range.

However, the

𝑚𝑀
experimental 𝐴𝑊
𝑚𝑎𝑥 and 𝐴𝑚𝑎𝑥 data clearly show that this is not the case for the adsorption

of PVP onto indomethacin crystals indicating that not all monomeric units are bonded to
the surface of indomethacin. Since all PVP monomeric units are not attached to the
indomethacin surface, loops and tails of the polymer must extend from the indomethacin
surface.
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When the 𝐴𝑊
𝑚𝑎𝑥 of PVP is plotted against its molecular weight, a linear

relationship with a slope (α) of 0.36 is obtained (Eq. 6.2), indicative of both loops and
tails in a random coil conformation extending from the indomethacin crystal surface
(Figure 6.6).173 The values of α for PVP adsorbed onto polystyrene latex and kaolinite
suspended in aqueous media were reported to be α=0.2 and 0.44.175,176 Alternatively,
PVP could be adsorbed in a train conformation (α=0) or a tail conformation

(α=1).175,176,193 For example, PVP adsorbed in a train conformation onto titanium dioxide
dispersed in methanol resulting in the extent of adsorption being independent of the
molecular weight.193
2
2
The experimental 𝐴𝑊
𝑚𝑎𝑥 of PVP K12 (0.8 mg/m ) and PVP K16-18 (0.9 mg/m )

2
were similar to the theoretical 𝐴𝑊
𝑚𝑎𝑥 of PVP (i.e., ~1 mg/m ) calculated based on the

condensed monolayer adsorption of the monomeric units of PVP having the estimated
area of 0.2 nm2.174,175 This indicated that a majority fraction of the adsorbed of PVP K12
and K16-18 could be in a train conformation with fewer loops and tails. It should be
noted that instead of being either equal to or slightly higher than the theoretical 𝐴𝑊
𝑚𝑎𝑥 of

PVP (i.e., ~1 mg/m2), the experimental 𝐴𝑊
𝑚𝑎𝑥 values for PVP K12 and K16-18 were

slightly lower. This may be attributable to an overestimation of the effective surface area
available for the adsorption of larger molecules such as PVP polymers onto indomethacin
crystals using smaller adsorbate molecules such as nitrogen. Unlike PVP K12 and PVP
K16-18, the experimental 𝐴𝑊
𝑚𝑎𝑥 of PVP K29-32 was almost 2-fold higher than the
theoretical 𝐴𝑊
𝑚𝑎𝑥 , indicating that a significant fraction of the adsorbed PVP K29-32 could

reside in loops and tails extending away from the surface. Moreover, assuming that all

three PVPs were occupying similar number of sites on the surface, the additional extent
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2
of adsorption of PVP K29-32 above the theoretical 𝐴𝑊
𝑚𝑎𝑥 (i.e., ~1 mg/m ) could be

attributed to longer loops and tails and a thicker adsorption layer. The difference in the
thickness of the adsorption layer between the higher molecular weight PVP K29-32 and
lower molecular weight PVP K16-18 was estimated from their respective 𝐴𝑊
𝑚𝑎𝑥 values

(0.9 vs. 1.99 mg/m2) and previously determined thickness of the adsorption layer of PVP

K16-18 of ~4 nm. From the adsorption layer thickness of 4 nm and the 𝐴𝑊
𝑚𝑎𝑥 of 0.9

mg/m2 for PVP K16-18, the density of the adsorption layer could be calculated as 2.3 ×

108 mg/m3. If it is assumed that the density of the adsorbed layer would be similar
between the two polymers, then the thickness of the adsorption layer for PVP K29-32
2
could be estimated as ~9 nm using the 𝐴𝑊
𝑚𝑎𝑥 of PVP K29-32 of 1.99 mg/m . Thus, at

saturation, the thickness of PVP K29-32 adsorption layer for indomethacin could be more
than two-fold greater than that of PVP K16-18.
Overall, the above analysis of 𝐴𝑊
𝑚𝑎𝑥 of PVP for indomethacin crystals indicated

that, at saturation, the lower molecular weight PVP K12 and K16-18 could be adsorbed in
mostly train conformations with a fewer loops and tails than exhibited by the higher
molecular weight PVP K29-32. Similar correlations between the molecular weight of
PVP, the extent of PVP adsorption, and the thickness of PVP adsorption layer have been
made in previous studies.174,175,190,192,197 For example, the adsorption of PVP on kaolinite
increased with the molecular weight of PVP up to ≤ 44000 g/mol beyond which the
extent of PVP adsorption leveled off.175 The higher extent of adsorption with higher
molecular weight PVP was attributed to the change in the adsorbed PVP conformation
from trains at a lower molecular weight to loops and tails at a higher molecular weight.
In cases such as the adsorption of PVP onto halofantrine where the conformation of PVP
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remained unchanged while increasing the molecular weight of PVP over the average
weight range of 3−46 kg/mol, no significant effect of the molecular weight of PVP on the
extent of adsorption was seen.194 Smith et al.188 observed that there was no effect of PVP
molecular weight on the adsorption capacity of polystyrene lattices when they were
suspended in water. However, the adsorption capacity of polystyrene lattices for PVP
increased with an increase in the molecular weight of PVP when the lattices were
suspended in water containing 0.5 M NaCl.

This was attributed to the significant

weakening of the polar interactions between PVP and polystyrene due to shielding of
PVP dipoles by NaCl. PVP adopted a more extended conformation of loops and tails in
the presence of NaCl as compared to a flatter conformation of trains in water.188 Cohen
Stuart et. al.190 measured the fraction of bound PVP segments onto silica using NMR and
EPS at different molecular weights of PVP. A greater number of loops and tails was
observed for higher molecular weight PVP, whereas the lower molecular weight PVP
was mostly adsorbed in a train conformation at the silica-liquid interface. Sequaris et
al.192 showed that, unlike PVP K12, the fraction of higher molecular weight PVP K30
segments bound in train conformations to montmorillonite measured using a
microcalorimetric technique decreased from 1 to 0.3 when the adsorbed PVP K30
amount increased from 0 to ~4.5 mM/g, which was attributed to longer tail and loop
segments in the adsorbed layer at higher surface coverage. Kellaway et. al.176 attributed
the linear increase in the thickness of the PVP layer adsorbed onto polystyrene latex
measured by U-tube viscometry with an increase in the molecular weight of PVP to a
significant contribution of loops to the thickness of the adsorbed layer. Hild et. al.175 also
attributed the higher extent of adsorption by higher molecular weight PVP to loops and
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tails yielding a large increase in the thickness of the hydrodynamic layer measured using
microelectrophoresis. At low surface coverage, PVP chains lie flat in train conformations
onto kaolinite. However, at high surface coverage the polymer chains would be in loops
or random coil tail conformations yielding a large increase in the thickness of the
hydrodynamic layer in relative to the amount adsorbed for higher molecular weight PVP.
The thickness of the adsorbed PVP onto kaolinite particles was ~6-fold greater at higher
amounts of PVP adsorbed (≥0.6 mg/m2) as compared to lower amounts of PVP adsorbed
(<0.6 mg/m2).175
The inhibitory effect of PVP on the crystal growth of indomethacin is ~3-fold
greater for higher molecular weight PVP K29-32 as compared to those for the lower
molecular weight PVP K12 and PVP K16-18 (Table 6.2 and Figure 6.7). This could be
attributed to the greater affinity and greater extent of adsorption of higher molecular
weight PVP for indomethacin crystals as compared to lower molecular weight PVP. The
values of kG of indomethacin at a high degree of supersaturation (S~5) in the presence of
PVP K12, K16-18, and K29-32 (i.e., 1.0 ± 0.2 × 10-4, 1.1 ± 0.6 × 10-4, and 3.0 ± 1.9 × 105

cm/sec, respectively) were similar to the kG of the surface integration controlled crystal

growth of indomethacin as determined in a previous study (i.e., 5.5 ± 1.3 × 10-4
cm/sec).166 The kG of the bulk diffusion controlled crystal growth of indomethacin in the
absence of PVP is 4.7 ± 0.7 × 10-3 cm/sec.104 This suggested that the adsorbed PVP
changed the mechanism of indomethacin crystal growth at high S such that the rate
limiting step changed from bulk diffusion to surface integration.27,104,166 The change in
crystal growth mechanism could be attributed to the inhibition of the formation a high
energy surface layer on indomethacin crystals by the adsorbed PVP as indicated by the
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similarity between the apparent solubility of indomethacin after crystal growth in the
presence of PVP and the equilibrium solubility in the presence of PVP without any
crystal growth.27

To further understand the crystal inhibitory effect of PVP, we

determined the crystal growth inhibition of indomethacin at different extents of PVP
K29-32 adsorption (Figure 6.8A). The extent of PVP adsorption was also represented as
the fractional surface coverage of indomethacin while assuming a complete surface
2
coverage of indomethacin by PVP at an 𝐴𝑊
𝑚𝑎𝑥 of 1 mg/m . The fractional surface

coverage was correlated with the degree of crystal growth inhibition (1/R) (Figure 6.8B).

The degree of indomethacin crystal growth inhibition increased as the fractional surface
coverage of the surface of indomethacin increased from 0 to 1 indicating the significant
impact of surface coverage on the inhibition of crystal growth. Moreover, the degree of
crystal growth inhibition was even greater at fractional surface coverages of higher than
1. As discussed earlier, at lower extents of adsorption, a majority of the adsorbed PVP
K29-32 molecules could be in a much flatter “train” conformation providing a thinner
layer of the adsorbed polymer. As the extent of adsorption increases, the fraction of PVP
K29-32 molecules with a “trains and loops” conformation could grow significantly
resulting in a thicker layer of the adsorbed polymer.175 These results indicate that while
more surface coverage provides higher inhibition of the crystal growth, the greater
resistance for surface diffusion of indomethacin molecules provided by the thicker
adsorption layer of PVP enhances the crystal growth inhibitory effect further.

A

comparison between a low molecular weight PVP polymer (PVP K16-18) and a high
molecular weight PVP polymer (PVP K29-32) showed that the inhibition of
indomethacin crystal growth was ~3-fold greater when the thickness of the PVP
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adsorption layer increased ~2-fold. The stronger inhibitory effects of PVP K29-32 on the
crystal growth of indomethacin at higher fractional surface coverage may be attributed to
the thicker adsorbed layer and larger barrier for indomethacin crystal growth provided by
the adsorbed PVP K29-32.
CONCLUSIONS
The relationship between the adsorption and crystal growth inhibitory effect of
PVP on indomethacin seed crystals was explored at different molecular weights and bulk
concentrations of PVP. The adsorption of PVP was successfully modeled using the
Langmuir equation. PVP exhibited significantly higher affinity and extent of maximum
adsorption for indomethacin crystals as compared to its monomer (N-vinylpyrrolidone),
indicating stronger interactions of PVP with the surface of indomethacin. The extent of
maximum adsorption for PVP onto indomethacin crystals increased with the molecular
weight of PVP. The higher extent of adsorption with longer chain, higher molecular
weight PVP was attributed not only to stronger interactions between PVP and the
indomethacin crystal surface but also to a greater thickness of the adsorbed layer due to
the formation of loops and tails. Unlike N-vinylpyrrolidone, PVP significantly inhibited
the crystal growth of indomethacin at high degree of supersaturation, which was
attributed to the change in the indomethacin crystal growth mechanism that also resulted
in a change in the rate limiting step from bulk diffusion to surface integration at a high S.
The adsorption and crystal growth inhibitory effect of PVP for indomethacin correlated
well across different molecular weights and concentrations of PVP. The crystal growth
inhibitory effect of PVP for indomethacin was greater at higher extents of PVP
adsorption. The effectiveness of PVP K29-32 as a crystal growth inhibitor was about 3210

fold greater than that of PVP K16-18 and PVP K12 (0.05% w/w), which was attributed to
a greater thickness of the adsorbed PVP layer. Finally, the greater effectiveness of PVP
as a crystal growth inhibitor of indomethacin was not only attributed to higher surface
coverage of indomethacin crystals but also to a greater barrier for the surface diffusion of
indomethacin molecules provided by a thicker PVP adsorption layer.

Copyright © Dhaval D. Patel 2015
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Chapter Seven
Conclusions and Future Studies
A non-invasive, online, simple and reliable method to determine crystal growth
rates using a batch crystallization technique and second derivative UV spectroscopy was
been developed.

The second derivative UV spectroscopy successfully removed the

spectral interference due to the presence of seed crystals in the crystal growth samples
during indomethacin concentration measurements.

The presence of seed crystals

obviated primary nucleation of indomethacin at higher degrees of supersaturation during
crystal growth. The apparent equilibrium solubility of indomethacin after crystal growth
was about 55% higher than its equilibrium solubility, which could be attributed to the
growth of a higher energy indomethacin form on seed crystals of the thermodynamically
most stable form. The first order desupersaturation kinetic profiles and the similarity
between the mass transfer coefficients determined from indomethacin powder dissolution
and crystal growth clearly indicated that the indomethacin crystal growth at a high degree
of supersaturation of S=6 is bulk diffusion rate limited. Indomethacin crystal growth
kinetics from supersaturated aqueous suspensions was compared at varying degrees of
supersaturation (2 ≤ S ≤ 9). The higher indomethacin apparent solubility after crystal
growth at S between 2 and 9 indicated that a higher energy surface was formed on the
seed crystals initially having a lower energy surface. The indomethacin crystal growth
rate coefficient (kG) increased with S between an S of 2-6. At high S (6 ≤ S ≤ 9), the kG
reached a plateau value that was similar to the theoretically predicted kG assuming bulk
diffusion controlled crystal growth. The indomethacin kG at a low S of 2 was ~10 times
smaller than the theoretically predicted kG assuming bulk diffusion controlled crystal
growth. The smaller indomethacin kG at S=2 could be due to a change in the rate limiting
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step from bulk diffusion to surface integration. The change in rate-limiting step from
bulk diffusion to surface integration for the indomethacin crystal growth at a low S of 2
was attributed to a longer lag time for the conversion of initial lower energy
indomethacin seed crystal surface to a high energy surface due to reduced
thermodynamic driving force for crystal growth at the low S of 2. The kG determined at a
low S of 2 using higher energy seed crystals was similar to that predicted assuming bulk
diffusion controlled crystal growth. This result further verified the hypothesis that the
higher energy surface provided faster bulk diffusion controlled crystal growth. Using an
infusion-based method, the indomethacin kG at very low S (<1.6) was determined without
transforming the initial lower energy surface to the higher energy surface.

The

indomethacin apparent solubility after crystal growth at S<1.6 was lower and similar to
the equilibrium solubility indicating that crystal growth at S below the higher
indomethacin apparent solubility (i.e., S < 1.6) did not form the higher energy surface.
The kG at S < 1.6 was similar to that determined at an S of 2 supporting the hypothesis
that the smaller kG at low S could be attributed to the lower energy indomethacin seed
crystal surface.

Finally, the higher energy surface provided faster, bulk diffusion

controlled indomethacin crystal growth at high and low S, whereas the lower energy
surface was associated with significantly slower surface integration controlled crystal
growth rate at low S. The quantitative mechanistic understanding derived from the
indomethacin crystal growth kinetics at high and low S was useful in exploring the
inhibitory effects of model pharmaceutical excipients on indomethacin crystal growth
and, in turn, on its supersaturation maintenance. HP-β-CD significantly increased
indomethacin equilibrium solubility due to 1:1 complex formation between indomethacin
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and HP-β-CD. PVP and HPMC did not substantially alter the solubility of indomethacin.
Viscosity of HPMC solutions increased significantly as a function of HPMC
concentration. The rank order of solution viscosity at similar PPI concentrations was
HPMC > PVP > HP-β-CD. PVP and HPMC were better indomethacin crystal growth
inhibitors than HP-β-CD at high degrees of supersaturation (S), which was attributed
their ability to change the indomethacin crystal growth rate limiting step from bulk
diffusion to surface integration. HP-β-CD’s crystal growth inhibitory effects at high S
increased with an increase in its concentration up to 1% w/w concentration.

The

inhibitory effect of HP-β-CD on bulk diffusion controlled indomethacin crystal growth at
high S could be rationalized by reversible complexation between HP-β-CD and
indomethacin in the diffusion layer. The crystal growth inhibition factors of PVP and
HPMC were dramatically greater at high S than that for HP-β-CD, which indicated that
both PPIs changed the rate limiting step of indomethacin crystal growth at high S from
bulk diffusion to surface integration. At low S, the crystal growth rate of indomethacin
becomes surface integration controlled even in the absence of PPIs.

Under these

conditions all PPIs exhibited only modest inhibitory effects. For example, a twofold
greater indomethacin crystal growth inhibition factor was observed for HP-β-CD at low S
than that at high S, reflecting its effect on the rate of indomethacin surface integration at
low S. The relative effects of the model PPIs at low S may be attributable to their
adsorption onto the growing crystal surface and the effect of this adsorption on the rate of
surface integration.

The relationship between the adsorption and crystal growth

inhibitory effect of PVP for indomethacin was explored at different molecular weights
and bulk concentrations of PVP. The adsorption isotherms of PVP were successfully
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modeled using the Langmuir adsorption isotherm model. The adsorption isotherms of
PVP showed a high affinity character. PVP showed significantly higher affinity and the
extent of adsorption for indomethacin crystals as compared to its monomer (Nvinylpyrrolidone), which were attributed to stronger interactions of PVP with the surface
of indomethacin. The extent of adsorption for PVP onto indomethacin crystals was a
function of the molecular weight of PVP. The extent of adsorption for PVP K29-32 was
2-fold and 3-fold greater than those for PVP K 16-18 and PVP K12, respectively. The
higher extent of adsorption with longer chain higher molecular weight PVP was
attributed not only to stronger interactions between PVP and the surface of indomethacin
but also to a greater thickness of the adsorbed layer due to the formation of loops and
tails structures by the adsorbed longer chain higher molecular weight PVP. Unlike Nvinylpyrrolidone, PVP significantly inhibited the crystal growth of indomethacin at high
degree of supersaturation, which was attributed to the change in indomethacin crystal
growth mechanism resulting in a change in the rate limiting step from bulk diffusion to
surface integration at a high S. The adsorption and crystal growth inhibitory effect of
PVP for indomethacin correlated well across different molecular weights and
concentrations of PVP. The crystal growth inhibitory effect of PVP for indomethacin was
greater at higher extents of PVP adsorption onto indomethacin crystals. The effectiveness
of PVP K29-32 as a crystal growth inhibitor was about 3-fold greater than that of PVP
K16-18 and PVP K12 (0.05% w/w), which was attributed to higher thickness of the PVP
adsorption layer. The greater effectiveness of PVP as a crystal growth inhibitor of
indomethacin was not only attributed to higher surface coverage of indomethacin crystals
but also to greater barrier for the surface diffusion of indomethacin molecules provided
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by a thicker PVP adsorption layer. Overall, the PPI effect on the change in growth
mechanism, from bulk diffusion to surface integration, provided about 10-fold inhibition
of the crystal growth of indomethacin.

Additionally, the suppression of surface

integration by PPIs resulted in another 30-fold inhibition of indomethacin crystal growth.
The future studies could develop a similar quantitative and mechanistic
understanding of the effects of PIs on the inhibition of nucleation of poorly water soluble
drugs. Since the effects of PIs are highly drug molecule specific and vary with different
drugs, the next step could be to determine the molecular descriptors (e.g., hydrogen bond
donor-acceptor capacity, polymer chain length, and presence of rigid-planar structure and
its size) of drugs that significantly influence the effectiveness of PPIs. Quantitative
models that could predict the effect of PIs on the precipitation (i.e., nucleation and crystal
growth) of drugs could be created, and in turn facilitate the development of drug
candidates for the life-threatening diseases.

The quantitative models explaining

nucleation and crystal growth phenomena may be integrated into a master equation
predicting drug precipitation kinetics. A more extensive database of the effects of PIs on
the precipitation of poorly water soluble drugs could be created. A framework for
rational and efficient decision making leading to the rapid selection of excipient(s) or
excipient combinations specific to the drug candidate under evaluation could be created
that could provide high oral bioavailability for compounds that otherwise might exhibit
solubility-limited absorption or undergo extensive precipitation/recrystallization after
dissolution. Moreover, the understanding and predictive approaches emerging from the
future studies are likely to save significant amounts of time and resources, which will in

216

turn enable pharmaceutical scientists to support greater numbers of drug product
development programs for new therapeutic entities.
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Appendix 1: List of Abbreviations
SDDS: Supersaturating Drug Delivery Systems
S: Degrees of supersaturation
PIs: Precipitation inhibitors
PPIs: Polymeric precipitation inhibitors
PVP: Polyvinylpyrrolidone ()
PVP-VA: Polyvinylpyrrolidone-co-polyvinyl acetate
HPMC: Hydroxypropyl methylcellulose
HPMC-AS: Hydroxypropyl methylcellulose-acetate succinate
PEG: Polyethylene glycol
PVA: Polyvinyl alcohol
TPGS: d-α-tocopheryl polyethylene glycol 1000 succinate
HP-β-CD: Hydroxypropyl β-cyclodextrin
SBE-CD: β-cyclodextrin sulfobutyl ether
ASD: Amorphous solid dispersions
SEDDS: Self-emulsifying drug delivery systems
SMEDDS: Self-microemulsifying drug delivery systems
SNEDDS: Self-nanoemulsifying drug delivery systems
S-SEDDS: Supersaturable SEDDS
ADME: Absorption, distribution, metabolism, and excretion
BCS: Biopharmaceutical classification system
MAD: Maximum absorbable dose (MAD)
SIWV: Small intestinal water volume
SITT: Small intestinal transit time
BCF: Burton, Cabrera and Frank
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PXRD: Powder X-ray diffraction
SEM: Scanning electron microscopy
PLM: Polarized light microscopic analysis
UV: Ultraviolet
SEC: Size-exclusion chromatography
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